C:\Program Files\Stnexp\Queries\0071073.m





chain nodes :
7 8 10 11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5 6
chain bonds :
2-8 7-12 7-13 8-10 8-11 11-15 12-14 14-16 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-12 7-13 8-10 8-11 11-15 12-14 14-16 15-17
exact bonds :
2-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:CLASS

L3 460 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:31:40 ON 15 ARR 2003
L4 72 S L3

FILE 'USPATFULL' ENTERED AT 09:32:09 ON 15 APR 2003

=> s l3
L5 23 L3

=> d abs ibib fhitstr 1-23

L5 ANSWER 1 OF 23 USPATFULL
AB Selective MMP-13 inhibitors are pyridine derivatives of the formula ##STR1##

or a pharmaceutically acceptable salt thereof,

wherein:

R.sup.1 and R.sup.2 independently are hydrogen, halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, NO.sup.2, NR.sup.4R.sup.5, CN, or CF.sub.3,

E is independently O or S;

A and B independently are OR.sup.4 or NR.sup.4R.sup.5;

R.sup.4 and R.sup.5 independently are H. C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, (CH.sub.2).sub.n aryl, (CH.sub.2).sub.n cycloalkyl, (CH.sub.2).sub.n heteroaryl, or R.sup.4 and R.sup.5 when taken together with the nitrogen to which they are attached complete a 3 to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted,

n is an integer of from 0 to 6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:288130 USPATFULL
TITLE: Pyridine matrix metalloproteinase inhibitors
INVENTOR(S): Barvian, Nicole Chantel, Ann Arbor, MI, UNITED STATES
Connor, David Thomas, Ann Arbor, MI, UNITED STATES
O'Brien, Patrick Michael, Stockbridge, MI, UNITED STATES
Ortwine, Daniel Fred, Saline, MI, UNITED STATES
Patt, William Chester, Chelsea, MI, UNITED STATES
Shuler, Kevon Ray, Chelsea, MI, UNITED STATES
Wilson, Michael William, Ann Arbor, MI, UNITED STATES

applicant's own

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002161000	A1	20021031	
APPLICATION INFO.:	US 2002-71073	A1	20020208	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-268781P	20010214	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Claude F. Purchase, Jr., Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105
NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1
LINE COUNT: 1991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **449734-09-2P**, Pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)
(prepn. of pyridine-2,4-dicarboxamide and -dicarboxylic acid derivs. as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)
RN 449734-09-2 USPATFULL
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 23 USPATFULL
AB Pyridine-2,3-dicarboxamides of the formula I ##STR1##

in which the variables are as defined in the description, which are suitable for use as herbicides or for the desiccation or defoliation of plants are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:283245 USPATFULL
TITLE: Pyridine-2,3-dicarboxylic acid diamides
INVENTOR(S): Hamprecht, Gerhard, Weinheim, GERMANY, FEDERAL REPUBLIC OF
Menges, Markus, Harthausen, GERMANY, FEDERAL REPUBLIC OF
Menke, Olaf, Altleiningen, GERMANY, FEDERAL REPUBLIC OF
Reinhard, Robert, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Sagasser, Ingo, Eppelheim, GERMANY, FEDERAL REPUBLIC OF
Zagar, Cyrill, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Westphalen, Karl-Otto, Speyer, GERMANY, FEDERAL REPUBLIC OF
Otten, Martina, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Walter, Helmut, Obrigheim, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6472349	B1	20021029	
	WO 2000058288		20001005	←
APPLICATION INFO.:	US 2001-937843		20010928	(9)
	WO 2000-EP2899		20000331	
			20010928	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-19914721	19990331

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: Keil & Weinkauf

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3503
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **298221-10-0P**
(prepn. of pyridine-2,3-dicarboxylic acid diamides as herbicides, desiccants, and defoliants)
RN 298221-10-0 USPATFULL
CN 2,3-Pyridinedicarboxamide, N3-(3-chloro-2-cyanophenyl)-N2-(cyclopropylmethyl)-6-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 23 USPATFULL
AB Coumermycin analogs of general formula I: ##STR1##

wherein X, a linking group, is selected from the group consisting of alkyl, aryl, diaryl, substituted alkyl, substituted aryl, alkyl with hereroatoms in the chain, heteroaryl, cyclic and bicyclic alkyl, and a combination of alkyl, aryl and heteroaryl substituents. The compounds are suitable for use as chemical dimerizers of chimeric proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:179234 USPATFULL
TITLE: Coumermycin analogs as chemical dimerizers of chimeric proteins
INVENTOR(S): Farrar, Michael A., Minneapolis, MN, UNITED STATES
Olson, Steven H., Metuchen, NJ, UNITED STATES
Perlmutter, Roger M., Seattle, WA, UNITED STATES
Slossberg, Llnon H., New Brunswick, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002095026	A1	20020718	
APPLICATION INFO.:	US 2001-840260	A1	20010423	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-203656P	20000512 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 868
CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L5 ANSWER 4 OF 23 USPATFULL
AB Substituted 4-phenyl-pyridine compounds with activity as antagonists of Neurokinin 1 receptors, methods of making these compounds and preparing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:72900 USPATFULL
TITLE: Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors
INVENTOR(S): Godel, Thierry, Basle, SWITZERLAND
Hoffmann, Torsten, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF
Schnider, Patrick, Oberwil, SWITZERLAND
Stadler, Heinz, Rheinfelden, SWITZERLAND

09/922066

8/3/01

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002040040	A1	20020404
APPLICATION INFO.:	US 2001-922066	A1	20010803 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2000-117003	20000808

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS: 70
EXEMPLARY CLAIM: 1
LINE COUNT: 3260
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **401891-81-4P**
(prepn. of 4-phenylpyridines as neurokinin-1 receptor antagonists)
RN 401891-81-4 USPATFULL
CN 2,5-Pyridinedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N'-cyclopropyl-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 23 USPATFULL
AB The present invention provides novel compounds possessing one or more of

the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): ##STR1##

Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:67203 USPATFULL
TITLE:	Novel compounds possessing antibacterial, antifungal or antitumor activity
INVENTOR(S):	Zhang, Wentao, Foster City, CA, UNITED STATES Liehr, Sebastian Johannes Reinhard, East Palo Alto, CA, UNITED STATES Velligan, Mark Douglas, Montara, CA, UNITED STATES Dyatkina, Natalia B., Mountain View, CA, UNITED STATES Botyanszki, Janos, Cupertino, CA, UNITED STATES Shi, Dong-Fang, San Mateo, CA, UNITED STATES Roberts, Christopher Don, Belmont, CA, UNITED STATES Khorlin, Alexander, Mountain View, CA, UNITED STATES Nelson, Peter Harold, Los Altos, CA, UNITED STATES Muchowski, Joseph Martin, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002037856	A1	20020328	
APPLICATION INFO.:	US 2001-892327	A1	20010626	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214478P	20000627 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Gerald F. Swiss, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	16 Drawing Page(s)
LINE COUNT:	3872

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **386250-77-7P**
(prepn. of novel compds. possessing antibacterial, antifungal or antitumor activity)

RN 386250-77-7 USPATFULL

CN 2,5-Pyridinedicarboxamide, N,N'-bis[5-[[(4-amino-4-iminobutyl)amino]carbonyl]-1-(3-methylbutyl)-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L5 ANSWER 6 OF 23 USPATFULL

AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:185480 USPATFULL

TITLE: Heterocyclic 2-substituted ketoamides

INVENTOR(S): McIver, John McMillan, Cincinnati, OH, United States
Degenhardt, Charles Raymond, Cincinnati, OH, United States
Eickhoff, David Joseph, Edgewood, KY, United States

PATENT ASSIGNEE(S): The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6307049	B1	20011023	
APPLICATION INFO.:	US 1999-400681		19990921	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102449P	19980930	(60)
	US 1999-122925P	19990305	(60)
	US 1999-147279P	19990805	(60)
	US 1999-147313P	19990805	(60)
	US 1999-147280P	19990805	(60)
	US 1999-147278P	19990805	(60)
	US 1999-147276P	19990805	(60)
	US 1999-136996P	19990601	(60)
	US 1999-137024P	19990601	(60)
	US 1999-137022P	19990601	(60)
	US 1999-137023P	19990601	(60)
	US 1999-137052P	19990601	(60)
	US 1999-137063P	19990601	(60)
	US 1999-136958P	19990601	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Seaman, D. Margaret
LEGAL REPRESENTATIVE: Brown, Catherine U., Lewis, Len W., McDow-Dunham, Kelly L.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1840

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **262843-24-3P**
(prepn. of N-(arylglyoxyloyl)azacycloalkane-2-carboxamides for treating hair loss)
RN 262843-24-3 USPATFULL
CN 2,3-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 23 USPATFULL
AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:173595 USPATFULL
TITLE:	2-substituted heterocyclic sulfonamides
INVENTOR(S):	McIver, John McMillan, Cincinnati, OH, United States Degenhardt, Charles Raymond, Cincinnati, OH, United States Eickhoff, David Joseph, Edgewood, KY, United States
PATENT ASSIGNEE(S):	The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6300341	B1	20011009	
APPLICATION INFO.:	US 1999-400679		19990921	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102539P	19980930	(60)
	US 1999-122925P	19990305	(60)
	US 1999-147279P	19990805	(60)
	US 1999-147313P	19990805	(60)
	US 1999-147280P	19990805	(60)
	US 1999-147278P	19990805	(60)
	US 1999-147276P	19990805	(60)
	US 1999-136996P	19990601	(60)
	US 1999-137024P	19990601	(60)
	US 1999-137022P	19990601	(60)
	US 1999-137023P	19990601	(60)
	US 1999-137052P	19990601	(60)
	US 1999-137063P	19990601	(60)
	US 1999-136958P	19990601	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Dentz, Bernard
LEGAL REPRESENTATIVE:	McDow-Dunham, Kelly, Brown, Catherine U., Miller, Steven W.

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **262843-24-3P**
(prepn. of heterocyclic sulfonamides as non-immunosuppressive hair growth promoters)
RN 262843-24-3 USPATFULL
CN 2,3-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 23 USPATFULL
AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:128907 USPATFULL
TITLE: Heterocyclic 2-substituted ketoamides
INVENTOR(S): McIver, John McMillan, Cincinnati, OH, United States
Degenhardt, Charles Raymond, Cincinnati, OH, United States
Eickhoff, David Joseph, Edgewood, KY, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001012895	A1	20010809
APPLICATION INFO.:	US 2000-736540	A1	20001213 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-400681, filed on 21 Sep 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102449P	19980930 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Catherine U. Brown - Box 633, The Procter & Gamble Company, Miami Valley Laboratories, P. O. Box 538707, Cincinnati, OH, 45253-8707
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 1794
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **262843-24-3P**
(prepn. of N-(arylglyoxyloyl)azacycloalkane-2-carboxamides for treating hair loss)
RN 262843-24-3 USPATFULL
CN 2,3-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 9 OF 23 USPATFULL

AB Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R.sup.1 is for example H and further values as defined in the specification; R.sup.2 is for example H and further values as defined in the specification; R.sup.3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R.sup.3 values can be the same or different; L is a linking moiety for example --CO--NH.sub.2 -- and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a --S--S-- dimer thereof when R.sup.2 =H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:71572 USPATFULL

TITLE: 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors

INVENTOR(S): Davies, David Huw, Macclesfield, United Kingdom
Boyle, Francis Thomas, Macclesfield, United Kingdom
Wardleworth, James Michael, Macclesfield, United Kingdom
Kenny, Peter Wedderburn, Macclesfield, United Kingdom
Scholes, Peter Beverley, Macclesfield, United Kingdom
Matusiak, Zbigniew Stanely, Macclesfield, United Kingdom

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6232338	B1	20010515	
	WO 9706138		19970220	
APPLICATION INFO.:	US 1998-11135		19980203	(9)
	WO 1996-GB1810		19960730	
			19980203	PCT 371 date
			19980203	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1995-15975	19950804

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ramsuer, Robert W.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P..
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 3849

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **188353-08-4P**
(prepn. of 2-aminomethyl-4-mercaptopyrrolidines and analogs as farnesyl transferase inhibitors)
RN 188353-08-4 USPATFULL
CN 2,5-Pyridinedicarboxamide, N5-[(3,4-dichlorophenyl)methyl]-N2-[(4-mercapto-2-pyrrolidinyl)methyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 10 OF 23 USPATFULL
AB Compounds of formula (I) and their pharmaceutically active salts are gastrin and CCK receptor ligands, where Ar is a monocyclic aromatic group, R.sup.1 is halo, amino, nitro, cyano, sulphamoyl, sulphonyl, trifluoromethyl, C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 alkylamino, C.sub.1 to C.sub.3 dialkylamino, phenyl, substituted phenyl, C.sub.1 to C.sub.3 alkoxy, hydroxy, esterified hydroxy, C.sub.1 to C.sub.3 hydroxyalkyl, C.sub.1 to C.sub.3 alkylcarboxyamino, carboxy, esterified carboxy and amidated carboxy, m is 0, 1, 2, 3, or 4, provided that m is not more than 2 unless R.sup.1 is exclusively halo, x+y=0 or 1, R.sup.2 and R.sup.4 independently are II, or C.sub.1 to C.sub.3 alkyl, R.sup.3 is H or C.sub.1 to C.sub.15 hydrocarbyl, where one or more hydrogen atoms of die hydrocarbyl group may be replaced by a halogen atom, and where up to two of the carbon atoms may be replaced by a nitrogen, oxygen or sulphur atom, provided that R.sup.3 does not contain a --O--O-- group, R.sup.5 is H or C.sub.1 to C.sub.3 alkyl, U is a cyclic moiety, selected from the group consisting of aryl, aromatic heterocyclic, non-aromatic heterocyclic, and cycloalkyl groups, where the aryl or aromatic group contains up to 3 substituents selected from the group consisting of halo, amino, nitro, cyano, sulphamoyl, sulphonyl, trifluoromethyl, C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 alkylamino, C.sub.1 to C.sub.3 dialkylamino, phenyl, C.sub.1 to C.sub.3 alkoxy, hydroxy, esterified hydroxy, C.sub.1 to C.sub.3 hydroxyalkyl, C.sub.1 to C.sub.3 alkylcarboxyamino, carboxy, esterified carboxy and amidated carboxy, Z is a group of the formula (IIa) or (IIb) where R.sup.6 is H or C.sub.1 to C.sub.3 alkyl, X is --CO.sub.2 H, esterified carboxy, amidated carboxy, tetrazolyl, hydroxy, cyano, amidino, --CH.sub.2 OH, --SO.sub.2 NHCOR.sup.7, --SONHCOR.sup.7, --COR.sup.7, --NHSO.sub.2 R.sup.7, --CONHSO.sub.2 R.sup.7,--NHCOR.sup.7 or --SO.sub.2 NHR.sup.8, where R.sup.7 is C.sub.1 to C.sub.6, alkyl, C.sub.1 to C.sub.6 aryl or substituted aryl, and R.sup.8 is --OH, --CN, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 haloalkyl, aryl or substituted aryl, Y is H or a group selected from those recited above for X, and a is 0, 1, or 2. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:96388 USPATFULL
TITLE: CCK and gastrin receptor ligands
INVENTOR(S): Kalindjian, Sarkis Barret, Banstead, United Kingdom
Steel, Katherine Isobel Mary, Beckenham, United Kingdom
Dunstone, David John, London, United Kingdom
Buck, Ildiko Maria, London, United Kingdom
PATENT ASSIGNEE(S): James Black Foundation Limited, London, United Kingdom

(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5939437		19990817	
	WO 9530647		19951116	
APPLICATION INFO.:	US 1996-737317		19961220	(8)
	WO 1995-GB997		19950502	
			19961220	PCT 371 date
			19961220	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-9150	19940509

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1129
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **174604-24-1P**
(prepn. of amide group-contg. cholecystokinin and gastrin receptor antagonists)
RN 174604-24-1 USPATFULL
CN 1,3-Benzenedicarboxylic acid, 5-[[1-oxo-3-phenyl-2-[[[3-[[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]carbonyl]-2-pyridinyl]carbonyl]amino]propyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 11 OF 23 USPATFULL
AB The present invention provides a pyridine-2,3-dicarboxylic acid diamide derivatives represented by the following formula (I) and herbicides containing them as an active ingredient. ##STR1## [wherein R.sub.1 represents one to three substituents such as H, halogen, cyano, nitro, (halo)alkyl, (halo)alkoxy, (halo)alkylthio, (C.sub.3-6)cycloalkyl, alkenyl, alkynyl, substituted phenyl, substituted phenoxy, etc. and R.sub.1 may represent alkylene or alkenylene together with an adjacent carbon atom; R.sub.2 represents H, halogen, cyano, nitro, (halo)alkyl or (halo)alkoxy; R.sub.3 represents H or alkyl; R.sub.4 and R.sub.5 each represent H, (halo)alkyl, cycloalkyl, substituted cycloalkylalkyl, etc.; and n represents an integer of 0 or 1].

The present compounds exhibit excellent effect for controlling paddy field weeds and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:150872 USPATFULL
TITLE:	Pryidine-2,3-dicarboxylic acid diamide derivatives and herbicides comprising said derivatives as active ingredient
INVENTOR(S):	Tonishi, Masanori, Sakai, Japan Katsuhira, Takeshi, Kawachinagano, Japan Ohtsuka, Takashi, Tondabayashi, Japan Miura, Yuzo, Tondabayashi, Japan
PATENT ASSIGNEE(S):	Nihon Nohyaku Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843868		19981201
APPLICATION INFO.:	US 1997-825642		19970401 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-104580	19960402

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Fan, Jane
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
LINE COUNT:	1833

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **197918-60-8P**
(prepn. of pyridine-2,3-dicarboxamides as herbicides)

RN 197918-60-8 USPATFULL

CN 2,3-Pyridinedicarboxamide, N2-cyclopentyl-N3-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 23 USPATFULL

AB A compound of formula I ##STR1## X is O or S; A is 6-alkoxy-3-pyridyl optionally substituted by halogen;

Y is hydrogen or alkyl;

R.sup.3 is alkyl or a metal salt complex thereof. This invention contains fungicidal compositions and are used to combat cytopathogenic

fungi.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:57948 USPATFULL
TITLE:	Anilide derivatives as fungicides
INVENTOR(S):	Riordan, Peter Dominic, Dunmow, England Osbourn, Susan Elizabeth, Cambridge, England Boddy, Ian Kenneth, Hamilton, New Zealand
PATENT ASSIGNEE(S):	Agrevo UK Limited, Cambridge, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5756524		19980526	
	WO 9525723		19950928	
APPLICATION INFO.:	US 1996-714149		19960918	(8)
	WO 1995-GB570		19950316	
			19960918	PCT 371 date
			19960918	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-5347	19940318

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Rotman, Alan L.
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP
NUMBER OF CLAIMS:	17
EXEMPLARY CLAIM:	1
LINE COUNT:	821

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **173056-91-2P**
(prepn. of anilide derivs. as fungicides)

RN 173056-91-2 USPATFULL

CN Benzoic acid, 2,2'-[2,5-pyridinediylbis(carbonylimino)]bis-, dimethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 23 USPATFULL

AB Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure ##STR1## wherein Z, X.sup.1, X.sup.2, x and R.sup.5 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:9505 USPATFULL
TITLE:	Inhibitors of microsomal triglyceride transfer protein and method
INVENTOR(S):	Biller, Scott A., Hopewell, NJ, United States Dickson, John K., Eastampton, NJ, United States Lawrence, R. Michael, Yardley, PA, United States

Magnin, David R., Hamilton, NJ, United States
Poss, Michael A., Lawrenceville, NJ, United States
Robl, Jeffrey A., Newtown, PA, United States
Sulsky, Richard B., Franklin Park, NJ, United States
Tino, Joseph A., Lawrenceville, NJ, United States

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5712279		19980127
APPLICATION INFO.:	US 1996-548811		19960111 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-472067, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-391901, filed on 21 Feb 1995, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Wong, King Lit
LEGAL REPRESENTATIVE: Rodney, Burton
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 2204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **182431-37-4P**
(prepn. of 9-thioxanthenecarboxamides and 9-fluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein)

RN 182431-37-4 USPATFULL

CN 2,3-Pyridinedicarboxamide, N2-[1-[4-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-4-piperidinyl]-N3-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L5 ANSWER 14 OF 23 USPATFULL

AB The invention relates to pyridine-2,4- and -2,5-dicarboxylic acid derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X have the meanings given, a process for the preparation of these compounds and their use, in particular in medicaments for influencing the metabolism of collagen and collagen-like substances or the biosynthesis of Cl.sub.q.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:88994 USPATFULL

TITLE: Pharmaceutical use of pyridine-2,4- and -2,5-dicarboxylic acid amides

INVENTOR(S): Bickel, Martin, Bad Homburg, Germany, Federal Republic of
Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of
Burghard, Harald, Schmitten, Germany, Federal Republic of
Gunzler, Volkmar, Marburg-Cappel, Germany, Federal Republic of
Henke, Stephan, Bad Soden am Taunus, Germany, Federal Republic of
Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of
Mohr, Jurgen, Grunstadt, Germany, Federal Republic of
Tschank, Georg, Mainz, Germany, Federal Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5672614		19970930
APPLICATION INFO.:	US 1995-482815		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-367770, filed on 3 Jan 1995, now patented, Pat. No. US 5512586 which is a continuation of Ser. No. US 1993-66922, filed on 25 May 1993, now abandoned which is a continuation of Ser. No. US 1992-906676, filed on 30 Jun 1992, now abandoned which is a division of Ser. No. US 1991-726727, filed on 1 Jul 1991, now patented, Pat. No. US 5153208 which is a continuation of Ser. No. US 1989-434309, filed on 13 Nov 1989, now abandoned which is a continuation of Ser. No. US 1988-153087, filed on 8 Feb 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703959	19870210

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 916

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **117517-24-5P**
(prepn. of, as collagen formation -inhibiting drug)
RN 117517-24-5 USPATFULL
CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 23 USPATFULL
AB Oligopeptide antiretroviral agents are represented by formula (I), wherein A is a moiety bearing a positive charge and of a size which avoids steric inhibition of binding of said compound to nucleic acid sequences associated with the cellular activity of retroviruses; R.sub.1 is a moiety derived from a dicarboxylic acid; Hew is a five-membered heterocyclic moiety; y and z are independently 0, 1, 2 or 3; and x is 0 or 1. These compounds exhibit antiretroviral activity, especially against Human Immunodeficiency Virus (HIV). ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:27193 USPATFULL
TITLE: Oligopeptide antiretroviral agents
INVENTOR(S): Lown, J. William, Edmonton, Canada
Micetich, Ronald G., Sherwood Park, Canada
PATENT ASSIGNEE(S): Synphar Laboratories, Inc., Alberta, Canada (non-U.S. corporation)
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5616606		19970401
APPLICATION INFO.:	US 1995-510333		19950802 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-102715, filed on 6 Aug 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bond, Robert T.
LEGAL REPRESENTATIVE: Nikaido, Marmelstein, Murray & Oram LLP
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1,21
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 2157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **142482-41-5P**
(prepn. of lexitropsin and distamycin analogs and related compds. as antiretroviral agents)
RN 142482-41-5 USPATFULL
CN 2,5-Pyridinedicarboxamide, N,N'-bis[5-[[[5-[[[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl

PAGE 1-B



PAGE 1-C



L5 ANSWER 16 OF 23 USPATFULL

AB The invention relates to pyridine-2,4- and -2,5-dicarboxylic acid derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2, 3.sup.3, R.sup.4 and X have the meanings given, a process for the preparation of these compounds and their use, in particular in medicaments for influencing the metabolism of collagen and collagen-like substances or the biosynthesis of Cl.sub.q.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:36582 USPATFULL

TITLE: Medicaments based on pyridine-2,4- and 2,5-dicarboxylic acid amides

INVENTOR(S): Bickel, Martin, Bad Homburg, Germany, Federal Republic of

Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of
Burghard, Harald, Schmitten, Germany, Federal Republic of
Gunzler, Volkmar, Marburg-Cappel, Germany, Federal Republic of
Henke, Stephan, Bad Soden am Taunus, Germany, Federal Republic of
Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of
Mohr, Jurgen, Grunstadt, Germany, Federal Republic of
Tschank, Georg, Mainz, Germany, Federal Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5512586		19960430
APPLICATION INFO.:	US 1995-367770		19950103 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-66922, filed on 25 May 1993, now abandoned which is a continuation of Ser. No. US 1992-906676, filed on 30 Jun 1992, now abandoned which is a division of Ser. No. US 1991-726727, filed on 1 Jul 1991, now patented, Pat. No. US 5153208, issued on 6 Oct 1992 which is a continuation of Ser. No. US 1989-434309, filed on 13 Nov 1989, now abandoned which is a continuation of Ser. No. US 1988-153087, filed on 8 Feb 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703959	19870210

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **117517-24-5P**
(prepn. of, as collagen formation -inhibiting drug)
RN 117517-24-5 USPATFULL
CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 23 USPATFULL
AB 2,4- and 2,5-substituted pyridine-N-oxides are provided which are effective as fibrosuppressives and immunosuppressives. Said compounds

are also suitable for the treatment of disorders of the metabolism of collagen and collagen-like substances or the biosynthesis of Clq.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	93:93813 USPATFULL
TITLE:	2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
INVENTOR(S):	Baader, Ekkehard, Konigstein/Taunus, Germany, Federal Republic of Bickel, Martin, Bad Homburg, Germany, Federal Republic of Gunzler-Pukall, Volkmar, Marburg, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5260323		19931109
APPLICATION INFO.:	US 1992-978467		19921119 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-721681, filed on 26 Jun 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1990-4020570	19900628

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Richter, Johann
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
LINE COUNT:	605

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **139994-20-0**
(N-oxidn. of, by chloroperbenzoic acid, in prepn. of fibrosuppressive and immunosuppressive agents)

RN 139994-20-0 USPATFULL

CN 2,4-Pyridinedicarboxamide, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 23 USPATFULL

AB The invention relates to pyridine-2,4- and -2,5-dicarboxylic acid derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X have the meanings given, a process for the preparation of these compounds and their use, in particular in medicaments for influencing the metabolism of collagen and collagen-like

substances or the biosynthesis of Cl.sub.q.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	92:82789 USPATFULL
TITLE:	Pyridine-2,4- and -2,5-dicarboxylic acid amides and their medicinal compositions and methods of use
INVENTOR(S):	Bickel, Martin, Bad Homburg, Germany, Federal Republic of Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of Burghard, Harald, Schmitten, Germany, Federal Republic of Gunzler, Volkmar, Marburg-Cappel, Germany, Federal Republic of Henke, Stephan, Bad Soden am Taunus, Germany, Federal Republic of Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of Mohr, Jurgen, Grunstadt, Germany, Federal Republic of Tschank, Georg, Mainz, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5153208		19921006
APPLICATION INFO.:	US 1991-726727		19910701 (7)
DISCLAIMER DATE:	20080806		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-434309, filed on 13 Nov 1989, now abandoned which is a continuation of Ser. No. US 1988-153087, filed on 8 Feb 1988, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703959	19870210

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Dentz, Bernard
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett and Dunner
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
LINE COUNT:	763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **117517-24-5P**
(prepn. of, as collagen formation -inhibiting drug)

RN 117517-24-5 USPATFULL

CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 19 OF 23 USPATFULL

AB Cephalosporin antibiotics having a 3-position substituent of the formula:

--CH.sub.2 NR.sup.1 --Y--A--Z--Q

are described, wherein R.sup.1 is hydrogen or certain optionally substituted alkyl groups; Y is --CO-- or --SO.sub.2 --; A is optionally substituted phenylene or heterocyclylene; Z is a linking group and Q is a catechol or related ring system. Processes for their preparation and use are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 92:78992 USPATFULL
TITLE: Intermediates for cephalosporin compounds
INVENTOR(S): Davies, Gareth M., Macclesfield, England
Strawson, Colin J., Congleton, England
Lohmann, Jean J., Hermonville, France
PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, London, England (non-U.S. corporation)
ICI Pharma, Cergey Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5149803		19920922
APPLICATION INFO.:	US 1991-732478		19910718 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-349662, filed on 10 May 1989, now patented, Pat. No. US 5055462, issued on 8 Oct 1991

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1988-11055	19880510

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rizzo, Nicholas S.
LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1120

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **127431-47-4P**
(prepn. of, as antibiotic)
RN 127431-47-4 USPATFULL
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-2-[(1-carboxy-1-methylethoxy)imino]ethyl]amino]-3-[[[[6-[[[3,4-bis(acetyloxy)phenyl]amino]carbonyl]-3-pyridinyl]carbonyl]amino]methyl]-8-oxo-, [6R-[6.alpha.,7.beta.(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L5 ANSWER 20 OF 23 USPATFULL

AB Cephalosporin antibiotics having a 3-position substituent of the formula:

--CH.sub.2 NR.sup.1 --Y--A--Z--Q

are described, wherein R.sup.1 is hydrogen or certain optionally substituted alkyl groups; Y is --CO-- or --SO.sub.2 --; A is optionally substituted phenylene or heterocyclylene; Z is a linking group and Q is a catechol or related ring system. Processes for their preparation and use are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 91:82210 USPATFULL
TITLE: Cephalosporin compounds
INVENTOR(S): Davies, Gareth M., Macclesfield, England
Strawson, Colin J., Congleton, England
Lohmann, Jean J., Hermonville, France
PATENT ASSIGNEE(S): Imperial Chemical Industries plc, London, England (non-U.S. corporation)
ICI Pharma, Cergy Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5055462		19911008	
APPLICATION INFO.:	US 1989-349662		19890510	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1988-11055	19880510

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rizzo, Nicholas S.
LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1

LINE COUNT: 1181
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **127431-47-4P**
(prepn. of, as antibiotic)
RN 127431-47-4 USPATFULL
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-2-[(1-carboxy-1-methylethoxy)imino]ethyl]amino]-3-[[[[6-[[[3,4-bis(acetyloxy)phenyl]amino]carbonyl]-3-pyridinyl]carbonyl]amino]methyl]-8-oxo-, [6R-[6.alpha.,7.beta.(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L5 ANSWER 21 OF 23 USPATFULL
AB The invention relates to pyridine-2,4- and -2,5-dicarboxylic acid derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X have the meanings given, a process for the preparation of these compounds and their use, in particular in medicaments for influencing the metabolism of collagen and collagne-like substances or the biosynthesis of Cl.sub.q.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 91:62801 USPATFULL
TITLE: Pyridine-2,4-and -2,5-dicarboxylic acid amides and medicaments based on these compounds
INVENTOR(S): Bickel, Martin, Bad Homburg, Germany, Federal Republic of
Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of
Burghard, Harald, Schmitten, Germany, Federal Republic of
Gunzler, Volkmar, Marburg-Cappel, Germany, Federal Republic of
Henke, Stephan, Bad Soden am Taunus, Germany, Federal Republic of

Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of
Mohr, Jurgen, Grunstadt, Germany, Federal Republic of
Tschank, Georg, Mainz, Germany, Federal Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5037839		19910806
APPLICATION INFO.:	US 1989-434402		19891113 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1988-153087, filed on 8 Feb 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703959	19870210

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard I.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett and Dunner
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **117517-24-5P**
(prepn. of, as collagen formation -inhibiting drug)
RN 117517-24-5 USPATFULL
CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 22 OF 23 USPATFULL
AB Pyridine-2,4- and 2,5-dicarboxylic acid derivatives, a process for their preparation, the use thereof, and medicaments based on these compounds.

The invention relates to pyridine-2,4- and -2,5-dicarboxylic acid derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2 and X have the indicated meanings, to a process for the preparation of these compounds, and to their use, in particular in medicaments for influencing the metabolism of collagen and collagen-like substances and the biosynthesis of C1q.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 90:85607 USPATFULL
TITLE: Pyridine-2,4- and 2,5-dicarboxylic acid derivatives, a process for their preparation, the use thereof, and medicaments based on these compounds
INVENTOR(S): Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of
Burghard, Harald, Schmitten, Germany, Federal Republic

of
Gunzler, Volkmar, Marburg-Cappel, Germany, Federal Republic of
Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4968670		19901106
APPLICATION INFO.:	US 1988-153440		19880208 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703962	19870210

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ford, John M.
ASSISTANT EXAMINER: Richter, J.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett, and Dunner
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,3
LINE COUNT: 358
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **117319-49-0P**
(prepn. of, as immunosuppressant and fibrosuppressant)
RN 117319-49-0 USPATFULL
CN L-Tryptophan, N,N'-(2,4-pyridinediyldicarbonyl)bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 23 OF 23 USPATFULL
AB Polyazo dyestuffs of the formula

A--N=N--M--D--M'--N=N--A'

wherein A and A' each represents a 2(8)-amino-8(2)-hydroxynaphthalene radical further substituted with a sulphonic acid group, M and M' each represents a substituted 1,4- or 1,3-phenylene radical and D represents an organic radical bonded in the manner of an amide to M and M', said dyestuffs containing at least two sulphonic acid groups in the molecule, as well as photographic material containing in at least one layer a

polyazo dyestuff of the above formula are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	76:877 USPATFULL
TITLE:	Heterocyclic containing disazo compounds
INVENTOR(S):	Lenoir, John, Marly-le-Petit, Switzerland Tschopp, Paul, Marly-le-Petit, Switzerland Loeffel, Hansrolf, Bern, Switzerland DE Montmollin: Rene, Riehen, Switzerland
PATENT ASSIGNEE(S):	Ciba-Geigy AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3931142		19760106
APPLICATION INFO.:	US 1973-408769		19731023 (5)

RELATED APPLN. INFO.: Division of Ser. No. US 1971-183244, filed on 23 Sep 1971, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Warren, Charles F.
LEGAL REPRESENTATIVE:	Kolodny, Joseph G., Roberts, Edward McC., Almaula, Prabodh I.
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
LINE COUNT:	856

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **37410-45-0P**
(prepn. and absorption max. of)

RN 37410-45-0 USPATFULL

CN 2-Naphthalenesulfonic acid, 5,5'-[2,5-pyridinediylbis[carbonylimino[2-(aminosulfonyl)-4,1-phenylene]azo]]bis[6-amino-4-hydroxy- (9CI) (CA INDEX NAME)



```
=> s us6472349/pn
L6            1 US6472349/PN

=> d bib abs

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS
AN   2000:707145  CAPLUS
DN   133:266737
TI   Preparation of pyridine-2,3-dicarboxylic acid diamides as herbicides,
     desiccants, and defoliants.
IN   Hamprecht, Gerhard; Menges, Markus; Menke, Olaf; Reinhard, Robert;
     Sagasser, Ingo; Zagar, Cyrill; Westphalen, Karl-Otto; Otten, Martina;
     Walter, Helmut
PA   BASF Aktiengesellschaft, Germany
SO   PCT Int. Appl., 127 pp.
     CODEN: PIXXD2
DT   Patent
LA   German
FAN.CNT 2
     PATENT NO.         KIND  DATE           APPLICATION NO.   DATE
     ---------------    ----  --------       ---------------   --------
PI   WO 2000058288      A1    20001005       WO 2000-EP2899    20000331
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1165515          A1    20020102       EP 2000-925152    20000331
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     BR 2000009410       A     20020213       BR 2000-9410      20000331
     JP 2002540193       T2    20021126       JP 2000-607991    20000331
     US 6472349          B1    20021029       US 2001-937843    20010928 <--
PRAI DE 1999-19914721    A     19990331
     WO 2000-EP2899      W     20000331
OS   MARPAT 133:266737
GI
```



I

AB Title compds. [I; R1 = halo, cyano, NO2, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, halloalkylthio, alkenyl, haloalkenyl, alkynyl, haloalkynyl, amino, alkylcarbonyl, cycloalkyl, alkylsulfonyl, etc.; Q = (substituted) Ph, naphthyl, tetralinyl, quinolyl, isoquinolyl, etc.; R5 = H, alkyl, alkoxy; R6 = H, alkyl, haloalkyl, cyanoalkyl, cycloalkenyl, substituted cycloalkyl, etc.; m = 0, 1; n = 0-3], were prepd. Thus, N-(2-methyl-3-methylthiophenyl)-6-methylpyridine-2,3-dicarboximide (prepn. given) was stirred 22 h with PrNH2 in ClCH2CH2Cl to give 3-(2-methyl-3-methylthiophenyl)aminocarbonyl-6-methylpyridin-2-carboxylic acid N-propylamide. Several I at 0.5 kg/ha postemergent gave 100% control of barnyard grass.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l11 bib abs hitstr 1-2

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1992:214352 CAPLUS
DN 116:214352
TI Preparation of 2,4- and 2,5-substituted pyridine N-oxides as fibrosuppressive and immunosuppressive agents
IN Baader, Ekkehard; Bickel, Martin; Guenzler-Pukall, Volkmar
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 463592	A1	19920102	EP 1991-110343	19910622
	EP 463592	B1	19940817		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 4020570	A1	19920102	DE 1990-4020570	19900628
	ES 2061118	T3	19941201	ES 1991-110343	19910622
	FI 9103118	A	19911229	FI 1991-3118	19910626
	FI 101070	B	19980415		
	IL 98629	A1	19960514	IL 1991-98629	19910626
	CZ 283782	B6	19980617	CZ 1991-1959	19910626
	CA 2045868	AA	19911229	CA 1991-2045868	19910627
	NO 9102541	A	19911230	NO 1991-2541	19910627
	NO 178026	B	19951002		
	NO 178026	C	19960110		
	AU 9179356	A1	19920102	AU 1991-79356	19910627
	AU 636990	B2	19930513		
	CN 1057649	A	19920108	CN 1991-104308	19910627
	CN 1038585	B	19980603		
	BR 9102699	A	19920204	BR 1991-2699	19910627
	ZA 9104958	A	19920325	ZA 1991-4958	19910627
	HU 59104	A2	19920428	HU 1991-2158	19910627
	HU 214627	B	19980428		
	JP 04230264	A2	19920819	JP 1991-156562	19910627
	JP 08032687	B4	19960329		
→	US 5260323	A	19931109	US 1992-978467	19921119
	LV 10431	B	19960220	LV 1993-284	19930504
	LT 3918	B	19960425	LT 1993-1464	19931112
PRAI	DE 1990-4020570		19900628		
	US 1991-721681		19910626		

OS MARPAT 116:214352
GI



AB Title compds. I [R1 = COXR3; X = O, NR; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R = R3 or NRR3 = Q; n = 1-3; A = O, S, CH2, NR7; R7 = H, (substituted) Ph, alkyl, alkenyl, alkynyl, alkoxycarbonyl, cycloalkyl; R2 = COXR3; with provisos] were prepd. as proline- and lysine hydroxylase inhibitors useful as

fibrosuppressive and immunosuppressive agents. Thus, N-oxidn. of 1 g bis[N,N'-2-methoxyethyl)pyridine-2,4-dicarboxamide by 0.62 g m-chloroperbenzoic acid gave 620 mg of the bis(N,N'-2-methoxyethyl)pyridine-2,4-dicarboxamide N-oxide (II). II was tested as a proline hydroxylase inhibitor.

IT **139994-20-0 139994-21-1 139994-22-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-oxidn. of, by chloroperbenzoic acid, in prepn. of fibrosuppressive and immunosuppressive agents)

RN 139994-20-0 . CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



RN 139994-21-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139994-22-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



IT **139994-11-9P 139994-12-0P 139994-13-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as fibrosuppressive and immunosuppressive agent)
RN 139994-11-9 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-dicyclohexyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 139994-12-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-chlorophenyl)methyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 139994-13-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-methylphenyl)methyl]-, 1-oxide (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1960:56555 CAPLUS
DN 54:56555
OREF 54:11057e-i,11058a
TI Condensation of pyridinedicarboxylic acids with aminoanthraquinones
IN Pizzarello, Roy A.; Resnick, Paul; Schneid, Alfred F.
PA Interchemical Corp.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2925421		19600216	US	

GI For diagram(s), see printed CA Issue.
AB The prepn. of the condensation products of 1 mole of a pyridinedicarbonyl chloride and 2 moles of a 1-aminoanthraquinone for use as pigments for textile coloring was described. Thus, 250 ml. o-C6H4Cl2, 20 g.

2,3-pyridinedicarboxylic acid, and 37 ml. SOCl2 was heated 48 hrs. at 100.degree., excess SOCl2 distd. at 160.degree. and the soln. of 2,3-pyridinedicarbonyl chloride (I) cooled to 100.degree. clarified with C and filter-cel, and divided into 2 parts. One part of I and 18.5 g. 1-aminoanthraquinone (II) was heated 3 hrs. at 150.degree., cooled, treated with 0.5 l. Me2CO, filtered, washed with Me2CO until the washings were colorless, and dried overnight at 60.degree. to give 16 g. yellow N:C(CONHR).C(CONHR:CH.CH:CH (III) (R = 1-anthraquinonylamino). Similarly prepd. from I and 1-amino-4-methoxyanthraquinone (IV) was III (R = 4-methoxy-1-anthraquinonylamino). From I and 1-amino-5-chloroanthraquinone, III (R = 5-chloro-1-anthraquinonylamino) was prepd. 2,5-Pyridinedicarbonyl chloride reacted with II, 1-amino-8-chloroanthraquinone, 1-amino-4-benzamidoanthraquinone (V), and IV to give N:C(CONHR).CH:CH.C(CONHR):CH (R = 1-anthraquinonylamino), and the 8-chloro, 4-benzamido, and 4-methoxy derivs., resp. The condensation of 3,4-pyridinedicarbonyl chloride with II, V, and IV yielded N:CH.C(CONHR):C(CONHR).CH:CH (R = 1-anthraquinonylamino), and the 4-benzamido, and 4-methoxy derivs., resp. The reaction of 2,4-pyridinedicarbonyl chloride with II, 1-amino-4-benzamidoanthraquinone (VI), and 1-amino-4-chloroanthraquinone yielded N:C(CONHR).CH:C(CONHR).CH:CH (R = 1-anthraquinonylamino), and the 4-benzamido and 4-chloro derivs. II, VI, and IV with 2,6-pyridinedicarbonyl chloride gave N:C(CONHR).CH:CH.CH:C(CONHR) (R = 1-anthraquinonylamino), and the 4-benzamido and 4-methoxy derivs., resp.

IT **3587-92-6**, 2,3-Pyridinedicarboxamide, N,N'-di-1-anthraquinonyl- **117874-73-4**, 2,5-Pyridinedicarboxamide, N,N'-bis(8-chloro-1-anthraquinonyl)- **117874-74-5**, 2,3-Pyridinedicarboxamide, N,N'-bis(5-chloro-1-anthraquinonyl)- **117874-77-8**, **2,4-Pyridinedicarboxamide**, N,N'-di-1-anthraquinonyl- **117874-78-9**, 2,5-Pyridinedicarboxamide, N,N'-di-1-anthraquinonyl- **117875-00-0**, **2,4-Pyridinedicarboxamide**, N,N'-bis(4-chloro-1-anthraquinonyl)- **119393-73-6**, 2,3-Pyridinedicarboxamide, N,N'-bis(4-methoxy-1-anthraquinonyl)- **119393-74-7**, 2,5-Pyridinedicarboxamide, N,N'-bis(4-methoxy-1-anthraquinonyl)- **119925-17-6**, 2,5-Pyridinedicarboxamide, N,N'-bis(4-benzamido-1-anthraquinonyl)- **119925-49-4**, **2,4-Pyridinedicarboxamide**, N,N'-bis(4-benzamido-1-anthraquinonyl)-
(prepn. of)

RN 3587-92-6 CAPLUS

CN 2,3-Pyridinedicarboxamide, N,N'-di-1-anthraquinonyl- (6CI, 7CI, 8CI) (CA INDEX NAME)





RN 117874-73-4 CAPLUS
CN 2,5-Pyridinedicarboxamide, N,N'-bis(8-chloro-1-anthraquinonyl)- (6CI) (CA INDEX NAME)



RN 117874-74-5 CAPLUS
CN 2,3-Pyridinedicarboxamide, N,N'-bis(5-chloro-1-anthraquinonyl)- (6CI) (CA INDEX NAME)



RN 117874-77-8 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-di-1-anthraquinonyl- (6CI) (CA INDEX NAME)



RN 117874-78-9 CAPLUS
CN 2,5-Pyridinedicarboxamide, N,N'-di-1-anthraquinonyl- (6CI) (CA INDEX NAME)



RN 117875-00-0 CAPLUS

CN 2,4-Pyridinedicarboxamide, N,N'-bis(4-chloro-1-anthraquinonyl)- (6CI) (CA INDEX NAME)



RN 119393-73-6 CAPLUS
CN 2,3-Pyridinedicarboxamide, N,N'-bis(4-methoxy-1-anthraquinonyl)- (6CI) (CA INDEX NAME)



RN 119393-74-7 CAPLUS
CN 2,5-Pyridinedicarboxamide, N,N'-bis(4-methoxy-1-anthraquinonyl)- (6CI) (CA INDEX NAME)



RN 119925-17-6 CAPLUS
CN 2,5-Pyridinedicarboxamide, N,N'-bis(4-benzamido-1-anthraquinonyl)- (6CI) (CA INDEX NAME)



RN 119925-49-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(4-benzamido-1-anthraquinonyl)- (6CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=>

C:\Program Files\Stnexp\Queries\0071073.str





chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6
chain bonds :
2-8 6-7 7-9 7-10 8-11 8-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-9 7-10 8-11 8-12
exact bonds :
2-8 6-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:O,S

G2:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS

=> d l10 abs ibib fhitstr 1-22

L10 ANSWER 1 OF 22 USPATFULL

AB There is disclosed a genus of compounds and pharmaceutical compositions that are protective for mitigating damage associated with tissue ischemia, particularly stroke (CNS ischemia), and ischemia of the myocardium. The present invention further provides a method for treating tissue damage caused by ischemia. Lastly, the present invention provides a method for treating tissue damage caused by providing a compound that inhibits the cytotoxic activity of 3-aminopropanal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:338045 USPATFULL

TITLE: Compounds and compositions for treating tissue ischemia

INVENTOR(S): Tracey, Kevin J., Old Greenwich, CT, UNITED STATES
Al-Abed, Yousef, New York, NY, UNITED STATES
Ivanova, Svetlana, Astoria, NY, UNITED STATES
Bucala, Richard J., Cos Cob, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193412	A1	20021219
APPLICATION INFO.:	US 2002-140856	A1	20020507 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-118388, filed on 17 Jul 1998, GRANTED, Pat. No. US 6391899

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Elie H. Gendloff, Amster, Rothstein & Ebenstein, 90 Park Avenue, New York, NY, 10016

NUMBER OF CLAIMS: 27

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 1819

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **256337-80-1**
(drug treatment of cerebral and myocardial ischemia and detn. of 3-aminopropanal in brain ischemia tissues by HPLC)

RN 256337-80-1 USPATFULL

CN Pyridinium, 2,4-dicarboxy-1-(2-oxo-2-phenylethyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

L10 ANSWER 2 OF 22 USPATFULL

AB Selective **MMP**-13 inhibitors are pyridine derivatives of the formula ##STR1##

or a pharmaceutically acceptable salt thereof,

wherein:

R.sup.1 and R.sup.2 independently are hydrogen, halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, NO.sup.2, NR.sup.4R.sup.5, CN, or CF.sub.3,

E is independently O or S;

A and B independently are OR.sup.4 or NR.sup.4R.sup.5;

R.sup.4 and R.sup.5 independently are H. C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, (CH.sub.2).sub.n aryl, (CH.sub.2).sub.n cycloalkyl, (CH.sub.2).sub.n heteroaryl, or R.sup.4 and R.sup.5 when taken together with the nitrogen to which they are attached complete a 3 to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted,

n is an integer of from 0 to 6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:288130 USPATFULL
TITLE: Pyridine matrix metalloproteinase inhibitors
INVENTOR(S): Barvian, Nicole Chantel, Ann Arbor, MI, UNITED STATES
Connor, David Thomas, Ann Arbor, MI, UNITED STATES
O'Brien, Patrick Michael, Stockbridge, MI, UNITED STATES
Ortwine, Daniel Fred, Saline, MI, UNITED STATES
Patt, William Chester, Chelsea, MI, UNITED STATES
Shuler, Kevon Ray, Chelsea, MI, UNITED STATES
Wilson, Michael William, Ann Arbor, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002161000	A1	20021031
APPLICATION INFO.:	US 2002-71073	A1	20020208 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-268781P	20010214 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Claude F. Purchase, Jr., Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 1991

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **449734-09-2P**, Pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)
(prepn. of pyridine-2,4-dicarboxamide and -dicarboxylic acid derivs. as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)

RN 449734-09-2 USPATFULL
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 USPATFULL

AB There is disclosed a genus of compounds and pharmaceutical compositions that are protective for mitigating damage associated with tissue ischemia, particularly stroke (CNS ischemia), and ischemia of the myocardium. The present invention further provides a method for treating tissue damage caused by ischemia. Lastly, the present invention provides a method for treating tissue damage caused by providing a compound that inhibits the cytotoxic activity of 3-aminopropanal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:116288 USPATFULL
TITLE:	Compounds and compositions for treating tissue ischemia
INVENTOR(S):	Tracey, Kevin J., Old Greenwich, CT, United States Al-Abed, Yousef, New York, NY, United States Ivanova, Svetlana, Astoria, NY, United States Bucala, Richard J., Cos Cob, CT, United States
PATENT ASSIGNEE(S):	North Shore--Long Island Jewish Research Institute, Manhasset, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391899	B1	20020521
APPLICATION INFO.:	US 1998-118388		19980717 (9)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Gerstl, Robert
LEGAL REPRESENTATIVE:	Amster, Rothstein & Ebenstein
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:	1786

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **256337-80-1**
(drug treatment of cerebral and myocardial ischemia and detn. of 3-aminopropanal in brain ischemia tissues by HPLC)

RN 256337-80-1 USPATFULL

CN Pyridinium, 2,4-dicarboxy-1-(2-oxo-2-phenylethyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

L10 ANSWER 4 OF 22 USPATFULL

AB The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): ##STR1##

Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:67203 USPATFULL
TITLE: Novel compounds possessing antibacterial, antifungal or antitumor activity
INVENTOR(S): Zhang, Wentao, Foster City, CA, UNITED STATES
Liehr, Sebastian Johannes Reinhard, East Palo Alto, CA, UNITED STATES
Velligan, Mark Douglas, Montara, CA, UNITED STATES
Dyatkina, Natalia B., Mountain View, CA, UNITED STATES
Botyanszki, Janos, Cupertino, CA, UNITED STATES
Shi, Dong-Fang, San Mateo, CA, UNITED STATES
Roberts, Christopher Don, Belmont, CA, UNITED STATES
Khorlin, Alexander, Mountain View, CA, UNITED STATES
Nelson, Peter Harold, Los Altos, CA, UNITED STATES
Muchowski, Joseph Martin, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002037856	A1	20020328	
APPLICATION INFO.:	US 2001-892327	A1	20010626	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214478P	20000627 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gerald F. Swiss, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 3872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **386251-16-7P**
(prepn. of novel compds. possessing antibacterial, antifungal or antitumor activity)
RN 386251-16-7 USPATFULL
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L10 ANSWER 5 OF 22 USPATFULL
AB Caprolactam inhibitors are provided which have the structure ##STR1##

including pharmaceutically acceptable salts thereof and all

stereoisomers thereof, and prodrugs thereof, wherein n is 1 to 5; and

and Y R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.5a, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:168117 USPATFULL			
TITLE:	Lactam inhibitors of FXa and method			
INVENTOR(S):	Stein, Philip D., Pennington, NJ, United States Bisacchi, Gregory S., Ringoes, NJ, United States Shi, Yan, Flourtown, PA, United States O'Connor, Stephen P., Lambertville, NJ, United States Li, Chi, Randolph, NJ, United States			
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6297233	B1	20011002	
APPLICATION INFO.:	US 2000-496571		20000202	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Kifle, Bruck			
LEGAL REPRESENTATIVE:	Rodney, Burton			
NUMBER OF CLAIMS:	18			
EXEMPLARY CLAIM:	1			
LINE COUNT:	4323			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **288083-76-1P**
(prepn. of caprolactams as Factor Xa inhibitors in prevention or treatment of thromboses, coronary artery disease, or cerebrovascular disease in mammals)

RN 288083-76-1 USPATFULL

CN 2-Pyridinecarboxylic acid, 4-[[[[[(3S)-hexahydro-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-azepin-3-yl]amino][(2-methyl-5-benzofuranyl)amino]methylene]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 22 USPATFULL

AB The invention relates to compounds of the formula (I), wherein R1, R2, R3, R4, R5 and n have the meanings cited in the description said compounds being new effective bronchial therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:37819 USPATFULL

TITLE: (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors

INVENTOR(S): Bar, Thomas, Constance, Germany, Federal Republic of
Ulrich, Wolf-Rudiger, Constance, Germany, Federal Republic of

PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6043263		20000328	
	WO 9821207		19980522	
APPLICATION INFO.:	US 1999-284989		19990512	(9)
	WO 1997-EP6131		19971105	
			19990522	PCT 371 date
			19990522	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19646503	19961112
	EP 1996-118414	19961116

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Jacobson, Price, Holman & Stern, PLLC
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1074

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **204075-07-0**, Ethyl 4-thioamidopyridine-2-carboxylate (for prepn. of (2,3-dihydrobenzofuranyl)thiazoles as phosphodiesterase inhibitors)

RN 204075-07-0 USPATFULL

CN 2-Pyridinecarboxylic acid, 4-(aminothioxomethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 7 OF 22 USPATFULL

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:159968 USPATFULL

TITLE: Substituted 3-aminoquinuclidines

INVENTOR(S): Ito, Fumitaka, Chita-Taketoyo, Japan
Kokura, Toshihide, Handa, Japan
Nakane, Masami, Showakyu, Japan
Satake, Kunio, Handa, Japan
Wakabayashi, Hiroaki, Kiriya, Japan

PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5852038		19981222
APPLICATION INFO.:	US 1996-950043		19961118 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-175353, filed on 20 Dec 1993, now patented, Pat. No. US 5716965

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1991-46826	19910522

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wu, Shean C.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Dryer, Mark
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 2341
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **24195-03-7P**
(prepn. and reaction of, in prepn. of substance P antagonists)
RN 24195-03-7 USPATFULL
CN 2,4-Pyridinedicarboxylic acid, 4-methyl ester (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 22 USPATFULL
AB Compounds of the formula ##STR1## wherein W, Ar.sup.1, Ar.sup.2 and Ar.sup.3 are defined as below; and the pharmaceutically acceptable salts of such compounds.

These compounds are substance P antagonists and useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:14812 USPATFULL
TITLE: Substituted 3-aminoquinuclidines
INVENTOR(S): Ito, Fumitaka, Chita-Taketoyo, Japan
Kokura, Toshihide, Handa, Japan
Nakane, Masami, Showakyu, Japan
Satake, Kunio, Handa, Japan
Wakabayashi, Hiroaki, Kiriya, Japan
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5716965		19980210	
	WO 9220676		19921126	
APPLICATION INFO.:	US 1993-175353		19931220	(8)
	WO 1992-US4002		19920519	
			19931220	PCT 371 date
			19931220	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1991-46826	19910522

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wu, Shean C.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., DeBenedicts, Karen
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 2436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **24195-03-7P**
(prepn. and reaction of, in prepn. of substance P antagonists)
RN 24195-03-7 USPATFULL
CN 2,4-Pyridinedicarboxylic acid, 4-methyl ester (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 22 USPATFULL
AB A thiazole derivative of the general formula: ##STR1## The thiazole derivatives have an excellent inhibitory activity for superoxide radical.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:52016 USPATFULL
TITLE: Thiazole derivatives
INVENTOR(S): Chihiro, Masatoshi, Naruto, Japan
Komatsu, Hajime, Tokyo, Japan
Tominaga, Michiaki, Itano-Gun, Japan
Yabuuchi, Yoichi, Tokushima, Japan
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5639770		19970617
APPLICATION INFO.:	US 1995-570187		19951211 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-182001, filed on 25 Jan 1994, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1992-138165	19920529

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 2397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **155467-98-4P**

(prepn. of, as active oxygen inhibitor)
RN 155467-98-4 USPATFULL
CN 2,4-Pyridinedicarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 22 USPATFULL
AB Compounds of formula I ##STR1## wherein A, X.sub.1, X.sub.2, X.sub.3, X.sub.4, Y, Z and R.sub.1 to R.sub.6 have the meanings given in the description, have valuable pharmaceutical properties and are effective especially against tumors. They are prepared in a manner known per se.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	94:113048 USPATFULL		
TITLE:	Arylhydrazones using as SAMDC inhibitors		
INVENTOR(S):	Stanek, Jaroslav, Arlesheim, Switzerland Caravatti, Giorgio, Allschwil, Switzerland Frei, Jorg, Holstein, Switzerland Capraro, Hans-Georg, Rheinfelden, Switzerland		
PATENT ASSIGNEE(S):	Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5376685		19941227
APPLICATION INFO.:	US 1993-58111		19930507 (8)
DISCLAIMER DATE:	20090602		
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-849262, filed on 11 Mar 1992, now patented, Pat. No. US 5238941 which is a continuation-in-part of Ser. No. US 1990-574991, filed on 29 Aug 1990, now patented, Pat. No. US 5118709 which is a division of Ser. No. US 1989-324368, filed on 15 Mar 1989, now patented, Pat. No. US 4971986		
	NUMBER		DATE
PRIORITY INFORMATION:	CH 1988-113988		19880325
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Morris, Patricia L.		
ASSISTANT EXAMINER:	Haley, Jacqueline		
LEGAL REPRESENTATIVE:	Fishman, Irving M., Kaiser, Karen G.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1401		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **126534-91-6P**
(prepn. and reaction of, in prepn. of S-adenosylmethioninedecarboxylase inhibitors)
RN 126534-91-6 USPATFULL
CN 2-Pyridinecarboximidic acid, 4-(diethoxymethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 11 OF 22 USPATFULL

AB Compounds of formula I ##STR1## wherein A, X.sub.1, X.sub.2, X.sub.3, X.sub.4, Y, Z and R.sub.1 to R.sub.6 have the meanings given in the description, have valuable pharmaceutical properties and are effective especially against tumours. They are prepared in a manner known per se.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	93:69869 USPATFULL
TITLE:	Arylhydrazones and pharmaceutical compositions thereof
INVENTOR(S):	Stanek, Jaroslav, Arlesheim, Switzerland Caravatti, Giorgio, Allschwil, Switzerland Frei, Jorg, Holstein, Switzerland Capraro, Hans-Georg, Rheinfelden, Switzerland
PATENT ASSIGNEE(S):	Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5238941		19930824
APPLICATION INFO.:	US 1992-849262		19920311 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-574991, filed on 29 Aug 1990, now patented, Pat. No. US 5118709 which is a division of Ser. No. US 1989-324368, filed on 15 Mar 1989, now patented, Pat. No. US 4971986		

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1988-1139	19880325

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Brust, Joseph Paul
ASSISTANT EXAMINER:	Haley, Jacqueline
LEGAL REPRESENTATIVE:	Fishman, Irving M., Kaiser, Karen G.
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
LINE COUNT:	1393

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **126534-91-6P**
(prepn. and reaction of, in prepn. of S-adenosylmethioninedecarboxylase inhibitors)

RN 126534-91-6 USPATFULL

CN 2-Pyridinecarboximidic acid, 4-(diethoxymethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 12 OF 22 USPATFULL

AB An antipruritic composition for an oral medicine, injection, and external medicine, comprising an effective amount of a chelated zinc (e.g., zinc picolinate) as an antipruritic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 93:48506 USPATFULL

TITLE: Antipruritic composition

INVENTOR(S): Taguchi, Shigeru, Yokohama, Japan
Suzuki, Takashi, Yokohama, Japan
Nishino, Chikao, Yokohama, Japan
Fujinuma, Yoshimori, Yokohama, Japan
Yanagawa, Chuji, Sagamihara, Japan
Yamaguchi, Michihiro, Yokohama, Japan
Yamato, Miwako, Yokohama, Japan
Nakajima, Noriko, Yokohama, Japan
Kitano, Mie, Yokohama, Japan
Okazaki, Tomomi, Yokohama, Japan
Uemura, Masaki, Yokohama, Japan
Inada, Ryuhei, Yokohama, Japan
Tonomura, Yoshiko, Yokohama, Japan
PATENT ASSIGNEE(S): Shiseido Company, Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5219847		19930615
APPLICATION INFO.:	US 1992-918800		19920727 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-640428, filed on 31 Jan 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1989-150291	19890612
	JP 1990-40522	19900220
	JP 1990-83619	19900330

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schenkman, Leonard
LEGAL REPRESENTATIVE: Wegner, Cantor, Mueller & Player
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 2080

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **499-80-9P**, 2,4-Pyridinedicarboxylic acid
(prepn. and reaction of, for antipruritic zinc chelate prepn.)

RN 499-80-9 USPATFULL

CN 2,4-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 13 OF 22 USPATFULL

AB Compounds of formula I ##STR1## wherein A, X.sub.1, X.sub.2, X.sub.3, X.sub.4, Y, Z and R.sub.1 to R.sub.6 have the meanings given in the description, have valuable pharmaceutical properties and are effective especially against tumours. They are prepared in a manner known per se.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	92:44852 USPATFULL
TITLE:	Arylhydrazones and pharmaceutical compositions containing the same
INVENTOR(S):	Stanek, Erfinders J., Arlesheim, Switzerland Caravatti, Giorgio, Allschwil, Switzerland Frei, Jorg, Holstein, Switzerland Capraro, Hans-Georg, Rheinfelden, Switzerland
PATENT ASSIGNEE(S):	Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5118709		19920602
APPLICATION INFO.:	US 1990-574991		19900829 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1989-324368, filed on 5 Mar 1989, now patented, Pat. No. US 4971986		

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1988-1139	19880325

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Morris, Patricia L.
ASSISTANT EXAMINER:	Haley, Jacqueline
LEGAL REPRESENTATIVE:	Fishman, Irving M., Kaiser, Karen G.
NUMBER OF CLAIMS:	17
EXEMPLARY CLAIM:	1
LINE COUNT:	1324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **126534-91-6P**
(prepn. and reaction of, in prepn. of S-adenosylmethioninedecarboxylase inhibitors)

RN 126534-91-6 USPATFULL

CN 2-Pyridinecarboximidic acid, 4-(diethoxymethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 14 OF 22 USPATFULL

AB Compounds of formula I ##STR1## wherein A, X.sub.1, X.sub.2, X.sub.3, X.sub.4, Y, Z and R.sub.1 to R.sub.6 have the meanings given in the description, have valuable pharmaceutical properties and are effective especially against tumors. They are prepared in a manner known per se.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 90:89309 USPATFULL

TITLE: Arylhydrazones useful as SAMDC inhibitors

INVENTOR(S): Stanek, Jaroslav, Arlesheim, Switzerland
Caravatti, Giorgio, Allschwil, Switzerland
Frei, Jorg, Holstein, Switzerland
Capraro, Hans-Georg, Rheinfelden, Switzerland

PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4971986		19901120	
APPLICATION INFO.:	US 1989-324368		19890315	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1988-1139	19880325

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lee, Mary C.
ASSISTANT EXAMINER: Haley, Jacqueline
LEGAL REPRESENTATIVE: Villamizar, JoAnn
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1,14
LINE COUNT: 1349

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **126534-91-6P**
(prepn. and reaction of, in prepn. of S-adenosylmethioninedecarboxylase inhibitors)

RN 126534-91-6 USPATFULL

CN 2-Pyridinecarboximidic acid, 4-(diethoxymethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 15 OF 22 USPATFULL

AB Compounds of the formula I ##STR1## wherein the groups A, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification, exhibit valuable pharmacological properties, especially as antifibrotic agents. They are prepared by methods known per se.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	90:15563 USPATFULL
TITLE:	Phamacologically active 5-carboxy-2-(5-tetrazolyl) pyridines
INVENTOR(S):	Winter-Mihaly, Eva, Bernex/Geneva, Switzerland Borel, Christian, La Plaine/Geneva, Switzerland Weith, Andre J., Signy, Switzerland
PATENT ASSIGNEE(S):	Zyma SA, Nyon, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4904675		19900227	
APPLICATION INFO.:	US 1988-154217		19880210	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1987-2890	19870210

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Lee, Mary C.
ASSISTANT EXAMINER:	Dentz, Beranrd I.
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
LINE COUNT:	1221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **499-80-9**, 2,5-Dicarboxypyridine
(condensation of, with Et bromoethoxyacetate)

RN 499-80-9 USPATFULL

CN 2,4-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 16 OF 22 USPATFULL

AB A compound of the formula ##STR1## wherein R.sub.1 is a hydrogen atom or a lower alkyl group which may be substituted with hydroxy, lower alkyl or di-lower alkylamino; R.sub.2 is a hydrogen atom, an amino group or a lower alkylamino group; and R.sub.3 is a lower alkyl group, and a non-toxic salt thereof, and a process for preparing the same are disclosed.

The compound and the salts thereof exhibit anti-allergic effects by the two different mechanisms and are expected to be useful as drugs for treating allergic diseases such as asthma, pollen allergy, atopic dermatitis and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 87:62101 USPATFULL

TITLE: Pyridine derivatives and their use as anti-allergic agents

INVENTOR(S): Mori, Takashi, Tokyo, Japan
Ohi, Nobuhiro, Tokyo, Japan
Ohsugi, Yoshiyuki, Tokyo, Japan
Yamashita, Yasuhiro, Tokyo, Japan

PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4691018		19870901
APPLICATION INFO.:	US 1986-860211		19860506 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1985-110642	19850523

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Richter, J.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 271

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **66066-74-8**, Triethyl pyridine-2,4,6-tricarboxylate
(amidation of, carbamoylpyridine carboxylate from)

RN 66066-74-8 USPATFULL

CN 2,4,6-Pyridinetricarboxylic acid, triethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 17 OF 22 USPATFULL

AB Mercaptoalkylpyridines carrying an ethenyl or ethynyl substituent are prepared from known pyridine compounds, principally pyridoxine, by known chemical procedures, and are useful in the treatment of

rheumatoid arthritis and related inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	85:59607 USPATFULL
TITLE:	Anti-inflammatory 2-methyl-3-hydroxy-4-alkenoylthiomethyl-5-vinyl-pyridine derivatives
INVENTOR(S):	Shen, Tsung-Ying, Westfield, NJ, United States Jones, Howard, Holmdel, NJ, United States Dorn, Conrad P., Plainfield, NJ, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4546106		19851008
APPLICATION INFO.:	US 1982-400848		19820722 (6)
DISCLAIMER DATE:	19960313		

RELATED APPLN. INFO.: Division of Ser. No. US 1980-172104, filed on 25 Jul 1980, now patented, Pat. No. US 4355034 which is a division of Ser. No. US 1979-10099, filed on 7 Feb 1979, now patented, Pat. No. US 4217352 which is a division of Ser. No. US 1977-842692, filed on 17 Oct 1977, now patented, Pat. No. US 4144342 which is a division of Ser. No. US 1976-706033, filed on 6 Jul 1976, now patented, Pat. No. US 4061759 which is a division of Ser. No. US 1975-578692, filed on 19 May 1975, now abandoned which is a continuation-in-part of Ser. No. US 1974-464011, filed on 26 Apr 1974, now abandoned which is a continuation-in-part of Ser. No. US 1973-368772, filed on 15 Jun 1973, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Rotman, Alan L.
LEGAL REPRESENTATIVE:	Cheng, Theresa Y., Monaco, Mario A.
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1,9
LINE COUNT:	2108

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **55273-36-4P**
(prepn. and redn. of)

RN 55273-36-4 USPATFULL

CN 3,4-Pyridinedicarboxylic acid, 6-(diethoxymethyl)-5-(hydroxymethyl)-, diethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 18 OF 22 USPATFULL

AB Mercaptoalkylpyridines carrying an ethenyl or ethynyl substituent are prepared from known pyridine compounds, principally pyridoxine, by known chemical procedures, and are useful in the treatment of **rheumatoid** arthritis and related inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 82:50823 USPATFULL
TITLE: Ethenyl derivatives of mercaptoalkylpyridines as anti-inflammatory agents
INVENTOR(S): Shen, Tsung-Ying, Westfield, NJ, United States
Jones, Howard, Holmdel, NJ, United States
Dorn, Conrad P., Plainfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4355034		19821019
APPLICATION INFO.:	US 1980-172104		19800725 (6)

RELATED APPLN. INFO.: Division of Ser. No. US 1979-10099, filed on 7 Feb 1979, now patented, Pat. No. US 4217352 which is a division of Ser. No. US 1977-842692, filed on 17 Oct 1977, now patented, Pat. No. US 4144342 which is a division of Ser. No. US 1976-706033, filed on 16 Jul 1976, now patented, Pat. No. US 4061759 which is a division of Ser. No. US 1975-578692, filed on 19 May 1975, now abandoned which is a continuation-in-part of Ser. No. US 1974-464011, filed on 26 Apr 1974, now abandoned which is a continuation-in-part of Ser. No. US 1973-368772, filed on 15 Jun 1973, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Cheng, Theresa Y., Speer, Raymond M., Monaco, Mario A.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1,7
LINE COUNT: 2137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **55273-36-4P**
(prepn. and redn. of)
RN 55273-36-4 USPATFULL
CN 3,4-Pyridinedicarboxylic acid, 6-(diethoxymethyl)-5-(hydroxymethyl)-, diethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 19 OF 22 USPATFULL
AB Mercaptoalkylpyridines carrying an ethenyl or ethynyl substituent are prepared from known pyridine compounds, principally pyridoxine, by known chemical procedures, and are useful in the treatment of **rheumatoid** arthritis and related inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 80:39356 USPATFULL
TITLE: Anti-inflammatory 4H-1,3-oxathiino(4,5-c)
INVENTOR(S): Shen, Tsung-Ying, Westfield, NJ, United States
Jones, Howard, Holmdel, NJ, United States

	Dorn, Conrad P., Plainfield, NJ, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 4217352	19800812
APPLICATION INFO.:	US 1979-10099	19790207 (6)

RELATED APPLN. INFO.: Division of Ser. No. US 1977-842692, filed on 17 Oct 1977, now patented, Pat. No. US 4144312 which is a division of Ser. No. US 1976-706033, filed on 16 Jul 1976, now patented, Pat. No. US 4061759 which is a division of Ser. No. US 1975-578692, filed on 19 May 1975, now abandoned which is a continuation-in-part of Ser. No. US 1974-464011, filed on 26 Apr 1974, now abandoned which is a continuation-in-part of Ser. No. US 1973-368772, filed on 15 Jun 1973, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Speer, Raymond M., Nicholson, William H., Westlake, Jr., Harry E.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1,2
LINE COUNT: 2046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **55273-36-4P**
(prepn. and redn. of)
RN 55273-36-4 USPATFULL
CN 3,4-Pyridinedicarboxylic acid, 6-(diethoxymethyl)-5-(hydroxymethyl)-, diethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 20 OF 22 USPATFULL
AB Mercaptoalkylpyridines carrying an ethenyl or ethynyl substituent are prepared from known pyridine compounds, principally pyridoxine, by known chemical procedures, and are useful in the treatment of **rheumatoid** arthritis and related inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 79:13154 USPATFULL
TITLE: 2-Methyl-3-hydroxy-4-alkanoylthiomethyl-5-vinylpyridines
INVENTOR(S): Shen, Tsung-Ying, Westfield, NJ, United States
Jones, Howard, Holmdel, NJ, United States
Dorn, Conrad P., Plainfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 4144342 19790313
APPLICATION INFO.: US 1977-842692 19771017 (5)
RELATED APPLN. INFO.: Division of Ser. No. US 1976-706033, filed on 16 Jul 1976, now patented, Pat. No. US 4061759 which is a division of Ser. No. US 1975-578692, filed on 19 May 1975, now abandoned which is a continuation-in-part of Ser. No. US 1974-464011, filed on 26 Apr 1974, now abandoned which is a continuation-in-part of Ser. No. US 1973-368772, filed on 15 Jun 1973, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Speer, Raymond M., Monaco, Mario A.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1,3
LINE COUNT: 2100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **55273-36-4P**
(prepn. and redn. of)
RN 55273-36-4 USPATFULL
CN 3,4-Pyridinedicarboxylic acid, 6-(diethoxymethyl)-5-(hydroxymethyl)-, diethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 21 OF 22 USPATFULL
AB Mercaptoalkylpyridines carrying an ethenyl or ethynyl substituent are prepared from known pyridine compounds, principally pyridoxine, by known chemical procedures, and are useful in the treatment of **rheumatoid** arthritis and related inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 77:64011 USPATFULL
TITLE: Ethenyl and ethynyl mercaptoalkyl pyridines
INVENTOR(S): Shen, Tsung-Ying, Westfield, NJ, United States
Jones, Howard, Holmdel, NJ, United States
Dorn, Conrad P., Plainfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4061759		19771206
APPLICATION INFO.:	US 1976-706033		19760716 (5)

RELATED APPLN. INFO.: Division of Ser. No. US 1975-578692, filed on 19 May 1975, now abandoned which is a continuation-in-part of Ser. No. US 1974-464011, filed on 26 Apr 1974, now abandoned which is a continuation-in-part of Ser. No. US 1973-368772, filed on 15 Jun 1973, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.

LEGAL REPRESENTATIVE: Speer, Raymond M., Mahon, Frank M., Nicholson, William H.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1,15
LINE COUNT: 2114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **55273-36-4P**
(prepn. and redn. of)
RN 55273-36-4 USPATFULL
CN 3,4-Pyridinedicarboxylic acid, 6-(diethoxymethyl)-5-(hydroxymethyl)-, diethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 22 OF 22 USPATFULL
AB Mercaptoalkylpyridines carrying an ethenyl or ethynyl substituent are prepared from known pyridine compounds, principally pyridoxine, by known chemical procedures, and are useful in the treatment of **rheumatoid** arthritis and related inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 77:55231 USPATFULL
TITLE: Mercaptoalkylpyridine disulfides
INVENTOR(S): Shen, Tsung-Ying, Westfield, NJ, United States
Jones, Howard, Holmdel, NJ, United States
Dorn, Conrad P., Plainfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4053606		19771011
APPLICATION INFO.:	US 1976-706034		19760716 (5)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1975-578692, filed on 19 May 1975, now abandoned which is a continuation-in-part of Ser. No. US 1974-464011, filed on 26 Apr 1974, now abandoned which is a continuation-in-part of Ser. No. US 1973-368772, filed on 15 Jun 1973, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
LEGAL REPRESENTATIVE: Mahon, Frank M., Nicholson, William H., Speer, Raymond M.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1,9
LINE COUNT: 1572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **55273-36-4P**
(prepn. and redn. of)
RN 55273-36-4 USPATFULL
CN 3,4-Pyridinedicarboxylic acid, 6-(diethoxymethyl)-5-(hydroxymethyl)-, diethyl ester (9CI) (CA INDEX NAME)


OEt
EtO— CH
N
HO— CH2
C— OEt
O
EtO— C
O
O

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637657 CAPLUS
DN 137:185420
TI Preparation of pyridinedicarboxamide and -dicarboxylic acid derivatives as selective **MMP**-13 **matrix metalloproteinase** inhibitors with therapeutic uses
IN Barvian, Nicole Chantel; Connor, David Thomas; O'brien, Patrick Michael; Ortwine, Daniel Fred; Patt, William Chester; Shuler, Kevon Ray; Wilson, Michael William
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064568	A1	20020822	WO 2002-IB345	20020204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002161000	A1	20021031	US 2002-71073	20020208

PRAI US 2001-268781P P 20010214
OS MARPAT 137:185420
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

structures for 10/071073

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2,3-dimethoxyphenyl)methyl]- (9CI)
MF C25 H27 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):192

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 3-ethoxy- (9CI)
MF C10 H15 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 4-fluoro-.alpha.-methyl- (9CI)
MF C8 H10 F N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-fluorophenyl)methyl]- (9CI)
MF C21 H17 F2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N,N'-bis(1,3-benzodioxol-5-ylmethyl)-2-methoxy- (9CI)
MF C24 H21 N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 4-(trifluoromethyl)- (9CI)
MF C8 H8 F3 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[1-(3-methoxyphenyl)ethyl]- (9CI)
MF C25 H27 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(1-naphthalenylmethyl)- (9CI)
MF C29 H23 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 4-Pyridineethanamine (9CI)
MF C7 H10 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzoic acid, 4-[[[[5-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-3-pyridinyl]carbonyl]amino]methyl]-, methyl ester (9CI)
MF C24 H23 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2,4-dichlorophenyl)methyl]- (9CI)
MF C21 H15 Cl4 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 3-(trifluoromethyl)- (9CI)
MF C9 H10 F3 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2,4-dichloro- (9CI)
MF C7 H7 Cl2 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C23 H15 F8 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(2-ethoxyethyl)- (9CI)
MF C15 H23 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, .alpha.-methyl- (9CI)
MF C8 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(1-phenylethyl)- (9CI)
MF C23 H23 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N,N'-bis[(4-fluorophenyl)methyl]- (9CI)
MF C21 H17 F2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2-amino- (9CI)
MF C7 H10 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,4-dichlorophenyl)methyl]- (9CI)
MF C21 H15 Cl4 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3,4-dimethoxyphenyl)ethyl]- (9CI)
MF C27 H31 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyridineethanamine (9CI)
MF C7 H10 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N-(2,1,3-benzothiadiazol-5-ylmethyl)-N'-[(4-methoxyphenyl)methyl]- (9CI)
MF C22 H19 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-diethyl-N,N'-bis(4-pyridinylmethyl)- (9CI)
MF C23 H25 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 4-ethyl- (9CI)
MF C10 H15 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 4-chloro- (9CI)
MF C7 H8 Cl N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-aminophenyl)methyl]- (9CI)
MF C21 H21 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Collagenase 3 (9CI)
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1,3-Benzodioxole-5-methanamine (9CI)
MF C8 H9 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[4-(trifluoromethyl)phenyl]methyl]-
(9CI)
MF C23 H17 F6 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, 2-methoxy-N,N'-bis(phenylmethyl)- (9CI)
MF C22 H21 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenepropanamine, .gamma.-phenyl- (9CI)
MF C15 H17 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(1H-indol-3-yl)ethyl]- (9CI)
MF C27 H25 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3-chlorophenyl)ethyl]- (9CI)
MF C23 H21 Cl2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2-Thiopheneethanamine (9CI)
MF C6 H9 N S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 4-methoxy- (9CI)
MF C9 H13 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[3,5-bis(trifluoromethyl)phenyl]methyl]- (9CI)
MF C25 H15 F12 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 2,4-dimethyl- (9CI)
MF C10 H15 N

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenamine, 4-ethoxy- (9CI)
MF C8 H11 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(3,4-dimethoxyphenyl)- (9CI)
MF C23 H23 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N,N'-bis[(3-chlorophenyl)methyl]- (9CI)
MF C21 H17 Cl2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 4-methyl- (9CI)
MF C9 H13 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[3-(trifluoromethoxy)phenyl]methyl]-
(9CI)
MF C23 H17 F6 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(phenylmethyl)- (9CI)
MF C21 H19 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenebutanamine (9CI)
MF C10 H15 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzoic acid, 4-[[[[5-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-3-pyridinyl]carbonyl]amino]methyl]- (9CI)
MF C23 H21 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(1,2-diphenylethyl)- (9CI)
MF C35 H31 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Naphthalenemethanamine, .alpha.-methyl- (9CI)
MF C12 H13 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2-fluoro- (9CI)
MF C7 H8 F N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[2-(difluoromethoxy)phenyl]methyl]-
(9CI)
MF C23 H19 F4 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 2-phenoxy- (9CI)
MF C14 H15 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyridinecarboxylic acid, 1,2-dihydro-2-oxo- (9CI)
MF C6 H5 N O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3-methoxyphenyl)ethyl]- (9CI)
MF C25 H27 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(1,3-benzodioxol-5-ylmethyl)- (9CI)
MF C23 H19 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2,3-dimethoxy- (9CI)
MF C9 H13 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(2,3-dihydro-1H-inden-1-yl)- (9CI)
MF C25 H23 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-diethyl-N,N'-bis(phenylmethyl)- (9CI)
MF C25 H27 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 4-methoxy-.alpha.-(4-methoxyphenyl)- (9CI)
MF C15 H17 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-N'-(2,1,3-benzoxadiazol-5-ylmethyl)- (9CI)
MF C22 H17 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,4-dimethoxyphenyl)methyl]- (9CI)
MF C25 H27 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3-methoxy-.alpha.-methyl- (9CI)
MF C9 H13 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 4-methyl- (9CI)
MF C8 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2,4-difluorophenyl)methyl]- (9CI)
MF C21 H15 F4 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2-(trifluoromethoxy)- (9CI)
MF C8 H8 F3 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 4-methoxy- (9CI)
MF C8 H11 N O
CI COM





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(2-thienylmethyl)- (9CI)
MF C17 H15 N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxylic acid, 1,2-dihydro-2-oxo-, 5-methyl ester (9CI)
MF C8 H7 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Acetic acid, bromo-, 1,1-dimethylethyl ester (9CI)
MF C6 H11 Br O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(5-methoxy-1H-indol-3-yl)ethyl]-
(9CI)
MF C29 H29 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-fluorophenyl)ethyl]- (9CI)
MF C23 H21 F2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2-Thiophenemethanamine (9CI)
MF C5 H7 N S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Phenol, 4-(2-aminoethyl)- (9CI)
MF C8 H11 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(4-pyridinylmethyl)- (9CI)
MF C19 H17 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 4-bromo- (9CI)
MF C8 H10 Br N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 4-chloro- (9CI)
MF C8 H10 Cl N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(1-methyl-3-phenylpropyl)- (9CI)
MF C27 H31 N3 O2





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N,N'-bis[(4-chlorophenyl)methyl]- (9CI)
MF C21 H17 Cl2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2-(trifluoromethyl)- (9CI)
MF C8 H8 F3 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[1-(1-naphthalenyl)ethyl]- (9CI)
MF C31 H27 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-chlorophenyl)methyl]- (9CI)
MF C21 H17 Cl2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 3-chloro- (9CI)
MF C8 H10 Cl N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzoic acid, 4-[[[[5-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-3-pyridinyl]carbonyl]amino]methyl]- (9CI)
MF C23 H21 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(2-phenylpropyl)- (9CI)
MF C25 H27 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3,5-dichloro- (9CI)
MF C7 H7 Cl2 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2-chloro- (9CI)
MF C7 H8 Cl N

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[3-(difluoromethoxy)phenyl]methyl]-(9CI)
MF C23 H19 F4 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyridinecarboxylic acid, 5-bromo-1,2-dihydro-2-oxo- (9CI)
MF C6 H4 Br N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Indole-3-ethanamine, 5-methoxy- (9CI)
MF C11 H14 N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[2-(trifluoromethyl)phenyl]methyl]-
(9CI)
MF C23 H17 F6 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N,N'-bis(1,3-benzodioxol-5-ylmethyl)- (9CI)
MF C23 H19 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3-chloro- (9CI)
MF C7 H8 Cl N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-[3-(trifluoromethyl)phenyl]ethyl]-
(9CI)
MF C25 H21 F6 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-fluorophenyl)methyl]- (9CI)
MF C21 H17 F2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3,4,5-trimethoxy- (9CI)
MF C10 H15 N O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-N'-(2,1,3-benzothiadiazol-5-ylmethyl)- (9CI)
MF C22 H17 N5 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,5-dimethoxyphenyl)methyl]- (9CI)
MF C25 H27 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarbonyl dichloride (9CI)
MF C7 H3 Cl2 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3,4-dichloro- (9CI)
MF C7 H7 Cl2 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-chloro-4-fluorophenyl)methyl]-

(9CI)
MF C21 H15 Cl2 F2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-hydroxyphenyl)ethyl]- (9CI)
MF C23 H23 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 2-methoxy- (9CI)
MF C9 H13 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 2,4-Pyridinedicarboxamide, N,N'-bis(2-phenylethyl)- (9CI)
MF C23 H23 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-5-[[(phenylmethyl)amino]carbonyl]-, methyl ester (9CI)
MF C15 H14 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3-methoxy- (9CI)
MF C8 H11 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-thienyl)ethyl]- (9CI)
MF C19 H19 N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-methoxyphenyl)ethyl]- (9CI)
MF C25 H27 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, .alpha.-phenyl- (9CI)
MF C14 H15 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, 2-amino-N,N'-bis(1,3-benzodioxol-5-ylmethyl)-
(9CI)
MF C23 H20 N4 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-chlorophenyl)ethyl]- (9CI)
MF C23 H21 Cl2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3-chloro-4-fluoro- (9CI)
MF C7 H7 Cl F N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 3,4-dimethoxy- (9CI)
MF C10 H15 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(3,3-diphenylpropyl)- (9CI)
MF C37 H35 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-methoxyphenyl)methyl]- (9CI)
MF C23 H23 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, .alpha.-ethyl- (9CI)
MF C9 H13 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-aminophenyl)methyl]- (9CI)
MF C21 H21 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2,4-dimethoxyphenyl)methyl]- (9CI)
MF C25 H27 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2-methoxy- (9CI)
MF C8 H11 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzoic acid, 4-[[[[5-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-3-pyridinyl]carbonyl]amino]methyl]- (9CI)
MF C23 H19 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-ethylphenyl)ethyl]- (9CI)
MF C27 H31 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3,5-dimethoxy- (9CI)
MF C9 H13 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2-methyl- (9CI)
MF C8 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[2-(trifluoromethoxy)phenyl]methyl]-
(9CI)
MF C23 H17 F6 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3-(trifluoromethoxy)- (9CI)
MF C8 H8 F3 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, .beta.-methyl- (9CI)
MF C9 H13 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-chlorophenyl)methyl]- (9CI)
MF C21 H17 Cl2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N,N'-bis[(4-methoxyphenyl)methyl]- (9CI)
MF C23 H23 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 4-Pyridinemethanamine (9CI)
MF C6 H8 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-methoxyphenyl)ethyl]- (9CI)
MF C25 H27 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-methoxyphenyl)methyl]- (9CI)
MF C23 H23 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, N-ethyl- (9CI)
MF C9 H13 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzoic acid, 4-[[[[5-[[(3-thienylmethyl)amino]carbonyl]-3-pyridinyl]carbonyl]amino]methyl]- (9CI)
MF C20 H17 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,4,5-trimethoxyphenyl)methyl]- (9CI)
MF C27 H31 N3 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 2-methyl- (9CI)
MF C9 H13 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3-fluoro- (9CI)
MF C7 H8 F N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3-ethoxyphenyl)ethyl]- (9CI)
MF C27 H31 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-methylphenyl)methyl]- (9CI)
MF C23 H23 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 3-methoxy- (9CI)
MF C9 H13 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(4-ethoxyphenyl)- (9CI)
MF C23 H23 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-5-
[[(phenylmethyl)amino]carbonyl]- (9CI)
MF C14 H12 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Imidazole-1-propanamine (9CI)
MF C6 H11 N3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-pyridinyl)ethyl]- (9CI)
MF C21 H21 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI)
MF C27 H31 N3 O2





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenepropanamine, .alpha.-methyl- (9CI)
MF C10 H15 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N,N'-bis(1,3-benzodioxol-5-ylmethyl)-2-ethoxy- (9CI)
MF C25 H23 N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3-pyridinyl)ethyl]- (9CI)
MF C21 H21 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2,4-difluoro- (9CI)
MF C7 H7 F2 N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1-Naphthalenemethanamine (9CI)
MF C11 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[bis(4-methoxyphenyl)methyl]- (9CI)
MF C37 H35 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3-(difluoromethoxy)- (9CI)
MF C8 H9 F2 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3-(trifluoromethyl)- (9CI)
MF C8 H8 F3 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[1-(4-fluorophenyl)ethyl]- (9CI)
MF C23 H21 F2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Acetic acid, [[3,5-bis[[(phenylmethyl)amino]carbonyl]-2-pyridinyl]oxy]- (9CI)
MF C23 H21 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenamine, 3,4-dimethoxy- (9CI)
MF C8 H11 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(4-chlorophenyl)methyl]- (9CI)
MF C22 H18 Cl N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-methylphenyl)ethyl]- (9CI)
MF C25 H27 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Inden-1-amine, 2,3-dihydro- (9CI)

MF C9 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine (9CI)
MF C8 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[[3-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C23 H17 F6 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3,5-bis(trifluoromethyl)- (9CI)
MF C9 H7 F6 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxylic acid (8CI, 9CI)
MF C7 H5 N O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[3-(1H-imidazol-1-yl)propyl]- (9CI)
MF C19 H23 N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxylic acid, bis(1,3-benzodioxol-5-ylmethyl) ester (9CI)
MF C23 H17 N O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyridinemethanamine (9CI)
MF C6 H8 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(1-phenylpropyl)- (9CI)
MF C25 H27 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-methylphenyl)ethyl]- (9CI)
MF C25 H27 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2-Furanmethanamine, 5-methyl- (9CI)
MF C6 H9 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzoic acid, 4-[[[[5-[[(3-pyridinylmethyl)amino]carbonyl]-3-pyridinyl]carbonyl]amino]methyl]- (9CI)
MF C21 H18 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis([1,1'-biphenyl]-2-ylmethyl)- (9CI)
MF C33 H27 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneethanamine, 2-fluoro- (9CI)
MF C8 H10 F N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine (9CI)
MF C7 H9 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-methoxyphenyl)methyl]- (9CI)
MF C23 H23 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-chlorophenyl)methyl]- (9CI)
MF C21 H17 Cl2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN [1,1'-Biphenyl]-2-methanamine (9CI)
MF C13 H13 N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis(3-pyridinylmethyl)- (9CI)

MF C19 H17 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, 1,2-dihydro-2-oxo-N,N'-bis(phenylmethyl)- (9CI)
MF C21 H19 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 4-amino- (9CI)
MF C7 H10 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-bromophenyl)ethyl]- (9CI)
MF C23 H21 Br2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-phenoxyphenyl)ethyl]- (9CI)
MF C35 H31 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2,4-dimethoxy- (9CI)
MF C9 H13 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3,5-Pyridinedicarboxamide, N-(2,1,3-benzothiadiazol-5-ylmethyl)-N'-[(3-methoxyphenyl)methyl]- (9CI)
MF C22 H19 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-pyridinyl)ethyl]- (9CI)
MF C21 H21 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 4-fluoro-3-(trifluoromethyl)- (9CI)
MF C8 H7 F4 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Ethanamine, 2-ethoxy- (9CI)
MF C4 H11 N O
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-methylphenyl)methyl]- (9CI)
MF C23 H23 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 2-(difluoromethoxy)- (9CI)
MF C8 H9 F2 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2-Pyridineethanamine (9CI)
MF C7 H10 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(5-methyl-2-furanyl)methyl]- (9CI)
MF C19 H19 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Acetic acid, [[3,5-bis[[(phenylmethyl)amino]carbonyl]-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (9CI)
MF C27 H29 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanamine, 3,4-dimethoxy- (9CI)
MF C9 H13 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,5-dichlorophenyl)methyl]- (9CI)
MF C21 H15 Cl4 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2,4-dimethylphenyl)ethyl]- (9CI)
MF C27 H31 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 4-Pyridinemethanamine, N-ethyl- (9CI)
MF C8 H12 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 193 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Indole-3-ethanamine (9CI)
MF C10 H12 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

Welcome to STN International! Enter x:x

LOGINID:ssspta1203jxf

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS 28	Mar 20	EVENTLINE will be removed from STN
NEWS 29	Mar 24	PATDPAFULL now available on STN
NEWS 30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 31	Mar 24	Indexing from 1957 to 1966 added to records in CA/CAPLUS
NEWS 32	Apr 11	Display formats in DGENE enhanced

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:37:44 ON 14 APR 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:37:50 ON 14 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 APR 2003 HIGHEST RN 502841-39-6
DICTIONARY FILE UPDATES: 13 APR 2003 HIGHEST RN 502841-39-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10071073.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S
G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:38:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4915 TO ITERATE

20.3% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 94098 TO 102502
PROJECTED ANSWERS: 13488 TO 16788

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2,5-Pyridinedicarboxylic acid, 5-propyl ester, ion(1-) (9CI)
MF C10 H10 N O4
CI COM



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full
FULL SEARCH INITIATED 10:38:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 96742 TO ITERATE

100.0% PROCESSED 96742 ITERATIONS 13673 ANSWERS
SEARCH TIME: 00.00.01

L3 13673 SEA SSS FUL L1

=> d scan

L3 13673 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN INDEX NAME NOT YET ASSIGNED
MF C9 H9 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 148.55 | 148.76

FILE 'CAPLUS' ENTERED AT 10:39:10 ON 14 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 13 Apr 2003 (20030413/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:37:44 ON 14 APR 2003)

FILE 'REGISTRY' ENTERED AT 10:37:50 ON 14 APR 2003
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 13673 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:39:10 ON 14 APR 2003

=> s l3
L4 7367 L3

=> s l4 and benzodioxol?
3849 BENZODIOXOL?
L5 39 L4 AND BENZODIOXOL?

=> d l5 bib abs hitstr 1-39

L5 ANSWER 1 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2003:174548 CAPLUS
DN 138:221587
TI Preparation of azinyl- and azolylsulfones as chemokine IL-8 receptor binding inhibitors.
IN Brands, Michael; Gruetzmann, Rudi; Kalthof, Bernd; Keldenich, Jorg; Lang, Dieter; Mueller, Ullrich; Pernerstorfer, Josef; Raabe, Martin; Rank, Elisabeth; Schirok, Hartmut; Schmeck, Carsten; Schuhmacher, Joachim; Stelte, Ludwig Beatrix; Urbahns, Klaus; Zaiss, Siegfried
PA Bayer Ag, Germany

SO Brit. UK Pat. Appl., 138 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2379218	A1	20030305	GB 2001-23437	20010928
	GB 2380190	A1	20030402	GB 2001-20818	20010828
PRAI	GB 2001-20818	A	20010828		

OS MARPAT 138:221587
GI



I

AB Title compds. [I; Q = C-bound heterocyclyl; A = benzodioxanyl, **benzodioxolyl**, difluorobenzodioxolyl, tetrafluorobenzodioxanyl, H, OH, cyano, alkanoyl, alkoxycarbonyl, alkyl, alkoxy, etc.; D = (substituted) alkanediyl; E = CH:CH, CH:N; G = phenylaminocarbonyl, aroylamino; R1 = H, halo, OH, NO2, CF3, OCF3, hydroxymethyl alkoxy, alkoxycarbonyl, aryloxy, alkyl; m = 0-3], were prepd. Thus, 3-mercapto-1,3,4-thiadiazole, 4-chloromethyl-N-(4-fluorophenyl)benzamide, and Et3N were stirred together for 4 h in CH2Cl2 to give 73% sulfide coupling product, which was stirred with 3-ClC6H4CO(OOH) in DMF for 4 h to give 75% N-(4-fluorophenyl)-4-[[(1,3,4-thiadiazol-3-yl)sulfonyl]methyl]benzamide. I inhibited IL-8 receptor binding with IC50 = 40-470 nM.

IT **17874-79-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azinyl- and azolylsulfones as chemokine IL-8 receptor binding inhibitors)

RN 17874-79-2 CAPLUS
CN 2,5-Pyridinedicarboxylic acid, 5-methyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



IT **500568-46-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azinyl- and azolylsulfones as chemokine IL-8 receptor binding inhibitors)

RN 500568-46-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[(4-fluorophenyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2003:154251 CAPLUS
DN 138:205069
TI Preparation of 2H-phthalazin-1-ones as poly(ADP-ribose)polymerase inhibitors for treatment of cancer
IN Beaton, Graham; Moree, Wilna J.; Rueter, Jaimie K.; Dahl, Russell S.; McElligott, David L.; Goldman, Phyllis; Demaggio, Anthony J.; Christenson, Erik; Herendeen, Dan; Fowler, Kerry W.; Huang, Danwen; Bertino, Jaimie A.; Bourdon, Lisa H.; Fairfax, David J.; Jiang, Qin; Reisch, Helge A.; Song, Ren Hua; Zhichkin, Pavel E.
PA Icos Corporation, USA
SO PCT Int. Appl., 229 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003015785	A1	20030227	WO 2002-US26271	20020815

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-312540P P 20010815
OS MARPAT 138:205069
GI



I



II

AB Title compds. and derivs. thereof I [wherein Q1 and Q2 = independently N or CRa; Ra = H, halo, NO2, or alkyl; R = H, alkyl, or N-protecting group; Y = NR1R2, R3C(=X1)Y1, (alkylene)x-NR11R12NR13[C(=X3)]c(NR14)d(R15)e[C(=X4)]fR16, or NR11R12N=CR20R21; R1, R14, and R20 = independently H or alkyl; R2 = arylcarbonyl, heteroalkyl, cyclo(alkyl), alkenyl, alkynyl, etc.; R3 = alkylene; X1, X3, and X4 = independently O or S; Y1 = NR4R5; R4 = H, (hetero)alkyl, or aralkyl; R5 = (un)substituted aralkyl, heteroalkyl, heterocyclyl, heteroaryl(alkyl), arylsulfonylamino, etc.; x = 0-1; R11 = H, alkyl, or (un)substituted heteroaralkyl; R12 = (cyclo)alkylene,

heteroalkylene, aralkylene, or arylene; or NR11R12 = (un)substituted heterocyclyl; c = 0-2; d-f = independently 0-1; R13 = H, alkyl, arylcarbamoylalkylene, etc.; R15 = (hetero)alkylene or alkenylene; R16 = H, (un)substituted (hetero)aryl, (hetero)alkyl, cycloalkyl, aralkoxy, amino, arylsulfonylamino, etc.; R21 = alkyl, or substituted heteroaryl; and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof] were prepd. as poly(ADP-ribose)polymerase (PARP) inhibitors (no data). For example, condensation of 1,3-propanediamine with phthalic anhydride in EtOH gave 3,4-dihydropyrimido[1,2-a]indol-10(2H)-one, which was dissolved in ethylene glycol and reacted with NH2NH2.bul.H2O to afford II (51%). I are useful for radiosensitizing and chemosensitizing tumor cells for the treatment of cancer (no data).

IT **4733-65-7**, 3-Carbamoylpicolinic acid **5860-70-8**, 2-Carbamylnicotinic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of phthalazinone PARP inhibitors for treatment of cancer)

RN 4733-65-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 3-(aminocarbonyl)- (9CI) (CA INDEX NAME)



RN 5860-70-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-(aminocarbonyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2003:76621 CAPLUS
DN 138:122662
TI Preparation of quinoxalinecarboxamides which have poly(adenosine 5'-diphospho-ribose)polymerase inhibitory action
IN Hattori, Kouji; Yamamoto, Hirofumi; Mukoyoshi, Koichiro; Kuroda, Satoru
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003007959	A1	20030130	WO 2002-JP7078	20020711
	W: JP, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
PRAI	AU 2001-6396	A	20010716		
	AU 2002-774	A	20020226		

OS MARPAT 138:122662
GI



I

AB Quinoxalinecarboxamides (shown as I; variables defined below; e.g. 3-(4-diethylaminophenyl)quinoxaline-5-carboxamide) have poly(adenosine 5'-diphospho-ribose)polymerase (PARP) inhibitory action. A mixt. of 2-(4-chlorophenyl)quinoxaline-5-carboxamide and 3-(4-chlorophenyl)quinoxaline-5-carboxamide and also 3-(4-diethylaminophenyl)quinoxaline-5-carboxamide were tested as inhibitors of PARP and the IC50 values were < 100 nM. A process for prepg. I is claimed. For example, to a suspension of 2,3-diaminobenzamide dihydrochloride (1 mmol) in MeOH (10 mL) were added triethylamine (10 mmol) and 4-methoxyphenacyl bromide (1.5 mmol) at room temp.; workup gave a mixt. (yield 16 %) of 2-(4-methoxyphenyl)quinoxaline-5-carboxamide and 3-(4-methoxyphenyl)quinoxaline-5-carboxamide. Six example prepns. of intermediates and example prepns. and/or characterization data for I are included. For I: the A ring is an aryl group or a heterocyclic group; R1 is H, halo, lower alkyl or lower alkoxy; R2 is H, lower alkyl or aryl optionally substituted with halo. R3 is H, halo, cyano, nitro, amino, ar(lower)alkylamino, di(lower)alkylamino, heterocyclyl(lower)alkylamino, N-heterocyclyl-N-ar(lower)alkylamino, heterocyclylamino optionally substituted with ar(lower)alkyl, cycloalkylamino, (lower)alkylsulfonylamino, arylsulfonylamino, heterocyclylsulfonylamino, acylamino, lower alkoxy, alkyl optionally substituted with lower alkylthio, halo(lower)alkyl, ar(lower)alkyl, heterocyclyl(lower)alkyl , cycloalkyl(lower)alkyl, cycloalkenyl(lower)alkyl, aryl, heterocyclic group, or heterocyclylthio. R4 is H, halo, lower alkoxy or lower alkyl, or in the case where both of R2 and R3 are a lower alkyl group, they may be combined to form a lower alkylene group, or in the case where both of R3 and R4 are a lower alkoxy group, they may be combined to form a lower alkylenedioxy group or a salt thereof.

IT **489459-22-5P**, 3-(3-(((Pyridin-2-yl)carbonyl)amino)phenyl)quinoxaline-5-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of quinoxalinecarboxamides as poly(adenosine 5'-diphospho-ribose)polymerase inhibitors with various therapeutic uses)

RN 489459-22-5 CAPLUS

CN 5-Quinoxalinecarboxamide, 3-[3-[(2-pyridinylcarbonyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:964216 CAPLUS
DN 138:33356
TI Medicinal compositions as p38MAP kinase and/or TNF-.alpha. prodn. inhibitor for pain
IN Ohkawa, Shigenori; Naruo, Kenichi; Morimoto, Shigeru; Nagase, Yoshinori; Miwatashi, Seiji
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 563 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100433	A1	20021219	WO 2002-JP5726	20020610
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2003063993	A2	20030305	JP 2002-168226	20020610
PRAI	JP 2001-175224	A	20010611		
	JP 2001-175273	A	20010611		

OS MARPAT 138:33356
AB Prevention/treatment for pain and/or suppression of the activation and/or inhibition of the formation of osteoclasts by using a p38MAP kinase inhibitor and/or a TNF-.alpha. prodn. inhibitor. A method of HDL1 relieving a P 450-inhibitory effect of a compd. having a pyridyl group or its salt characterized by introducing a substituent into the .alpha.-position of the nitrogen atom in the pyridyl group of the above compd. or its salt, or for relieving a P 450-inhibitory effect of a compd. having a pyridyl group and an arom. hydrocarbyl group or its salt characterized by introducing a polar group into the arom. hydrocarbyl group of the above compd. or its salt.
IT **478706-57-9**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. as p38MAP kinase and/or TNF-.alpha. prodn. inhibitor for pain)
RN 478706-57-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[2-(acetylamino)-4-(3,5-dimethylphenyl)-5-thiazolyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:832787 CAPLUS
DN 137:337786
TI Preparation of chiral alkylaminochroman derivatives as .beta.3-adrenoreceptor agonists
IN O'Connor, Stephen J.; Ladouceur, Gaetan H.; Bullock, William H.; Campbell, Ann-Marie; Dai, Miao; Dally, Robert; Dumas, Jacques; Hatoum-Mokdad, Holia N.; Khire, Uday; Lee, Wendy; Liu, Qingjie; Lowe, Derek B.; Magnuson, Steven R.; Qi, Ning; Shelekhin, Tatiana E.; Shen, Quanrong; Smith, Roger A.; Wang, Ming
PA Bayer Corporation, USA
SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085891	A1	20021031	WO 2002-US12940	20020422
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-285719P P 20010423
US 2001-324518P P 20010926
OS MARPAT 137:337786
GI



I



II

AB This invention relates to novel 2,6-substituted chroman derivs. which are useful in the treatment of .beta.3-adrenoreceptor mediated conditions. Title compds. I [wherein R = independently OH, :O, halo, CN, NO2, (halo)alkyl, CF3, NR1R1, SR1, OR1, SO2R2, OCOR2, NR1COR2, COR2, NR1SO2R2, or (un)substituted Ph or heterocyclyl; R1 = independently H, (CH2)mO(CH2)mR5, or (un)substituted (cyclo)alkyl, Ph, or naphthyl; or NR1R1 = heterocyclyl; R2 = independently R1, OR1, NR1R1, or (un)substituted NHSO0-2-Ph, NHSO0-2-naphthyl, NHSO0-2-alkyl, or heterocyclyl; R3 = H, alkyl, or COR3; R4 = H, alkyl(phenyl), or alkylpyridyl; R5 = H or CO2H; R6 = H or (un)substituted alkyl or alkyl-SO0-2-alkyl; Ar = Ph or (fused) hetero(aryl); Y = halo, NO2, R6, SR1, SO0-2C6H4CO2R1, (CONR4CR4R4)pCO2R1, or (un)substituted Ph or heterocyclyl; m = 1-3; n = 0-5; p = 1 or 2; and pharmaceutically acceptable salts and esters thereof] were prepd. as .beta.3-adrenoceptor agonists. For example, coupling of (2R)-6-iodo-3,4-dihydro-2H-chromene-2-carboxylic acid and (1R)-2-amino-1-(3-pyridinyl)ethanol.bul.2HCl with 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.bul.HCl, and TEA in CH2Cl2 gave the amide (74%). Redn. using borane-dimethylsulfide complex in THF afforded the chromanmethaneamine II (84%). Over one hundred compds. of the invention demonstrated .beta.3-adrenergic receptor agonist activity with EC50 values .ltoreq. 1.mu.M. I are useful in the treatment of .beta.3-adrenergic receptor mediated conditions, including obesity, diabetes, gastrointestinal disorders, cardiovascular disorders, and urinary disorders (no data).

IT **474111-59-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(.beta.3-adrenoreceptor agonist; prepn. of chiral alkylaminochroman derivs. as .beta.3-adrenoreceptor agonists)

RN 474111-59-6 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl][(2R)-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(3-pyridinyl)ethyl]amino]methyl]-3,4-dihydro-2H-1-benzopyran-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:814891 CAPLUS
DN 137:325335
TI Preparation of (hetero)arylamides as inhibitors of microsomal triglyceride transfer protein
IN Booth, Richard John; Lee, Helen Tsenwhei; Pontrello, Jason Keith; Ramharack, Randy Ranjee; Roth, Bruce David
PA USA
SO U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 422,568.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002156281	A1	20021024	US 2001-21633	20011212
PRAI US 1998-107119P	P	19981105		
US 1999-422568	B2	19991021		

OS MARPAT 137:325335
AB R3(CH2)nNR1COR2 [I, R1 = (substituted) pyridyl, pyridylmethyl, Ph, quinolyl, benzothienyl, etc.; R2 = Ph, PhCH2OC6H4, PhCH2SC6H4, PhCH2SOC6H4, naphthylmethyl, benzodioxanyl, benzothienyl, amino, aminoalkyl, etc.; R3 = biphenyl, benzothienyl, tetramethyltetralinyl, naphthalenyl; n = 0-2], were prepd. Thus, reaction of 2-ethoxy-N-pyridin-3-ylbenzamide and 2-phenylbenzyl bromide gave N-biphenyl-2-ylmethyl-2-ethoxy-N-pyridin-3-ylbenzamide. The latter inhibited lipoprotein A3 prodn. with IC50 = 0.9 .mu.M. The present invention also provides pharmaceutical compns. comprising I and methods of treatment of atherosclerosis, obesity, restenosis, coronary heart disease, hyperlipoproteinemia, hypercholesterolemia, and hypertriglyceridemia.
IT **69873-67-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of (hetero)arylamides as inhibitors of microsomal triglyceride transfer protein)
RN 69873-67-2 CAPLUS
CN Benzoic acid, 2-[(2-pyridinylcarbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:754196 CAPLUS
DN 137:257677
TI Methods of treating or preventing Alzheimer's disease using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes
IN Nieman, James A.; Fang, Lawrence; Jagodzinska, Barbara
PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SO PCT Int. Appl., 449 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076440	A2	20021003	WO 2002-US9100	20020321
WO 2002076440	A3	20021128		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-278371P P 20010323
US 2001-308729P P 20010730
OS MARPAT 137:257677
GI



I

AB Disclosed are methods for treating or preventing Alzheimer's disease, and other diseases, and/or inhibiting .beta.-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, using 3,4-disubstituted piperidinyl compds. (I) wherein the variables R1, R2, R3, R4, Q, W, X, Z, m, and n are defined below. Although neither the compds. nor the methods of prepn. are claimed, .apprx.150 example prepns., translations from the German examples of patent WO 9709311, are included. I inhibit .beta.-secretase with IC50 < 50 .mu.M; compds. that are effective inhibitors of .beta.-secretase activity demonstrate reduced cleavage of the substrate as compared to a control. In I, R1 is aryl, heterocycle; R2 is Ph, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diazinyl, triazolyl, thienyl,

oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, or furyl, optionally substituted. R3 is: H, hydroxy, lower-alkoxy, or lower-alkenyloxy; R4 is: H, lower-alkyl, lower-alkenyl, lower-alkoxy, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, benzyl, oxo, or where R3 and R4 together are a bond, or as specified in the claims. Q is: ethylene, or is absent; X is: a bond, -O-, -S-, -CH-R11- (R11 defined in claims), -CHOR9- (R9 defined in claims), -OCO, -CO-, or C:NOR10- (R10 is carboxyalkyl, alkoxycarbonylalkyl, alkyl or H), with the bond emanating from an O or S atom joining to a satd. C atom of group Z or to R1; W is: -O-, or -S-; Z is: lower-alkylene, lower-alkenylene, hydroxy-lower-alkylidene, -O-, -S-, -O-Alk- (Alk is a lower alkylene), -S-Alk-, -Alk-O-, or -Alk-S. N is: 1, or 0 or 1 when X is -O-CO; and where m is 0 or 1; with provisos.

IT **188864-31-5P**, 1-Piperidinecarboxylic acid, 3-(2-naphthalenylmethoxy)-4-[4-[[[(2-pyridinylcarbonyl)amino]oxy]methyl]phenyl]-, 1,1-dimethylethyl ester, trans- **188865-09-0P**, 1-Piperidinecarboxylic acid, 3-(2-naphthalenylmethoxy)-4-[4-[2-[[(2-pyridinylcarbonyl)amino]oxy]ethyl]phenyl]-, 1,1-dimethylethyl ester, trans- **188865-12-5P**, 2-Pyridinecarboxylic acid, 2-[4-[1-[(1,1-dimethylethoxy)carbonyl]-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]ethyl ester, trans- **188871-07-0P**, 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-3-[[2-[[(2-pyridinylcarbonyl)amino]methyl]phenyl]methoxy]-, 1,1-dimethylethyl ester, trans-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods of treating or preventing Alzheimer's and other diseases using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes)

RN 188864-31-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-(2-naphthalenylmethoxy)-4-[4-[[[(2-pyridinylcarbonyl)amino]oxy]methyl]phenyl]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 188865-09-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-(2-naphthalenylmethoxy)-4-[4-[2-[[(2-pyridinylcarbonyl)amino]oxy]ethyl]phenyl]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 188865-12-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 2-[4-[(3R,4R)-1-[(1,1-dimethylethoxy)carbonyl]-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 188871-07-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-3-[[2-[[(2-pyridinylcarbonyl)amino]methyl]phenyl]methoxy]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 8 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2002:637657 CAPLUS
DN 137:185420
TI Preparation of pyridinedicarboxamide and -dicarboxylic acid derivatives as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses
IN Barvian, Nicole Chantel; Connor, David Thomas; O'brien, Patrick Michael; Ortwine, Daniel Fred; Patt, William Chester; Shuler, Kevon Ray; Wilson, Michael William
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064568	A1	20020822	WO 2002-IB345	20020204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002161000	A1	20021031	US 2002-71073	20020208

PRAI US 2001-268781P P 20010214
OS MARPAT 137:185420
GI



I

AB Selective MMP-13 inhibitors are pyridine derivs. (I; e.g. pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)) or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are H, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the N to which they are attached complete a 3- to 8-membered ring contg. C atoms and optionally contg. a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6. Although I and other Markush structures in the patent show 2,4- derivs., many specific 3,5- derivs. are included in the claims and examples. Combinatorial and non-combinatorial methods were used to prep. numerous claimed compds. and characterization data is reported for about 90 compds. IC50 values for various claimed compds. show the selectivity towards MMP-13 vs. MMP-1 and MMP-3 and the potent MMP-13 inhibitory activity (e.g. 0.033 .mu.M for pyridine-2,4-dicarboxylic acid bis[((1,3-**benzodioxol**-5-yl)methyl)amide]).

IT **449734-09-2P**, Pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide) **449734-16-1P**, Pyridine-2,4-dicarboxylic acid bis[((1,3-**benzodioxol**-5-yl)methyl)amide]

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of pyridine-2,4-dicarboxamide and -dicarboxylic acid derivs. as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)

RN 449734-09-2 CAPLUS

CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-16-1 CAPLUS

CN 2,4-Pyridinedicarboxamide, N,N'-bis(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)



IT **134377-73-4P**, Pyridine-2,4-dicarboxylic acid bis[(2-ethoxyethyl)amide] **139994-21-1P**, Pyridine-2,4-dicarboxylic acid bis(3-chlorobenzylamide) **139994-22-2P**, Pyridine-2,4-dicarboxylic acid bis(4-methylbenzylamide) **149521-51-7P**, Pyridine-2,4-dicarboxylic acid bis[[2-(4-hydroxyphenyl)ethyl]amide] **449734-25-2P**, Pyridine-2,4-dicarboxylic acid bis(2,4-dimethoxybenzylamide) **449734-26-3P**, Pyridine-2,4-dicarboxylic acid bis(4-chlorobenzylamide) **449734-27-4P**, Pyridine-2,4-dicarboxylic acid bis(benzylamide) **449734-28-5P**, Pyridine-2,4-dicarboxylic acid bis[(naphthalen-1-ylmethyl)amide] **449734-29-6P**, Pyridine-2,4-dicarboxylic acid bis[(2-p-tolylethyl)amide] **449734-30-9P**, Pyridine-2,4-dicarboxylic acid bis(4-methoxybenzylamide) **449734-31-0P**, Pyridine-2,4-dicarboxylic acid bis(3-fluorobenzylamide) **449734-32-1P**, Pyridine-2,4-dicarboxylic acid bis[(benzyl)ethylamide] **449734-33-2P**, Pyridine-2,4-dicarboxylic acid bis[[2-(3,4-dimethoxyphenyl)ethyl]amide] **449734-34-3P**, Pyridine-2,4-dicarboxylic acid bis[[2-(2-phenoxyphenyl)ethyl]amide] **449734-35-4P**, Pyridine-2,4-dicarboxylic acid bis[(4-phenylbutyl)amide] **449734-36-5P**, Pyridine-2,4-dicarboxylic acid bis[[2-(4-methoxyphenyl)ethyl]amide] **449734-37-6P**, Pyridine-2,4-dicarboxylic acid bis[[2-(2-fluorophenyl)ethyl]amide] **449734-38-7P**, Pyridine-2,4-dicarboxylic acid bis[[2-(3-chlorophenyl)ethyl]amide] **449734-39-8P**, Pyridine-2,4-dicarboxylic acid bis[[2-(2,4-dimethylphenyl)ethyl]amide] **449734-40-1P**, Pyridine-2,4-dicarboxylic acid bis[(2-o-tolylethyl)amide] **449734-41-2P**, Pyridine-2,4-dicarboxylic acid bis[[2-(4-ethylphenyl)ethyl]amide] **449734-42-3P**, Pyridine-2,4-dicarboxylic acid bis[(2-phenylpropyl)amide] **449734-43-4P**, Pyridine-2,4-dicarboxylic acid bis[(1,2-diphenylethyl)amide] **449734-44-5P**, Pyridine-2,4-dicarboxylic acid bis(2,4-dichlorobenzylamide) **449734-45-6P**, Pyridine-2,4-dicarboxylic acid bis[[(biphenyl)-2-ylmethyl]amide] **449734-46-7P**, Pyridine-2,4-dicarboxylic acid bis(3,4,5-

trimethoxybenzylamide) **449734-47-8P**, Pyridine-2,4-dicarboxylic acid bis(3,5-dimethoxybenzylamide) **449734-48-9P**, Pyridine-2,4-dicarboxylic acid bis(3,4-dimethoxybenzylamide) **449734-49-0P**, Pyridine-2,4-dicarboxylic acid bis[(ethyl)pyridin-4-ylmethylamide] **449734-50-3P**, Pyridine-2,4-dicarboxylic acid bis[(2-(pyridin-4-yl)ethyl)amide] **449734-51-4P**, Pyridine-2,4-dicarboxylic acid bis[(2-(pyridin-3-yl)ethyl)amide] **449734-52-5P**, Pyridine-2,4-dicarboxylic acid bis[[2-(4-chlorophenyl)ethyl]amide] **449734-53-6P**, Pyridine-2,4-dicarboxylic acid bis[((pyridin-4-yl)methyl)amide] **449734-54-7P**, Pyridine-2,4-dicarboxylic acid bis[3,5-bis(trifluoromethyl)benzylamide] **449734-55-8P**, Pyridine-2,4-dicarboxylic acid bis(2,3-dimethoxybenzylamide) **449734-56-9P**, Pyridine-2,4-dicarboxylic acid bis(3-trifluoromethylbenzylamide) **449734-57-0P**, Pyridine-2,4-dicarboxylic acid bis(2-trifluoromethoxybenzylamide) **449734-58-1P**, Pyridine-2,4-dicarboxylic acid bis(3-difluoromethoxybenzylamide) **449734-59-2P**, Pyridine-2,4-dicarboxylic acid bis(2-difluoromethoxybenzylamide) **449734-60-5P**, Pyridine-2,4-dicarboxylic acid bis(4-fluoro-3-trifluoromethylbenzylamide) **449734-61-6P**, Pyridine-2,4-dicarboxylic acid bis(2-methoxybenzylamide) **449734-62-7P**, Pyridine-2,4-dicarboxylic acid bis[[2-(3-ethoxyphenyl)ethyl]amide] **449734-63-8P**, Pyridine-2,4-dicarboxylic acid bis(3-chloro-4-fluorobenzylamide) **449734-64-9P**, Pyridine-2,4-dicarboxylic acid bis(2,4-difluorobenzylamide) **449734-65-0P**, Pyridine-2,4-dicarboxylic acid bis(4-aminobenzylamide) **449734-66-1P**, Pyridine-2,4-dicarboxylic acid bis(2-methylbenzylamide) **449734-67-2P**, Pyridine-2,4-dicarboxylic acid bis[[bis(4-methoxyphenyl)methyl]amide] **449734-68-3P**, Pyridine-2,4-dicarboxylic acid bis[(3,3-diphenylpropyl)amide] **449734-69-4P**, Pyridine-2,4-dicarboxylic acid bis[(1-methyl-3-phenylpropyl)amide] **449734-70-7P**, Pyridine-2,4-dicarboxylic acid bis[(3,4-dimethoxyphenyl)amide] **449734-71-8P**, Pyridine-2,4-dicarboxylic acid bis(2-fluorobenzylamide) **449734-72-9P**, Pyridine-2,4-dicarboxylic acid bis[(3-imidazol-1-ylpropyl)amide] **449734-73-0P**, Pyridine-2,4-dicarboxylic acid bis(2-chlorobenzylamide) **449734-74-1P**, Pyridine-2,4-dicarboxylic acid bis(2-trifluoromethylbenzylamide) **449734-75-2P**, Pyridine-2,4-dicarboxylic acid bis[[2-(3-methoxyphenyl)ethyl]amide] **449734-76-3P**, Pyridine-2,4-dicarboxylic acid bis[(1-phenylethyl)amide] **449734-77-4P**, Pyridine-2,4-dicarboxylic acid bis[((pyridin-3-yl)methyl)amide] **449734-78-5P**, Pyridine-2,4-dicarboxylic acid bis[(4-ethoxyphenyl)amide] **449734-79-6P**, Pyridine-2,4-dicarboxylic acid bis[(phenethyl)amide] **449734-80-9P**, Pyridine-2,4-dicarboxylic acid bis[(thiophen-2-ylmethyl)amide] **449734-81-0P**, Pyridine-2,4-dicarboxylic acid bis(4-trifluoromethylbenzylamide) **449734-82-1P**, Pyridine-2,4-dicarboxylic acid bis[(5-methylfuran-2-ylmethyl)amide] **449734-83-2P**, Pyridine-2,4-dicarboxylic acid bis[[1-(4-fluorophenyl)ethyl]amide] **449734-84-3P**, Pyridine-2,4-dicarboxylic acid bis(2-aminobenzylamide) **449734-85-4P**, Pyridine-2,4-dicarboxylic acid bis[(1-(naphthalen-1-yl)ethyl)amide] **449734-86-5P**, Pyridine-2,4-dicarboxylic acid bis(3-trifluoromethoxybenzylamide) **449734-87-6P**, Pyridine-2,4-dicarboxylic acid bis[[1-(3-methoxyphenyl)ethyl]amide] **449734-88-7P**, Pyridine-2,4-dicarboxylic acid bis[(1-phenylpropyl)amide] **449734-89-8P**, Pyridine-2,4-dicarboxylic acid bis[[2-(2-methoxyphenyl)ethyl]amide] **449734-90-1P**, Pyridine-2,4-dicarboxylic acid bis[[2-(3-trifluoromethylphenyl)ethyl]amide] **449734-91-2P**, Pyridine-2,4-dicarboxylic acid bis(indan-1-ylamide) **449734-92-3P**, Pyridine-2,4-dicarboxylic acid bis(3,4-dichlorobenzylamide) **449734-93-4P**, Pyridine-2,4-dicarboxylic acid bis[[2-(4-bromophenyl)ethyl]amide] **449734-94-5P**, Pyridine-2,4-dicarboxylic acid bis[(2-(pyridin-2-

yl)ethyl)amide] **449734-95-6P**, Pyridine-2,4-dicarboxylic acid bis[(2-(thiophen-2-yl)ethyl)amide] **449734-96-7P**, Pyridine-2,4-dicarboxylic acid bis[[2-(5-methoxy-1H-indol-3-yl)ethyl]amide] **449734-97-8P**, Pyridine-2,4-dicarboxylic acid bis[[2-(1H-indol-3-yl)ethyl]amide] **449734-98-9P**, Pyridine-2,4-dicarboxylic acid bis(3,5-dichlorobenzylamide)
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of pyridine-2,4-dicarboxamide and -dicarboxylic acid derivs. as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)

RN 134377-73-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 139994-21-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139994-22-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 149521-51-7 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-25-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-26-3 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-27-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449734-28-5 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 449734-29-6 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-30-9 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-31-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-32-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-diethyl-N,N'-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449734-33-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-34-3 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-phenoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-35-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 449734-36-5 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-37-6 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-38-7 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-39-8 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2,4-dimethylphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-40-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-41-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-ethylphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-42-3 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(2-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449734-43-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(1,2-diphenylethyl)- (9CI) (CA INDEX NAME)



RN 449734-44-5 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-45-6 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis([1,1'-biphenyl]-2-ylmethyl)- (9CI) (CA INDEX NAME)



RN 449734-46-7 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-47-8 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,5-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-48-9 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-49-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-diethyl-N,N'-bis(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449734-50-3 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-51-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-52-5 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-53-6 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449734-54-7 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[3,5-bis(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-55-8 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2,3-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-56-9 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-57-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[2-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-58-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[3-(difluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-59-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[2-(difluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-60-5 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-61-6 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-62-7 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3-ethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-63-8 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-64-9 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-65-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-aminophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-66-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 449734-67-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[bis(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-68-3 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(3,3-diphenylpropyl)- (9CI) (CA INDEX NAME)



RN 449734-69-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(1-methyl-3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449734-70-7 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 449734-71-8 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-72-9 CAPLUS.
CN 2,4-Pyridinedicarboxamide, N,N'-bis[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 449734-73-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-74-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-75-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-76-3 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 449734-77-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449734-78-5 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 449734-79-6 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 449734-80-9 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 449734-81-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-82-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(5-methyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-83-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[1-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-84-3 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(2-aminophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-85-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[1-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-86-5 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449734-87-6 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-88-7 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(1-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449734-89-8 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-90-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 449734-91-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis(2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)



RN 449734-92-3 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449734-93-4 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(4-bromophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-94-5 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-95-6 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-96-7 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-97-8 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 449734-98-9 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,5-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



IT **499-80-9**, 2,4-Pyridinedicarboxylic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of pyridine-2,4-dicarboxamide and -dicarboxylic acid derivs. as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)
RN 499-80-9 CAPLUS
CN 2,4-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:487577 CAPLUS
DN 137:63420
TI Preparation of lactone ketolide macrolide erythromycin antibiotics
IN Andreotti, Daniele; Arista, Luca; Biondi, Stefano; Cardullo, Francesca; Damiani, Frederica; Lociuro, Sergio; Marchioro, Carla; Merlo, Giancarlo; Mingardi, Anna; Niccolai, Daniela; Paio, Alfredo; Piga, Elisabetta; Pozzan, Alfonso; Seri, Catia; Tarsi, Luca; Terreni, Silvia; Tibasco, Jessica
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2002050091	A1	20020627	WO 2001-GB5665	20011220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002017277	A5	20020701	AU 2002-17277	20011220
PRAI	GB 2000-31309	A	20001221		
	GB 2001-26276	A	20011101		
	GB 2001-26277	A	20011101		
	WO 2001-GB5665	W	20011220		
OS	MARPAT 137:63420				

GI



I

AB The present invention relates to lactone ketolides I wherein R is H, CN, substituted alkyl; R1 is alkyl, alkenyl; R2 is H, hydroxy protecting group; R3 is H, halogen, and pharmaceutically acceptable salts and solvates thereof, to process for their prepn. and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body. Thus, (11S,21R)-3-decladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl-(cyano)-methylene]erythromycin A was prepd. and tested as antibacterial agent against Streptococcus pneumoniae and Streptococcus pyogenes (MIC .ltoreq. 1 .mu.g/mL).

IT **439104-92-4P 439105-06-3P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of lactone ketolide macrolide erythromycin antibiotics and their use in therapy or prophylaxis of systemic or topical bacterial infections)

RN 439104-92-4 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[[2-[[(3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-ethyltetradecahydro-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-9-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-2H-furo[2,3-c]oxacyclotetradecin-3-yl]amino]ethyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 439105-06-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[[2-[[(3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-ethyltetradecahydro-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-9-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-2H-furo[2,3-c]oxacyclotetradecin-3-yl]amino]ethyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





IT **17874-79-2 24195-07-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of lactone ketolide macrolide erythromycin antibiotics and their use in therapy or prophylaxis of systemic or topical bacterial infections)
RN 17874-79-2 CAPLUS
CN 2,5-Pyridinedicarboxylic acid, 5-methyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 24195-07-1 CAPLUS
CN 2,3-Pyridinedicarboxylic acid, 2-methyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:275966 CAPLUS
DN 136:294739
TI Preparation of pyridinyl-substituted benzamides as Apo B secretion inhibitors
IN Takasugi, Hisashi; Terasawa, Takeshi; Inoue, Yoshikazu; Nakamura, Hideko; Nagayoshi, Akira; Ohtake, Hiroaki; Furukawa, Yoshiro; Mikami, Masafumi; Hinoue, Kazumasa; Ohtsubo, Makoto
PA Fujisawa Pharmaceutical Co., Ltd., Japan; Daiso Co., Ltd.
SO PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2002028835	A1	20020411	WO 2001-JP8581	20010928
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001092315	A5	20020415	AU 2001-92315	20010928
PRAI	AU 2000-583	A	20001005		
	AU 2001-6666	A	20010727		
	WO 2001-JP8581	W	20010928		
OS	MARPAT 136:294739				
GI					



I



II

AB Title compds. I [wherein R1 and R2 = independently alkyl, alkenyl, acyl, amino, (cyclo)alkoxy, aryl(oxy), sulfoxy, mercapto, sulfo, H, halo, NO2, CN, or OH; or R1R2 = a ring; Q1 = N or CH; L = (un)substituted unsatd. 3 to 10-membered heterocyclic group; X = (un)substituted monocyclic (hetero)arylene; Y = (A1)m(A2)n(A4)k; Z = direct bond, CH2, NH, or O; R = H or alkyl; A1 = (un)substituted alkylene or alkenylene; A2 = NR3, CONR3, NHCONH, CO2, O, O(CH2)2NR3, S, SO, or SO2; A4 = alkylene, alkenylene, or alkynylene; R3 = H or suitable substituent; k, m, and m = independently 0 or 1; or a salt thereof] were prepd. as apolipoprotein B (Apo B) secretion inhibitors. For example, to a suspension of N-(4-aminophenyl)-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide, 2-pyridinylacetic acid.bul.HCl, and HOBT.bul.H2O in CH2Cl2 was added to WSC.bul.HCl, followed by TEA at 5.degree.C. The mixt. was stirred at room temp. for 24 h and worked up to give II. The latter inhibited Apo B secretion by 100% at 10-6 M in HepG2 cells and lowered cholesterol by 83% and triglyceride by 35% after 2 h at a dose of 32 mg/kg in ddY-mice. I are useful for the

prophylaxis and treatment of diseases or conditions resulting from elevated circulating levels of Apo B, such as hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus, obesity, coronary heart diseases, myocardial infarction, stroke, restenosis, and Syndrome X.

IT **408368-76-3P**, 2-[[4-[[[6-[(tert-Butoxycarbonyl)amino]-2-pyridinyl]carbonyl]amino]methyl]anilino]carbonyl]-4'-(trifluoromethyl)-1,1'-biphenyl **408368-77-4P**, 6-Amino-N-[4-[[[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]benzyl]-2-pyridinecarboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Apo B inhibitor; prepn. of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related conditions)

RN 408368-76-3 CAPLUS

CN Carbamic acid, [6-[[[[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]methyl]amino]carbonyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 408368-77-4 CAPLUS

CN 2-Pyridinecarboxamide, 6-amino-N-[[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **408365-48-0P**, N-[4-[[[4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]benzyl]-2-pyridinecarboxamide **408365-51-5P**, N-[3-[[[4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]benzyl]-2-pyridinecarboxamide **408365-52-6P**, N-[4-[(1,1'-Biphenyl-2-ylcarbonyl)amino]benzyl]-2-pyridinecarboxamide **408365-53-7P**, N-[4-[[2-[3-(Trifluoromethyl)anilino]benzoyl]amino]benzyl]-2-pyridinecarboxamide **408365-58-2P**, N-[4-[[(4'-Methyl-1,1'-biphenyl-2-yl)carbonyl]amino]benzyl]-2-pyridinecarboxamide **408365-59-3P**, N-[4-[[(4'-Chloro-1,1'-biphenyl-2-

yl)carbonyl]amino]benzyl]-2-pyridinecarboxamide **408368-67-2P**, N-[(1R)-1-[4-[[[4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]phenyl]ethyl]-2-pyridinecarboxamide **408368-71-8P**, N-[(11S)-1-[4-[[[4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]phenyl]ethyl]-2-pyridinecarboxamide **408368-78-5P**, 6-(Acetylamino)-N-[4-[[[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]benzyl]-2-pyridinecarboxamide **408368-90-1P**, 4-[[[4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]benzyl 2-pyridinecarboxylate **408370-22-9P**, N-Methyl-N-[4-[[[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]benzyl]-2-pyridinecarboxamide **408370-25-2P**, N-[2-[4-[[[4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl]amino]phenyl]ethyl]-2-pyridinecarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Apo B inhibitor; prepn. of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related conditions)

RN 408365-48-0 CAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 408365-51-5 CAPLUS
CN 2-Pyridinecarboxamide, N-[[3-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 408365-52-6 CAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[([1,1'-biphenyl]-2-ylcarbonyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 408365-53-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[[2-[[3-(trifluoromethyl)phenyl]amino]benzoyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 408365-58-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[[(4'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 408365-59-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[[4-[[(4'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 408368-67-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1R)-1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 408368-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1S)-1-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 408368-78-5 CAPLUS
CN 2-Pyridinecarboxamide, 6-(acetylamino)-N-[[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 408368-90-1 CAPLUS
CN 2-Pyridinecarboxylic acid, [4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 408370-22-9 CAPLUS
CN 2-Pyridinecarboxamide, N-methyl-N-[[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 408370-25-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)



IT **408368-74-1P**, tert-Butyl 6-[[(4-nitrobenzyl)amino]carbonyl]-2-pyridinylcarbamate **408368-75-2P**, tert-Butyl 6-[[(4-aminobenzyl)amino]carbonyl]-2-pyridinylcarbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related conditions)

RN 408368-74-1 CAPLUS
CN Carbamic acid, [6-[[[(4-nitrophenyl)methyl]amino]carbonyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 408368-75-2 CAPLUS
CN Carbamic acid, [6-[[[(4-aminophenyl)methyl]amino]carbonyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **258497-21-1**, 6-[(tert-Butoxycarbonyl)amino]-2-pyridinecarboxylic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related conditions)

RN 258497-21-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:237356 CAPLUS
DN 136:263090
TI Preparation of cyclic amine derivatives for inhibition of the action of chemokines such as MIP-1.alpha. and/or MCP-1 on target cells
IN Shiota, Tatsuki; Kataoka, Ken-Ichiro; Imai, Minoru; Tsutsumi, Takaharu; Sudoh, Masaki; Sogawa, Ryo; Morita, Takuya; Hada, Takahiko; Muroga, Yumiko; Takenouchi, Osami; Furuya, Minoru; Endo, Noriaki; Tarby, Christine M.; Moree, Wilna; Teig, Steven
PA Teijin Limited, Japan; Dupont Pharmaceuticals Research Laboratories
SO U.S., 364 pp., Cont. of U.S. Ser. No. 554,562.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6362177	B1	20020326	US 2001-905078	20010716
	US 6451842	B1	20020917	US 2000-554562	20000516
	US 6410566	B1	20020625	US 2001-905077	20010716
PRAI	US 2000-554562	A3	20000516		
	US 1997-972484	B1	19971118		
	US 1998-55285	B1	19980406		
	US 1998-133434	B1	19980813		
	WO 1998-US23254	W	19981117		

OS MARPAT 136:263090
GI



I



II

AB The title compds. [I; R1 = (un)substituted Ph, cycloalkyl, heteroaryl,

etc.; R2 = H, alkyl, alkoxycarbonyl, etc.; j = 0-2; k = 0-2; m = 3-4 and k+m = 5 or 6; n = 0-1; R3 = H, alkyl; R4, R5 = H, OH, Ph, etc.; p, q = 0-1; G = CO, SO, CO2, etc.; R6 = Ph, cycloalkyl, cycloalkenyl, etc.] and their pharmaceutically acceptable acid addn. salts which inhibit the action of chemokines such as MIP-1.alpha. and/or MCP-1 on target cells and may be useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues, were prepd. Thus, reaction of N-benzoylglycine with 3-amino-1-(4-chlorobenzyl)pyrrolidine.2HCl in the presence of 3-ethyl-1-[3-(dimethylaminopropyl)]carbodiimide.HCl, 1-hydroxybenzotriazole and Et3N in CHCl3 afforded 95% II which showed 50-80% inhibition of MIP-1.alpha. binding to THP-1 cells at 10 .mu.M.

IT **226242-70-2P**, 2-Pyridinecarboxamide, 4-chloro-N-[2-[[(3R)-1-[(4-chlorophenyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-
226242-73-5P, 2-Pyridinecarboxamide, N-[2-[[(3R)-1-[(4-chlorophenyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-6-methyl-
226242-77-9P, 2-Pyridinecarboxamide, 4-chloro-N-[2-[[(3R)-1-[(4-methylphenyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-
226242-82-6P, 2-Pyridinecarboxamide, 4-chloro-N-[2-[[(3R)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-
226242-84-8P, 2-Pyridinecarboxamide, N-[2-[[(3R)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-6-methyl-
226242-88-2P, 2-Pyridinecarboxamide, 4-chloro-N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-2-oxoethyl]-
226242-90-6P, 2-Pyridinecarboxamide, N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-2-oxoethyl]-6-methyl-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclic amine derivs. for inhibition of action of chemokines such as MIP-1.alpha. and/or MCP-1 on target cells)

RN 226242-70-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-chloro-N-[2-[[(3R)-1-[(4-chlorophenyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226242-73-5 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[[(3R)-1-[(4-chlorophenyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226242-77-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-chloro-N-[2-[[(3R)-1-[(4-methylphenyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226242-82-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-chloro-N-[2-[[(3R)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226242-84-8 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[[(3R)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226242-88-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-chloro-N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 226242-90-6 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-2-oxoethyl]-6-methyl- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:123617 CAPLUS
DN 136:183819
TI Preparation of (imidazolylalkyl)biphenylcarbonitriles and analogs as farnesyltransferase inhibitors
IN Wang, Wei-Bo; Curtin, Michael L.; Fakhoury, Stephen A.; Gwaltney, Stephen L.; Hasvold, Lisa A.; Hutchins, Charles W.; Li, Qun; Lin, Nan-Horng; Nelson, Lissa Taka Jennings; O'Connor, Steve; Sham, Hing L.; Sullivan, Gerard M.; Wang, Gary T.; Wang, Xilu
PA USA
SO U.S. Pat. Appl. Publ., 189 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002019527	A1	20020214	US 2001-842391	20010425
PRAI US 2000-200165P	P	20000427		

OS MARPAT 136:183819

GI



II

AB Title compds. (I) were prepd. Thus, 2-MeC6H4C6H3(CN)(CHO)-2,5 was condensed with 1-methyl-2-triethylsilyl-1H-imidazole (prepn. each given) and the product O-arylated to give title compd. II. Data for biol. activity of I were given.

IT **881-86-7**, Dimethyl 2,5-pyridinedicarboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of (imidazolylalkyl)biphenylcarbonitriles and analogs as farnesyltransferase inhibitors)

RN 881-86-7 CAPLUS

CN 2,5-Pyridinedicarboxylic acid, dimethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2002:89041 CAPLUS

DN 136:386093

TI Solid-phase synthesis of .alpha.-substituted 3-bisarylthio N-Hydroxy propionamides as Specific MMP Inhibitors

AU Chollet, Anne-Marie; Le Diguarher, Thierry; Kucharczyk, Nathalie; Loynel, Armelle; Bertrand, Marc; Tucker, Gordon; Guilbaud, Nicolas; Burbridge, Mike; Pastoureau, Philippe; Fradin, Armel; Sabatini, Massimo; Fauchere; Jean-Luc; Casara, Patrick

CS Institut de Recherches Servier, Croissy sur Seine, 78290, Fr.

SO Bioorganic & Medicinal Chemistry (2002), 10(3), 531-544
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

AB A novel series of potent and specific MMP-2,3,9,13 inhibitors has been obtained by modulation on solid phase by .alpha. and aryl substitutions on 3-arylthio-N-hydroxy-propionamides starting from itaconic acid. Example compds. thus prepd. and evaluated included .alpha.-[([1,1'-biphenyl]-4-ylthio)methyl]-N-hydroxy-4-oxo-1,2,3-benzotriazine-3(4H)-butanamide, and derivs. and analogs thereof, such as .alpha.-[[(4'-chloro[1,1'-biphenyl]-4-yl)thio]methyl]-N-hydroxy-4-oxo-1,2,3-benzotriazine-3(4H)-butanamide, N-hydroxy-4-oxo-.alpha.-[[[4-(3-thienyl)phenyl]thio]methyl]-1,2,3-benzotriazine-3(4H)-butanamide, N-hydroxy-4-oxo-.alpha.-[[[4-(3-pyridinyl)phenyl]thio]methyl]-1,2,3-benzotriazine-3(4H)-butanamide, N-hydroxy-4-oxo-.alpha.-[[[4-(5-pyrimidinyl)phenyl]thio]methyl]--1,2,3-

benzotriazine-3(4H)-butanamide, .alpha.-[[(4'-chloro[1,1'-biphenyl]-4-yl)thio]methyl]-N-hydroxy-2H-isoindole-2-butanamide, .alpha.-[[(4'-chloro[1,1'-biphenyl]-4-yl)thio]methyl]-N-hydroxy-4-oxo-3(4H)-quinazolinebutanamide, etc.

IT **427895-45-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of 2-[[[4'-chloro-[1,1-biphenyl]-4-yl]thio]methyl]-N-hydroxybutanamide derivs. as specific metalloproteinase inhibitors)

RN 427895-45-2 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[(4'-chloro[1,1'-biphenyl]-4-yl)thio]methyl]-4-(hydroxyamino)-4-oxobutyl]- (9CI) (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2002:31432 CAPLUS
DN 136:102378
TI Preparation of thiazoles and oxazoles as antiinflammatories
IN Fujiwara, Norio; Fujita, Hitoshi; Antoku, Fujio; Sugasawa, Toshinari; Kawakami, Hajime
PA Sumitomo Pharmaceuticals Company, Limited, Japan
SO PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002002542	A1	20020110	WO 2001-JP5540	20010628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1300401	A1	20030409	EP 2001-943850	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI JP 2000-198074 A 20000630
WO 2001-JP5540 W 20010628

OS MARPAT 136:102378

GI



I



II

AB Title compds. [I; X = O, S; R1 = H, alkyl; R2 = H, alkyl, aryl; R3 = aryl; R4 = H, alkanoyl, alkyl; R5 = H, alkyl; Y1 = single bond, alkylene CO(CH2)n; Y2 = alkylene; wavy bond = (E), (Z)] and salts are prepd. and formulations are discussed. Title compds. I inhibit infiltration of leukocytes, such as eosinophil and lymphocytes, and are hence useful for the treatment of various kinds of inflammation. Thus, the title compd. II was prepd. and in vitro tested for receptor inhibition activity in rat lung membrane.

IT **389147-77-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiazoles and oxazoles as antiinflammatories)

RN 389147-77-7 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-[3-(acetylamino)propyl]-4-[4-(trifluoromethoxy)phenyl]-2(3H)-thiazolylidene]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2002:31402 CAPLUS

DN 136:102190

TI Preparation of substituted amines to treat Alzheimer's disease

IN Maillaird, Michel; Hom, Court; Gailunas, Andrea; Jagodzinska, Barbara; Fang, Lawrence Y.; John, Varghese; Freskos, John N.; Pulley, Shon R.; Beck, James P.; Tenbrink, Ruth E.

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 651 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002512	A2	20020110	WO 2001-US21012	20010629
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL; TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002128255	A1	20020912	US 2001-896139	20010629
PRAI	US 2000-215323P	P	20000630		
	US 2000-252736P	P	20001122		
	US 2000-255956P	P	20001215		
	US 2001-268497P	P	20010213		
	US 2001-279779P	P	20010329		
	US 2001-295589P	P	20010604		
OS	MARPAT 136:102190				
GI					



I



II

AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; R4 = XR; X = CO, SO2, a bond, etc.; R = Ph, naphthyl, indanyl, etc.; R5 = (un)substituted alkyl, (CH2)0-3cycloalkyl, etc.], useful in treating Alzheimer's disease and other similar diseases, were prepd. Thus, reacting (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate with 5-methyl-N,N-dipropylisophthalamic acid in the presence of Et3N, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in DMF afforded (1S,2R)-II. The compds. I exhibit an IC50 of < 50 .mu.M against beta-secretase.

IT **388063-70-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted amines for treating Alzheimer's disease)

RN 388063-70-5 CAPLUS

CN 2,4-Pyridinedicarboxamide, N4-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[(phenylmethyl)amino]propyl]-N2,N2-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **388072-33-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of substituted amines for treating Alzheimer's disease)

RN 388072-33-1 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[(dipropylamino)carbonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 16 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2002:11099 CAPLUS

DN 136:69597

TI Synthesis of hydrazide and .alpha.-alkoxyamide angiogenesis inhibitors

IN Craig, Richard A.; Kawai, Megumi; Lynch, Linda M.; Patel, Jyoti R.; Sheppard, George S.; Wang, Jieyi; Yang, Fan; Ba-Maung, Nwe

PA USA

SO U.S. Pat. Appl. Publ., 78 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002002152	A1	20020103	US 2001-833917	20010412
PRAI US 2000-197262P	P	20000414		

OS MARPAT 136:69597

GI



I



II



III

AB Title compds. I [R1 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, R5S-alkylene; R3 = H, alkyl, arylalkyl; R4 = NR6R7, OR8; R5 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl; R6-7 = H, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylthioalkyl, aryl, arylalkanoyl, etc.; or R6-7 together are arylalkylidene; or R6-7 together with the nitrogen atom to which they are attached, form a heterocycle; R8 = H, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, etc.; R9-10 = H, alkyl, aryl] were prepd. Over 450 synthetic examples were reported. For instance, (2R)-2-(Boc)amino-3-cyclohexylpropanoic acid was reduced to the corresponding alc. (PhMe, Red-Al, 0.degree.C, room temp. 1 h) and oxidized to II (DMSO, Py.bul.SO3, Et3N, room temp. 30 min). II was converted to the bisulfite addn. product (H2O, NaHSO3, 5.degree.C, 24 h) and reacted with KCN to give the .alpha.-hydroxy nitrile intermediate which was hydrolyzed to the carboxylic acid (12 N HCl, reflux, 21 h) and converted to III by condensation with benzylhydrazine (DCM/DMA, DIC, NMM, HOBt). Selected compds. I had IC50 < 0.1 .mu.M for MetAP2. I are useful for inhibiting angiogenesis.

IT **369356-11-6P 369358-72-5P 369359-90-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of hydrazide and .alpha.-alkoxyamide angiogenesis inhibitors)

RN 369356-11-6 CAPLUS

CN 2-Pyridinecarboxylic acid, 2-[(3R)-3-amino-4-cyclohexyl-2-hydroxy-1-oxobutyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369358-72-5 CAPLUS

CN D-glycero-Pentonic acid, 3-amino-3,4-dideoxy-5-S-ethyl-5-thio-, 2-(2-pyridinylcarbonyl)hydrazide, (2.xi.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369359-90-0 CAPLUS
CN D-glycero-Pentonic acid, 3-amino-3,4-dideoxy-5-S-(1-methylethyl)-5-thio-, 2-(2-pyridinylcarbonyl)hydrazide, (2.xi.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:923616 CAPLUS
DN 136:53691
TI Preparation of 4-amino-azepan-3-one protease inhibitors
IN Marquis, Robert W., Jr.; Ru, Yu; Veber, Daniel F.; Cummings, Maxwell D.; Thompson, Scott K.; Yamashita, Dennis
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001095911	A1	20011220	WO 2001-US19062	20010614

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-593845 A2 20000614
OS MARPAT 136:53691
GI



I



II

AB The title compds. [I; R1 = COCR13NR11R12, COCR13XR15, COCH2R13; R2 = H, alkyl, cycloalkylalkyl, etc.; R3 = H, alkyl, cycloalkylalkyl, etc.; R4 = H, alkyl, arylalkyl, etc.; R11 = H, alkyl, arylalkyl, etc.; R12 = H, alkyl, cycloalkyl, etc.; R13 = H, alkyl, alkenyl, etc.; R15 = H, alkyl, alkenyl, etc.] which inhibit proteases (no data), including cathepsin K, and are useful for treating diseases of excessive bone loss or cartilage or matrix degrdn. including osteoporosis, gingival disease including gingivitis and periodontitis, arthritis, more specifically, osteoarthritis and rheumatoid arthritis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease, were prepd. E.g., a multi-step synthesis of compd. II was given.

IT **281215-40-5P 381179-21-1P 381179-24-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-amino-azepan-3-one protease inhibitors)

RN 281215-40-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[hexahydro-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381179-21-1 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[(4R)-hexahydro-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381179-24-4 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[(4S)-hexahydro-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **281220-60-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-amino-azepan-3-one protease inhibitors)
RN 281220-60-8 CAPLUS
CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[hexahydro-3-hydroxy-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:780840 CAPLUS
DN 135:331197
TI Synthesis of hydrazide and .alpha.-alkoxyamide angiogenesis inhibitors
IN Craig, Richard A.; Kawai, Megumi; Lynch, Linda M.; Patel, Jyoti R.; Sheppard, George S.; Wang, Jieyi; Yang, Fan; Ba-Maung, Nwe Y.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001079157	A1	20011025	WO 2001-US12274	20010413
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1272456	A1	20030108	EP 2001-925029	20010413
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-549995	A	20000414		
	US 2001-813008	A	20010321		
	WO 2001-US12274	W	20010413		

OS MARPAT 135:331197
GI



I



II



III

AB Title compds. I [R1 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, R5S-alkylene; R3 = H, alkyl, arylalkyl; R4 = NR6R7, OR8; R5 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl; R6-7 = H, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylthioalkyl, aryl, arylalkanoyl, etc.; or R6-7 together are arylalkylidene; or R6-7 together with the nitrogen atom to which they are attached, form a heterocycle; R8 = H, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, etc.; R9-10 = H, alkyl, aryl] were prepd. Over 450 synthetic examples were reported. For instance, (2R)-2-(Boc)amino-3-cyclohexylpropanoic acid was reduced to the corresponding alc. (PhMe, Red-Al, 0.degree.C, room temp. 1 h) and oxidized to II (DMSO, Py.bul.SO3, Et3N, room temp. 30 min). II was converted to the bisulfite addn. product (H2O, NaHSO3, 5.degree.C, 24 h) and reacted with KCN to give the .alpha.-hydroxy nitrile intermediate which was hydrolyzed to the carboxylic acid (12 N HCl, reflux, 21 h) and converted to III by condensation with benzylhydrazine (DCM/DMA, DIC, NMM, HOBt). Selected compds. I had IC50 < 0.1 .mu.M for MetAP2. I are useful for inhibiting angiogenesis.

IT **369356-11-6P 369358-72-5P 369359-90-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of hydrazide and .alpha.-alkoxyamide angiogenesis inhibitors)
RN 369356-11-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 2-[(3R)-3-amino-4-cyclohexyl-2-hydroxy-1-oxobutyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369358-72-5 CAPLUS
CN D-glycero-Pentonic acid, 3-amino-3,4-dideoxy-5-S-ethyl-5-thio-, 2-(2-pyridinylcarbonyl)hydrazide, (2.xi.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369359-90-0 CAPLUS
CN D-glycero-Pentonic acid, 3-amino-3,4-dideoxy-5-S-(1-methylethyl)-5-thio-, 2-(2-pyridinylcarbonyl)hydrazide, (2.xi.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:578597 CAPLUS
DN 135:124156
TI Bactericide combinations in detergents
IN Elsmore, Richard; Houghton, Mark Phillip
PA Robert McBride Ltd., UK
SO Brit. UK Pat. Appl., 53 pp.
CODEN: BAXXDU
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2354771	A1	20010404	GB 1999-23253	19991001
PRAI	GB 1999-23253		19991001		

AB The detergent comprises a bactericide in combination with an anionic, cationic, nonionic or amphoteric surfactant which has a C12-18 alkyl group as the longest chain attached to the hydrophilic moiety. Creduret 50 (hydrogenated ethoxylated castor oil) 50, citric acid 12, formalin 10, sodium alkyl benzene sulfonate (C12-20) alkyl 1, perfume white line 0.5, detergent enzyme savingase 0.2, and bactericide Pr 4-hydroxybenzoate 1.0 parts formed a detergent, showing redn. activity after contact 2.

IT **136-45-8 499-83-2**, 2,6-Pyridinedicarboxylic acid
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); BIOL (Biological study); USES (Uses)
(bactericide combinations in detergents)

RN 136-45-8 CAPLUS

CN 2,5-Pyridinedicarboxylic acid, dipropyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 499-83-2 CAPLUS

CN 2,6-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



L5 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2001:489404 CAPLUS

DN 135:76901

TI Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors

IN Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanishi, Satoshi

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047931 A1		20010705	WO 2000-JP9160	20001222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR

PRAI JP 1999-366313 19991224

OS MARPAT 135:76901

GI



I



II

AB Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH,CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

IT **347161-15-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazolines and quinolines as remedies for diseases mediated by autophosphorylation of PDGF receptors)

RN 347161-15-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[[[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:489372 CAPLUS
DN 135:92649
TI Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors
IN Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi
PA Kirin Beer Kabushiki Kaisha, Japan
SO PCT Int. Appl., 1068 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001047890	A1	20010705	WO 2000-JP9157	20001222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 2001022232	A5	20010709	AU 2001-22232	20001222
	EP 1243582	A1	20020925	EP 2000-985844	20001222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	JP 1999-377486	A	19991224		
	JP 1999-374494	A	19991228		
	JP 2000-177790	A	20000614		
	WO 2000-JP9157	W	20001222		

OS MARPAT 135:92649

GI



I



II

AB Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH,CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

IT **347161-15-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazolines and quinolines as remedies for diseases mediated by autophosphorylation of PDGF receptors)

RN 347161-15-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[[[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:380556 CAPLUS
DN 135:5625
TI Diabetic remedy containing dipiperazine derivative
IN Yamaguchi, Hiroshi; Maruta, Katsunori; Nagata, Ryu; Ushiroda, Kantaro; Iwai, Kiyotaka
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001036386	A1	20010525	WO 2000-JP8065	20001115

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI JP 1999-326751 A 19991117
OS MARPAT 135:5625
GI



I

AB A remedy for diabetes contains a dipiperazine deriv. represented by formula (I) or a pharmacol. acceptable salt thereof. [wherein Ar1 and Ar2 each represents optionally substituted Ph, naphthyl, or heterocyclyl; A1 and A2 each represents optionally substituted alkylene or carbonyl (provided that not both of A1 and A2 are carbonyl); A represents methylene or ethylene; Y1, Y2, Y3, and Y4 each represents hydrogen or alkyl; L represents -L3-X1-L1-X2-L2-X3-L4-; L3 and L4 each represents carbonyl or sulfonyl; X1 and X3 each represents a single bond, NR1, or O; R1 represents hydrogen or alkyl; X2 represents a single bond, optionally substituted alkylene, heteroarylene, phenylene, or cycloalkylidene, cycloalkylene, divalent aliph. heterocyclic group, vinylene, ethynylene, S, O, NR2CO, NR3CONR4, NR2CO2, OCO2, O2C, CO, or N(COR5); etc.; R2, R3, R4, and R5 each represents hydrogen or alkyl; and L1 and L2 each represents a single bond, optionally substituted alkylene, vinylene, or phenylene; provided that when X2 is single bond, vinylene, ethynylene, S, O, NR2CO, NR3CONR4, NR2CO2, OCO2, O2C, CO, or N(COR5), L1 or L2 is not a single bond; or when L1 or L2 is vinylene, X1 and X3 are a single bond]. These compds. lower blood sugar level and improve insulin resistance. Thus, 110 mg N-[4-(1-piperazinylcarbonyl)phenyl]-1-piperazinecarboxamide (prepn. given) was dissolved in 6 mL DMF, treated with 195 mg K2CO3 and 270 mg 4-(trifluoromethyl)benzyl bromide, and stirred at 50.degree. for 5 h to give 4-[4-(trifluoromethyl)benzyl]-N-[4-[[4-[4-(trifluoromethyl)benzyl]-1-piperazinyl]carbonyl]phenyl]-1-piperazinecarboxamide (II). II was administered to mice at 3 mg/kg p.o., immediately followed by insulin 3 U/kg s.c. After 4 h, the blood sugar level lowered from 261.+-.92 (control) to 129.+-.43 mg/dL.

IT **100-26-5**, 2,5-Pyridinedicarboxylic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of dipiperazine derivs. as hypoglycemics and antidiabetics for improving insulin resistance)

RN 100-26-5 CAPLUS
CN 2,5-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:247328 CAPLUS
DN 134:266326

TI Preparation of substituted pyridines and pyridazines with angiogenesis inhibiting activity for pharmaceutical use as antitumor agents

IN Dumas, Jacques P.; Joe, Teddy Kite; Kluender, Harold C. E.; Lee, Wendy; Nagarathnam, Dhanapalan; Sibley, Robert N.; Su, Ning; Boyer, Stephen James; Dixon, Julie A.

PA Bayer Corporation, USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001023375	A2	20010405	WO 2000-US26500	20000926
	WO 2001023375	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1228063	A2	20020807	EP 2000-978215	20000926
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	NO 2002001520	A	20020523	NO 2002-1520	20020326
PRAI	US 1999-407600	A	19990928		
	WO 2000-US26500	W	20000926		

OS MARPAT 134:266326

GI



I



II

AB Fused ring systems with a pyridine or pyridazine subunit, such as I [X = connecting group, such as O, S, NH, etc.; Y = connecting group, such as O, S, CH2O, CH2S, NH, OCH2, SCH2, SO, SO2, etc.; Z = CH, N; R1R2 = fused ring, such as CH:CHCH:CH, CH:CHS, CH:CHO, CH:CHNH, N:CHNH, N:NNH, etc.; R3, R4 = aryl, heteroaryl, etc.; XR4 = nitrogen bound heterocyclyl, such as 1-indolinyl], with angiogenesis inhibiting activity were prepd. for pharmaceutical use as antitumor agents. Thus, substituted isoquinoline II was prepd. in a 3 step sequence which included bromination of isocarbostyril to form 1,4-dibromoisoquinoline in 96% yield, followed by monoamination with 4-chloroaniline to give 4-bromo-N-(4-chlorophenyl)-1-isoquinolinamine in 64.4% yield, and subsequent reaction with

4-mercaptopyridine to give II in 19% yield. The prepd. compds. were tested for KDR receptor inhibition.

IT **332012-41-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BYP (Byproduct); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted pyridines and pyridazines with angiogenesis inhibiting activity for pharmaceutical use as antitumor agents)

RN 332012-41-6 CAPLUS

CN Furo[2,3-d]pyridazine-2-carboxamide, 4-[(4-chlorophenyl)amino]-N-methyl-7-[[2-[(methylamino)carbonyl]-4-pyridinyl]methoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **332012-67-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted pyridines and pyridazines with angiogenesis inhibiting activity for pharmaceutical use as antitumor agents)

RN 332012-67-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[[4-[[4-(acetylmethylamino)phenyl]amino]furo[2,3-d]pyridazin-7-yl]oxy]methyl]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **332013-42-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of substituted pyridines and pyridazines with angiogenesis inhibiting activity for pharmaceutical use as antitumor agents)
RN 332013-42-0 CAPLUS
CN 4-Pyridinecarboxylic acid, 2-[(methylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:137023 CAPLUS
DN 134:178552
TI 3(5)-Acylaminopyrazole derivatives, process for their preparation and their use as antitumor agents

IN Pevarello, Paolo; Orsini, Paolo; Traquandi, Gabriella; Varasi, Mario; Fritzen, Edward L.; Warpehoski, Martha A.; Pierce, Betsy S.; Brasca, Maria Grabriella

PA Pharmacia & Upjohn S.p.A., Italy; Pharmacia & Upjohn Company

SO PCT Int. Appl., 123 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012189	A1	20010222	WO 2000-US6699	20000505
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1202733	A1	20020508	EP 2000-931906	20000505
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000013143	A	20020611	BR 2000-13143	20000505
	JP 2003507329	T2	20030225	JP 2001-516535	20000505
	US 6218418	B1	20010417	US 2000-667603	20000922
	NO 2002000684	A	20020403	NO 2002-684	20020211
PRAI	US 1999-372831	A	19990812		
	US 2000-560400	A1	20000428		
	WO 2000-US6699	W	20000505		

OS MARPAT 134:178552

GI



I

AB Compds. which are 3-acylaminopyrazole derivs. (I; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-2,2-diphenylacetamide) wherein R is C3-C6 cycloalkyl group optionally substituted by a straight or branched C1-C6 alkyl or arylalkyl group; R1 is a straight or branched C1-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be optionally further substituted as indicated in the description; or a pharmaceutically acceptable salt thereof, processes for their prepn. and their therapeutic uses. The compds. are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases, but no quant. test results are presented. The cancer is selected from carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma. The cell proliferative disorder is selected from benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation assocd. with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. The method of treatment provides tumor angiogenesis and metastasis inhibition, cell cycle inhibition or cdk/cyclin dependent inhibition, and treatment or prevention of

radiotherapy-induced or chemotherapy-induced alopecia. A process for prepg. the 3-aminopyrazole deriv. or the pharmaceutically acceptable salt thereof, comprising: (a) reacting RCO2R2 (R2 = alkyl), with MeCN in the presence of a basic agent, to obtain RC(O)CH2CN; (b) reacting RC(O)CH2CN with hydrazine hydrate to obtain an 3-amino-5-R-1H-pyrazole; (c) oxidizing the 3-amino-5-R-1H-pyrazole to obtain the nitro analog; (d) reacting the nitro compd. with tert-butoxycarbonyl anhydride (Boc2O) to obtain the N-Boc deriv.; (e) reducing this BOC deriv. to obtain the amino analog; (f) reacting this amino compd. with R1C(O)X (X = OH or a suitable leaving group) to obtain the N1-Boc-protected I; and (g) hydrolyzing this intermediate in an acidic medium to obtain I. Other methods of prepn. are also claimed.

IT **326826-76-0P**, 6-[4-[2-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]phenyl]-2-pyridinecarboxylic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(acylaminopyrazole derivs., process for prepn. and use as antitumor agents)

RN 326826-76-0 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[4-[2-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2001:31473 CAPLUS

DN 134:100864

TI Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

IN Kania, Robert Steven; Bender, Steven Lee; Borchardt, Allen J.; Braganza, John F.; Cripps, Stephan James; Hua, Ye; Johnson, Michael David; Johnson, Theodore Otto, Jr.; Luu, Hiep The; Palmer, Cynthia Louise; Reich, Siegfried Heinz; Tempczyk-russell, Anna Maria; Teng, Min; Thomas, Christine; Varney, Michael David; Wallace, Michael Brennan

PA Agouron Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 439 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002369	A2	20010111	WO 2000-US18263	20000630

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	BR 2000012352	A	20020514	BR 2000-12352	20000630
	EP 1218348	A2	20020703	EP 2000-943375	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003503481	T2	20030128	JP 2001-507809	20000630
	US 6531491	B1	20030311	US 2001-983786	20011025
	US 6534524	B1	20030318	US 2001-983783	20011025
	NO 2001005797	A	20020301	NO 2001-5797	20011128
PRAI	US 1999-142130P	P	19990702		
	US 2000-609335	B3	20000630		
	WO 2000-US18263	W	20000630		

OS MARPAT 134:100864

GI



I

AB Indazole compds. I [R1 = substituted or unsubstituted aryl or heteroaryl, R3CH:CH, R3N:CH; R2 = substituted or unsubstituted aryl, heteroaryl, Y-X; R3 = substituted or unsubstituted alkyl alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; Y = O, S, C(:CH2), CO, SO, SO2, alkylidene, NH, N(C1-C8 alkyl); X = substituted or unsubstituted aryl, heteroaryl, NH(alkyl), NH(cycloalkyl), NH(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH(alkoxy), NH(dialkylamide)] and their pharmaceutically acceptable prodrugs, active metabolites, and salts are disclosed. The compds. modulate and/or inhibit the activity of certain protein kinases. In particular, I and pharmaceutical compns. contg. them are capable of mediating tyrosine kinase signal transduction, and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compns. contg. such compds., and to methods of treating cancer and other disease states assocd. with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amts. of such compds. E.g., I [R1 = (E)-3,4-(MeO)2C6H3CH:CH; R2 = 4-HO-3-MeOC6H3] (II) was prepd. from 6-aminoindazole by diazotization and substitution with iodide, protection of the indazole nitrogen with 2,4,6-Me3C6H2SO2Cl, coupling of the regioisomeric mixt. with 4-(methoxymethoxy)-3-methoxybenzeneboronic acid in the presence of dichlorobis(triphenylphosphine)palladium, and deprotection of the indazole moiety and iodination at the 3-position of the indazole. Treatment of the 3-indazolyl iodide with sec-butyllithium, phenyllithium, and DMF, regioselective protection of the indazole with 2,4,6-Me3C6H2SO2Cl, olefination with 3,4-dimethoxybenzyltriphenylphosphonium bromide, deprotection of the indazole, deprotection of the methoxymethyl group, and equilibration of the double bond with iodine gave II. Biol. data on protein kinase inhibition, cell proliferation inhibition, neovascularization inhibition, and i.p. and oral bioavailability, are given.

IT **319467-94-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

RN 319467-94-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 2-[2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzoyl]hydrazide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2000:900607 CAPLUS
DN 134:56676
TI Preparation of arylsulfonamides as inhibitors of aspartyl protease
IN Hale, Michael Robin; Tung, Roger; Price, Stephen; Wilkes, Robin David; Schairer, Wayne Carl; Jarvis, Ashley Nicholas; Spaltenstein, Andrew; Furfine, Eric Steven; Samano, Vicente; Kaldor, Istvan; Miller, John Franklin; Brieger, Michael Stephen
PA Vertex Pharmaceuticals Inc., USA; et al.
SO PCT Int. Appl., 396 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076961	A1	20001221	WO 2000-US15781	20000608
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000011745	A	20020319	BR 2000-11745	20000608
	EP 1194404	A1	20020410	EP 2000-941279	20000608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003502309	T2	20030121	JP 2001-503821	20000608
	NO 2001006034	A	20020118	NO 2001-6034	20011210
PRAI	US 1999-139070P	P	19990611		
	US 2000-190211P	P	20000317		
	WO 2000-US15781	W	20000608		

OS MARPAT 134:56676
GI



I

AB The title arylsulfonamides, namely (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 3-arylsulfonylamino-1-(4-hydroxyphenyl)-2-hydroxypropylcarbamate derivs. (e.g. I) are prepd. These compds. are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. They are useful for treating with a patient diagnosed with AIDS, AIDS related complex (ARC), progressive generalized lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura, or AIDS-related neurol. conditions such as AIDS dementia complex, multiple sclerosis or tropical paraperesis, etc. Thus, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 3-[N-(1,3-**benzodioxol**-5-ylsulfonyl)-N-isobutylamino]-1-(4-hydroxyphenyl)-2-hydroxypropylcarbamate underwent Mitsunobu reaction with phenethyl alc. using Ph3P and di-tert-Bu azodicarbonate in CH2Cl2 at room temp. for 1.5 h to give 72% I. I showed IC50 of <0.001, <0.001, and 0.01-0.001 .mu.M against drug-resistant HIV strains, i.e. wild type, mutant HIV-1 EP13, and mutant D545701-14 HIV strains, resp., in MT-4 cells.

IT **313679-64-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arylsulfonamides as inhibitors of HIV aspartyl protease and antiviral agents)

RN 313679-64-0 CAPLUS

CN 2-Pyridinecarboxylic acid, 4-[(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-hydroxybutyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2000:456887 CAPLUS
DN 133:89444
TI Preparation of 4-amino-azepan-3-one protease inhibitors

IN Marquis, Robert Wells, Jr.; Ru, Yu; Veber, Daniel Frank; Cummings, Maxwell David; Thompson, Scott Kevin; Yamashita, Dennis

PA Smithkline Beecham Corp., USA

SO PCT Int. Appl., 273 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038687	A1	20000706	WO 1999-US30730	19991221
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2356671	AA	20000706	CA 1999-2356671	19991221
	BR 9916488	A	20011009	BR 1999-16488	19991221
	EP 1158986	A1	20011205	EP 1999-963112	19991221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002533397	T2	20021008	JP 2000-590640	19991221
	ZA 2001004208	A	20020523	ZA 2001-4208	20010523
	NO 2001003124	A	20010622	NO 2001-3124	20010622
	US 2002147188	A1	20021010	US 2002-74940	20020213
	US 2003044399	A1	20030306	US 2002-74639	20020213
PRAI	US 1998-113636P	P	19981223		
	US 1999-164581P	P	19991110		
	WO 1999-US30730	W	19991221		
	US 2000-593845	A1	20000614		
	US 2000-653815	A1	20000901		

OS MARPAT 133:89444

GI



I



II

AB The title compds. [I; R1 = COCR13NR11R12, COCR13XR15, COCH2R13; R2 = H, alkyl, cycloalkylalkyl, etc.; R3 = H, alkyl, cycloalkylalkyl, etc.; R4 = H, alkyl, arylalkyl, etc.; R11 = H, alkyl, arylalkyl, etc.; R12 = H, alkyl, cycloalkyl, etc.; R13 = H, alkyl, alkenyl, etc.; R15 = H, alkyl, alkenyl, etc.] which inhibit proteases (no data), including cathepsin K, and are useful for treating diseases of excessive bone loss or cartilage or matrix degrdn. including osteoporosis, gingival disease including gingivitis and periodontitis, arthritis, more specifically, osteoarthritis and rheumatoid arthritis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease, were prepd. E.g., a multi-step synthesis of

compd. II was given. Compds. I are effective at 0.4-400 mg/kg/day.

IT **281215-40-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-amino-azepan-3-one protease inhibitors)

RN 281215-40-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[hexahydro-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **281220-60-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-amino-azepan-3-one protease inhibitors)

RN 281220-60-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[hexahydro-3-hydroxy-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2000:441762 CAPLUS

DN 133:74323

TI Preparation of N-acylphenylalanine derivatives and analogs as inhibitors of .alpha.4.beta.1 mediated cell adhesion

IN Teegarden, Bradley R.; Jayakumar, Honnappa; Matsuki, Kenji; Chrusciel, Robert A.; Fisher, Jed F.; Tanis, Steven P.; Thomas, Edward W.; Blinn, James R.

PA Tanabe Seiyaku Co., Ltd., Japan; Pharmacia & Upjohn Company

SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2000037429	A2	20000629	WO 1999-US30665	19991220
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1144365	A2	20011017	EP 1999-966584	19991220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-113501P	P	19981222		
	WO 1999-US30665	W	19991220		
OS	MARPAT 133:74323				
GI					



I

AB Title compds. I [X = halo, CF3, NO2, OH, alkoxy, NH2, alkyl; n = 1-3; Z1, Z2 = CH or N; Y = OCH2 or NHCO; R = OH or alkoxy; R1 = acyl group] or their pharmaceutically acceptable salts were prepd. as inhibitors of .alpha.4.beta.1 mediated adhesion to either the vascular cell adhesion mol. (VCAM-1) or the CS-1 domain of fibronectin and are useful in the treatment of inflammatory diseases. Approx. 200 invention compds. and their intermediates were prepd. by various coupling methods and purified by chromatog. on silica gel. Thus, 4-[(2,6-dichlorobenzoyl)amino]-N-[[(3S)-7-hydroxy-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyl]-L-phenylalanine was prepd. by deprotection of resin-bound N-(tert-butoxycarbonyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine with 50% TFA/CH2Cl2, followed by treatment with (3S)-2-(tert-butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, deprotection, and hydrolysis with 2N LiOH. In vitro cell adhesion inhibitory and/or modulatory activities are reported for > 100 invention compds. tested in Jurkat CS-1 and/or Jurkat endothelial cell (EC) adhesion inhibition assays. Ten compds. showed IC50 values .ltoreq. 0.8 .mu.M in both assays.

IT **279239-68-8P 279239-69-9P 279239-77-9P**
279239-78-0P 279679-53-7P 279679-54-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-acylphenylalanine derivs. and analogs as inhibitors of .alpha.4.beta.1 mediated cell adhesion)

RN 279239-68-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[1-[[[(1S)-1-carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]cyclohexyl]amino]carbony

1]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279239-69-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[[1-[[[(1S)-1-carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]cyclohexyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279239-77-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[[[2-[[[(1S)-1-carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]cyclohexyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279239-78-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[[2-[[[(1S)-1-carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]cyclohexyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279679-53-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[[[2-[[[(1S)-1-carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]bicyclo[2.2.1]hept-2-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279679-54-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[[2-[[[(1S)-1-carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]bicyclo[2.2.1]hept-2-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1999:595127 CAPLUS
DN 131:228643
TI Preparation of oxalylaminothiophene derivatives as modulators of protein tyrosine phosphatases (PTPases)
IN Richter, Lutz Stefan; Andersen, Henrik Sune; Vagner, Josef; Jeppesen, Claus Bekker; Moller, Niels Peter Hundahl; Branner, Sven; Jeppesen, Lone; Olsen, Ole Hvilsted; Iversen, Lars Fogh; Holsworth, Daniel Dale; Axe, Frank Urban; Ge, Yu; Jones, Todd Kevin; Ripka, Wiliam Charles; Uyeda, Roy Teruyuki; Su, Jing; Bakir, Farid; Judge, Luke Milburn
PA Novo Nordisk A/S, Den.; Ontogen Corporation; Richter, Birgith
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9946237	A1	19990916	WO 1999-DK126	19990312
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6225329	B1	20010501	US 1999-265069	19990309
	US 2002019412	A1	20020214	US 1999-265316	19990309
	AU 9927139	A1	19990927	AU 1999-27139	19990311
	US 6262044	B1	20010717	US 1999-268490	19990311
	US 2002002199	A1	20020103	US 1999-266395	19990311
	CA 2323472	AA	19990916	CA 1999-2323472	19990312
	ZA 9902029	A	19990927	ZA 1999-2029	19990312
	ZA 9902032	A	19990927	ZA 1999-2032	19990312
	ZA 9902038	A	19990927	ZA 1999-2038	19990312
	ZA 9902036	A	19991001	ZA 1999-2036	19990312
	BR 9908723	A	20001121	BR 1999-8723	19990312
	EP 1080068	A1	20010307	EP 1999-907336	19990312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, FI, RO				
	NO 2000004526	A	20001108	NO 2000-4526	20000911
	US 6410586	B1	20020625	US 2001-810266	20010316
	US 2002165398	A1	20021107	US 2002-127043	20020419
	US 2003069267	A1	20030410	US 2002-158464	20020528

PRAI	DK 1998-350	A	19980312
	DK 1998-345	A	19980312
	DK 1998-343	A	19980312
	DK 1998-342	A	19980312
	DK 1998-344	A	19980312
	DK 1998-347	A	19980312
	DK 1998-346	A	19980312
	DK 1998-348	A	19980312
	DK 1998-479	A	19980403
	DK 1998-472	A	19980403
	DK 1998-473	A	19980403
	DK 1998-478	A	19980403
	DK 1998-475	A	19980403
	DK 1998-474	A	19980403
	DK 1998-476	A	19980403
	DK 1998-480	A	19980403
	US 1998-82912P	P	19980424
	DK 1998-667	A	19980515
	US 1998-88115P	P	19980605
	DK 1998-939	A	19980715
	DK 1998-940		19980715
	DK 1998-938		19980715
	DK 1998-1385		19981028
	DK 1998-1561		19981126
	DK 1998-1612		19981207
	US 1998-82365P	P	19980420
	US 1998-82368P	P	19980420
	US 1998-82371P	P	19980420
	US 1998-82373P	P	19980420
	US 1998-82913P	P	19980424
	US 1998-82914P	P	19980424
	US 1998-82915P	P	19980424
	US 1998-93525P	P	19980721
	US 1998-93620P	P	19980721
	US 1998-93638P	P	19980721
	US 1998-108747P	P	19981117
	US 1999-115528P	P	19990112
	US 1999-266395	B1	19990311
	US 1999-268490	A3	19990311
	WO 1999-DK126	W	19990312
	US 2001-810266	A3	20010316

GI



I

AB Oxalylaminoheterocycles (e.g., oxalylaminothiophene and oxalylaminothienopyran derivs., etc.) were prepd. as inhibitors of Protein Tyrosine Phosphatases (PTPases), such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTP.alpha., PTP.epsilon., PTP.mu., PTP.delta., PTP.sigma., PTP.zeta., PTP.beta., PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP. These compds. are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes. For instance, 2-amino-5-hydroxymethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid tert-Bu ester (prepn. given) was reacted with phthalimide in THF,

PPh3, and DIAD to form the 5-phthalimidomethyl deriv. (47%). The amine was amidated with imidazol-1-yloxoacetic acid tert-Bu ester in CH2Cl2 and TEA (99%), followed by hydrolysis of the ester function with TFA in CH2Cl2, to give 5-(1,3-dioxo-1,3-dihydroisoindol-2-ylmethyl)-2-(oxalylamino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid (I) in 57% yield. In an in vitro test against PTP1B expressed in E. coli and purified by known methods, Ki values at various inhibitor concns. were detd. An anal. of selectivity of two PTPase inhibitors against PTP1B, PTP-LAR, PTP.epsilon., CD45, and PTP.beta. showed that one compd. of the invention is a non-selective inhibitor, whereas another behaves like a selective inhibitor.

IT **243966-90-7P 243966-92-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of oxalylaminothiophene derivs. as modulators of protein tyrosine phosphatases (PTPases))

RN 243966-90-7 CAPLUS
CN 5H-Thieno[2,3-c]pyran-3-carboxylic acid, 2-[(carboxycarbonyl)amino]-4,7-dihydro-5-[[[(1-oxido-2-pyridinyl)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 243966-92-9 CAPLUS
CN 5H-Thieno[2,3-c]pyran-3-carboxylic acid, 2-[(carboxycarbonyl)amino]-4,7-dihydro-5-[[(2-pyridinylcarbonyl)amino]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1999:130571 CAPLUS
DN 130:168107
TI Preparation of cyclylcarboxylic acids as endothelin antagonist via asymmetric conjugate addition reaction
IN Devine, Paul N.; Heid, Richard M., Jr.; Tillyer, Richard D.; Tschaen, David M.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9907367	A1	19990218	WO 1998-US16251	19980804

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	US 6022972	A	20000208	US 1998-115493	19980714
	AU 9886901	A1	19990301	AU 1998-86901	19980804
	US 6353110	B1	20020305	US 1999-448775	19991124
PRAI	US 1997-55259P	P	19970808		
	GB 1998-10550	A	19980515		
	US 1998-87039P	P	19980528		
	US 1998-115493	A3	19980714		
	WO 1998-US16251	W	19980804		

OS CASREACT 130:168107; MARPAT 130:168107
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; A = 5 and 6 membered heterocyclyl, carbocyclyl, aryl; R1 = aryl, alkyl, heteroaryl; R2 = H, OH, alkoxy, alkylamino; R3 = alkyl, alkoxy, Br, Cl, F, I, aryl, CHO] and stereoisomers are prepd. as endothelin antagonists via an asym. conjugate addn. reaction in prepn. of intermediates. Thus, compd. II was prepd. as the key intermediate of the antagonist III from the lithium anion of 4-bromo-1,2-(methylenedioxy)benzene and chiral [[4,5-dihydro-4-(methoxymethyl)-5-[4-(methylthio)phenyl]-2-oxazolyl]methyl]-phosphonic acid di-Et ester in THF under 0.degree..

IT **203576-45-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of chiral 5-(1,3-**benzodioxol**-5-yl)-2-butyl-7-[2-(2-carboxypropyl)-4-methoxyphenyl]-6,7-dihydro-5H-Cyclopenta[b]pyridine-6-carboxylic acid as endothelin antagonists via asym. conjugate addn. reaction)

RN 203576-45-8 CAPLUS
CN 3-Pyridinepropanoic acid, .beta.-1,3-benzodioxol-5-yl-6-butyl-2-(methoxycarbonyl)-, 1-methylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1998:126238 CAPLUS
DN 128:192553
TI Preparation of diastereomeric pyrindanecarboxylates and analogs by

stereoselective hydroxyl group hydridation

IN Devine, Paul N.; Dolling, Ulf H.; Frey, Lisa F.; Tillyer, Richard D.; Tschaen, David M.; Kato, Yoshiaki

PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.; Devine, Paul N.; Dolling, Ulf H.; Frey, Lisa F.; Tillyer, Richard D.; Tschaen, David M.; Kato, Yoshiaki

SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806700	A1	19980219	WO 1997-US14045	19970808
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9739757	A1	19980306	AU 1997-39757	19970808
	AU 711936	B2	19991028		
	EP 923557	A1	19990623	EP 1997-937187	19970808
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	US 5962688	A	19991005	US 1997-907449	19970808
	JP 11514676	T2	19991214	JP 1997-509915	19970808
PRAI	US 1996-23614P	P	19960809		
	GB 1996-17900	A	19960828		
	US 1996-28438P	P	19961010		
	GB 1996-25806	A	19961212		
	WO 1997-US14045	W	19970808		

OS CASREACT 128:192553; MARPAT 128:192553

GI



I



II

AB Title compds. [I; R1 = (cyclo)alkyl, (hetero)aryl, etc.; R2 = alkoxy, dialkyl- or diarylamino; 1 of R,R3 = OH and the other = alkyl or (hetero)aryl or R = H and R3 = alkyl or (hetero)aryl; R4 = H and R5 = COR2, and R4 = COR2 and R5 = H; R6R7 = atoms to complete a carbocyclic, heterocyclic, or (hetero)arom. ring] were prepd. Thus, aroylpyridinepropionate II (R3 = 1,3-**benzodioxol**-5-yl)(prepn. given) underwent aldol cyclization and the product was treated with Et3SiH/TiCl4 to give I [R = R4 = H, R1 = (S)-4-(MeO)C6H3(CH2CHMeCH2OSiMe2CMe3)-2, R3 = 1,3-**benzodioxol**-5-yl, R5 = CO2Bu, R6R7 = N:CBuCH:CH].

IT **203576-45-8P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of diastereomeric pyrindanecarboxylates and analogs by stereoselective hydroxyl group hydridation)
RN 203576-45-8 CAPLUS
CN 3-Pyridinepropanoic acid, .beta.-1,3-benzodioxol-5-yl-6-butyl-2-(methoxycarbonyl)-, 1-methylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1997:307688 CAPLUS
DN 126:277402
TI New 4-aryl-3-aralkoxypiperidines and -azabicylooctanes for treating heart and kidney insufficiency
IN Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; Gueller, Rolf; Hirth, Georges; Maerki, Hans-Peter; Mueller, Marcel; Oefner, Christian; Stadler, Heinz; Vieira, Eric; Wilhelm, Maurice; Wostl, Wolfgang
PA F. Hoffmann-La Roche Ag, Switz.
SO PCT Int. Appl., 492 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709311	A1	19970313	WO 1996-EP3803	19960829
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2230931	AA	19970313	CA 1996-2230931	19960829
	AU 9667432	A1	19970327	AU 1996-67432	19960829
	AU 708616	B2	19990805		
	EP 863875	A1	19980916	EP 1996-927715	19960829
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1202152	A	19981216	CN 1996-197674	19960829
	JP 11500447	T2	19990112	JP 1996-510837	19960829
	BR 9610385	A	19990706	BR 1996-10385	19960829
	NZ 315677	A	20000228	NZ 1996-315677	19960829
	RU 2167865	C2	20010527	RU 1998-106388	19960829
	ZA 9607424	A	19970307	ZA 1996-7424	19960902
	TW 474932	B	20020201	TW 1996-85110684	19960902
	NO 9800954	A	19980428	NO 1998-954	19980305
	US 6051712	A	20000418	US 1999-255185	19990222
	US 6150526	A	20001121	US 1999-456283	19991207
PRAI	CH 1995-2548	A	19950907		
	CH 1996-1876	A	19960726		
	WO 1996-EP3803	W	19960829		

US 1996-711339 A3 19960906
US 1999-255185 A1 19990222
OS MARPAT 126:277402
GI



I

AB New piperidine and azabicyclooctane derivs. (> 1000 compds.) are renin inhibitors for treatment of high blood pressure, heart and kidney insufficiency. Thus, the piperidine deriv. I was prepd. from 1-benzyl-3-propyl-4-piperidinone by reaction with 4-FC6H4Br, followed by 1-benzyloxy-3-chloromethylnaphthalene and deblocking. I had a renin-inhibiting IC50 of 0.317 .mu.M.

IT **188864-31-5P 188865-09-0P 188865-12-5P 188871-07-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperidine and azabicyclooctane derivs. as renin inhibitors)

RN 188864-31-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-(2-naphthalenylmethoxy)-4-[4-[[[(2-pyridinylcarbonyl)amino]oxy]methyl]phenyl]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 188865-09-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-(2-naphthalenylmethoxy)-4-[4-[2-[[(2-pyridinylcarbonyl)amino]oxy]ethyl]phenyl]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 188865-12-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 2-[4-[(3R,4R)-1-[(1,1-dimethylethoxy)carbonyl]-3-(2-naphthalenylmethoxy)-4-piperidinyl]phenyl]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 188871-07-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-3-[[2-[[(2-pyridinylcarbonyl)amino]methyl]phenyl]methoxy]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1997:278986 CAPLUS
DN 126:251151
TI Preparation and formulation of **benzodioxoleacetic** acid and phenylacetic acid derivatives as endothelin antagonists
IN Hayashi, Kunio; Yamamori, Teruo; Kanda, Yasuhiko
PA Shionogi and Co., Ltd., Japan; Hayashi, Kunio; Yamamori, Teruo; Kanda, Yasuhiko
SO PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9710214	A1	19970320	WO 1996-JP2607	19960912
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
AU 9669446	A1	19970401	AU 1996-69446	19960912
PRAI JP 1995-262337		19950914		
WO 1996-JP2607		19960912		

OS MARPAT 126:251151
GI



I



II

AB The title compds. I [R1 to R7 represent each hydrogen, halogeno, optionally substituted lower alkyl, etc.; and X represents O, S or NR15; R15 represents hydrogen or optionally substituted lower alkyl; Y = OH, NHSO2Z; Z = (un)substituted aryl, etc.] are prepd. In the in vitro test for endothelin A receptor antagonism, the title compd. II showed IC50 of

2.4 nM. In the test for endothelin B receptor antagonism, the title compd. II showed IC50 of 290 nM.

IT **188668-43-1P 188669-48-9P 188669-50-3P 188669-52-5P 188669-54-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**benzodioxoleacetic** acid and phenylacetic acid derivs. as endothelin antagonists)

RN 188668-43-1 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, .alpha.-[[2-(aminocarbonyl)-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



RN 188669-48-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[1-(1,3-benzodioxol-5-yl)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-oxoethoxy]-6-propyl- (9CI) (CA INDEX NAME)



RN 188669-50-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[1-(1,3-benzodioxol-5-yl)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-oxoethoxy]-6-propyl-, methyl ester (9CI) (CA INDEX NAME)



RN 188669-52-5 CAPLUS
CN 2-Pyridinecarboxamide, 5-[1-(1,3-benzodioxol-5-yl)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-oxoethoxy]-6-propyl- (9CI) (CA INDEX NAME)



RN 188669-54-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[1-(1,3-benzodioxol-5-yl)-2-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]-2-oxoethoxy]-N,N-dimethyl-6-propyl- (9CI) (CA INDEX NAME)



L5 ANSWER 34 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1996:509477 CAPLUS
DN 125:141807

TI Preparation of aryl- and hetarylsulfonamide derivatives and their use as endothelin antagonists

IN Breu, Volker; Burri, Kaspar; Cassal, Jean-Marie; Clozel, Martine; Hirth, Georges; Loeffler, Bernd-Michael; Mueller, Marcel; Neidhart, Werner; Ramuz, Henri

PA F. Hoffmann-La Roche Ag, Switz.

SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9619455	A1	19960627	WO 1995-EP4762	19951204
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2208011	AA	19960627	CA 1995-2208011	19951204
AU 9643016	A1	19960710	AU 1996-43016	19951204
AU 695255	B2	19980813		
EP 799206	A1	19971008	EP 1995-941660	19951204
EP 799206	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
CN 1170405	A	19980114	CN 1995-196959	19951204
JP 10500997	T2	19980127	JP 1995-519459	19951204
JP 2930731	B2	19990803		
HU 77307	A2	19980330	HU 1997-1811	19951204
BR 9510533	A	19980714	BR 1995-10533	19951204
RU 2163598	C2	20010227	RU 1997-112144	19951204
CZ 289090	B6	20011017	CZ 1997-1873	19951204
AT 223899	E	20020915	AT 1995-941660	19951204
ES 2180664	T3	20030216	ES 1995-941660	19951204
TW 474920	B	20020201	TW 1995-84113009	19951206
ZA 9510614	A	19960620	ZA 1995-10614	19951213
IL 116410	A1	20000813	IL 1995-116410	19951215
FI 9702629	A	19970618	FI 1997-2629	19970618
NO 9702841	A	19970818	NO 1997-2841	19970619
US 5962682	A	19991005	US 1997-860985	19970818
US 6133442	A	20001017	US 1999-263034	19990305
PRAI CH 1994-3838	A	19941220		
CH 1995-3079	A	19951031		
WO 1995-EP4762	W	19951204		

OS MARPAT 125:141807

GI



I

AB I [R1 = Ph, substituted Ph or heterocyclyl; R2 = Ph or substituted phenyl; R3 = H, lower alkyl, cyano, carboxy, esterified carboxy, Ph, substituted Ph, heterocyclyl, CONR5R6, NR5COR7; R4 = H, lower alkyl; R5 = H, R7; R6 = (CH2)mR7; NR5R6 = heterocyclic residue; R7 = Ph, substituted Ph, cycloalkyl, heterocyclyl, lower alkyl, cyanoalkyl, hydroxyalkyl, dialkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl,

alkoxycarbonylaminoalkyl, phenylalkoxycarbonyl; Ra = H, lower alkyl, hydroxy; Rb = H, lower alkyl; Z = hydroxy, amino, OR8, OC(O)NHR8, -OC(O)OR8, NHC(O)NHR8, NHC(O)OR8; R8 = heterocyclyl, Ph, substituted Ph, lower alkyl; A and Y each independently signify O, S; X = N, CH; m = 0, 1 or 2; n = 0, 1 or 2; and pharmaceutically usable salts thereof] are prepd. as inhibitors of endothelin receptors. E.g., reaction of Et 4-[3-(2-hydroxyethoxy)-5-(5-isopropylpyridine-2-sulfonylamino)-4-(2-methoxyphenoxy)benzoyl]piperazine-1-carboxylate and 2-pyridylcarboxylic acid azide gave Et 4-{3-(5-isopropylpyridine-2-sulfonylamino)-4-(2-methoxyphenoxy)-5-[2-(pyridin-2-ylcarbamoyloxy)ethoxy]benzoyl}piperazine-1-carboxylate. Some examples of I exhibited selective inhibitory action on endothelin receptors A and B (ETA and ETB).

IT **180029-16-7P 180029-19-0P 180029-21-4P**
180029-23-6P 180029-24-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl- and hetarylsulfonamide derivs. and their use as endothelin antagonists)

RN 180029-16-7 CAPLUS
CN Benzoic acid, 3-[(1,3-benzodioxol-5-ylsulfonyl)amino]-4-(2-methoxyphenoxy)-5-[2-[[(2-pyridinylcarbonyl)amino]oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 180029-19-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[(1,3-benzodioxol-5-ylsulfonyl)amino]-4-(2-methoxyphenoxy)-5-[2-[[(2-pyridinylcarbonyl)amino]oxy]ethoxy]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 180029-21-4 CAPLUS
CN Benzoic acid, 4-(2-methoxyphenoxy)-3-[[(4-methoxyphenyl)sulfonyl]amino]-5-[2-[[(2-pyridinylcarbonyl)amino]oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 180029-23-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-(2-methoxyphenoxy)-3-[[[4-(methylthio)phenyl]sulfonyl]amino]-5-[2-[[(2-pyridinylcarbonyl)amino]oxy]ethoxy]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 180029-24-7 CAPLUS
CN Benzoic acid, 4-(2-methoxyphenoxy)-3-[[(4-methylphenyl)sulfonyl]amino]-5-[2-[[(2-pyridinylcarbonyl)amino]oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 35 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1996:494173 CAPLUS
DN 125:143330

TI Peptide compounds for prevention and/or treatment of nitric oxide (NO)-mediated diseases

IN Itoh, Yoshikuni; Iwamoto, Toshiro; Yatabe, Takumi; Hamashima, Hitoshi; Inoue, Takayuki; Hashimoto, Seiji; Oku, Teruo

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 739 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9616981	A2	19960606	WO 1995-JP2428	19951129
	WO 9616981	A3	19960906		
	W: AU, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9539937	A1	19960619	AU 1995-39937	19951129
	EP 796270	A2	19970924	EP 1995-938602	19951129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	ZA 9510201	A	19960625	ZA 1995-10201	19951130
	US 5932737	A	19990803	US 1997-849076	19970530
PRAI	GB 1994-24408	A	19941202		
	GB 1995-4891	A	19950310		
	GB 1995-10042	A	19950518		
	WO 1995-JP2428	W	19951129		

OS MARPAT 125:143330

GI



I

AB Peptides WA1NR8CH(A2T)CONR9CH(A3R3)R4 [W = alkyl, (un)substituted aryl or fluorenyl, etc.; A1 = alkylene, NHCO, CO, CS, SO2; A2 = alkylene; T = H, aryl, heterocyclyl, OH, etc.; R8 = H, alkyl; R8 may link with A2T to form CH2C6H4CH2-o (Q); A3 = bond, alkylene; R3 = H, aryl, OH, etc.; R9 = H, alkyl or may link with A3R3 to form Q; R4 = CO2H, protected carboxy, carboxamido, etc. or CH(A3R3)R4 = N-alkyl-2-oxoquinoline moiety] or their pharmaceutically acceptable salts were prepd. for use as medicaments. Thus, dipeptide I was prepd. by acylation of aspartylphenylalaninamide deriv. with 2-benzofurancarboxylic acid. I and six other peptides showed 100% inhibition of NO prodn. in tests of murine macrophage cells.

IT **179879-69-7P 179881-38-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptides for prevention and/or treatment of nitric oxide-mediated diseases)

RN 179879-69-7 CAPLUS

CN L-Phenylalaninamide, 4-(4-morpholinyl)-4-oxo-N-(2-pyridinylcarbonyl)-L-2-aminobutanoyl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179881-38-0 CAPLUS
CN L-Phenylalaninamide, N-(2-benzofuranylcarbonyl)-O-(2-pyridinylcarbonyl)-L-seryl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1996:333008 CAPLUS
DN 125:127644
TI Method for obtaining improved image contrast in migration imaging members
IN Limburg, William W.; Mammino, Joseph; Liebermann, George; Griffiths, Clifford H.; Shahin, Michael M.; Malhotra, Shadi L.; Chen, Liqin; Perron, Marie-Eve
PA Xerox Corp., USA
SO U.S., 147 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5514505	A	19960507	US 1995-441360	19950515
	CA 2169980	AA	19961116	CA 1996-2169980	19960221
	CA 2169980	C	20010424		
	JP 08314240	A2	19961129	JP 1996-113456	19960508
	EP 743573	A2	19961120	EP 1996-303359	19960514
	EP 743573	A3	19970305		
	EP 743573	B1	20000906		
	R: DE, FR, GB				
PRAI	US 1995-441360	A	19950515		

OS MARPAT 125:127644
AB Disclosed is a process which comprises (a) providing a migration imaging member comprising (1) a substrate and (2) a softenable layer comprising a

softenable material and a photosensitive migration marking material present in the softenable layer as a monolayer of particles situated at or near the surface of the softenable layer spaced from the substrate, (b) uniformly charging the imaging member, (c) imagewise exposing the charged imaging member to activating radiation at a wavelength to which the migration marking material is sensitive, (d) causing the softenable material to soften and enabling a first portion of the migration marking material to migrate through the softenable material toward the substrate in an imagewise pattern while a second portion of the migration marking material remains substantially unmigrated within the softenable layer, and (e) contacting the second portion of the migration marking material with a transparentizing agent which transparentizes the migration marking material.

IT **89-00-9**, 2,3-Pyridine dicarboxylic acid **100-26-5**, 2,5-Pyridine dicarboxylic acid **499-80-9**, 2,4-Pyridine dicarboxylic acid **499-83-2**, 2,6-Pyridine dicarboxylic acid **53636-70-7**, 6-Methyl-2,3-pyridine dicarboxylic acid
RL: DEV (Device component use); TEM (Technical or engineered material use); USES (Uses)
(transparentizing agent for electrophotog. migration imaging members)

RN 89-00-9 CAPLUS
CN 2,3-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



RN 100-26-5 CAPLUS
CN 2,5-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



RN 499-80-9 CAPLUS
CN 2,4-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



RN 499-83-2 CAPLUS
CN 2,6-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



RN 53636-70-7 CAPLUS
CN 2,3-Pyridinedicarboxylic acid, 6-methyl- (6CI, 9CI) (CA INDEX NAME)



L5 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1995:913757 CAPLUS
DN 124:116963
TI Macrocyclic immunomodulators
IN Luly, Jay R.; Kawai, Megumi; Or, Yat S.; Wiedeman, Paul; Wagner, Rolf
PA Abbott Laboratories, USA
SO U.S., 80 pp. Cont.-in-part of U.S. Ser. No. 32,958, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 18

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5457111	A	19951010	US 1993-149416	19931109
	WO 9421635	A1	19940929	WO 1994-US2711	19940314
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5604294	A	19970218	US 1994-213318	19940314
	US 5561139	A	19961001	US 1995-419784	19950411
	US 5561140	A	19961001	US 1995-419799	19950411
	US 5541193	A	19960730	US 1995-466302	19950606
	US 5604234	A	19970218	US 1995-529862	19950918
	US 5708002	A	19980113	US 1996-734793	19961023
PRAI	US 1991-755208	B2	19910905		
	US 1993-32958	B2	19930317		
	US 1993-100512	A1	19930730		
	US 1993-99975	A1	19930730		
	US 1993-149416	A	19931109		
	US 1994-212473	B1	19940314		
	US 1994-341255	A3	19941117		
	US 1994-343266	A3	19941121		
	US 1995-531534	A1	19950921		

OS MARPAT 124:116963
AB Derivs. of ascomycin and FK-506 were prepd. for use as immunosuppressants. Thus, ascomycin was converted to its 32-triflate which was converted to the (S)-azide and reduced to the amine. The latter compd. had an IC50 in the mixed lymphocyte reaction test of <1 x 10-6 M.
IT **148147-34-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of ascomycin and FK-506 derivs. as immunosuppressants)
RN 148147-34-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 8-ethyl-1,4,5,6,7,8,11,12,13,14,15,16,17,18,19,20,21,23,24,25,26,26a-docosahydro-19-hydroxy-14,16-dimethoxy-3-[2-[3-methoxy-4-[(2-pyridinylcarbonyl)oxy]cyclohexyl]-1-methylethenyl]-4,10,12,18-tetramethyl-1,7,20,21-tetraoxo-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosin-5-yl ester, [3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



L5 ANSWER 38 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1995:202937 CAPLUS
DN 122:153447
TI Multivariate QSAR analysis of a skin sensitization database
AU Cronin, M. T. D.; Basketter, D. A.
CS School of Pharmacy, Liverpool John Moores Univ., Liverpool, L3 3AF, UK
SO SAR and QSAR in Environmental Research (1994), 2(3), 159-79
CODEN: SQERED; ISSN: 1062-936X
PB Gordon & Breach
DT Journal
LA English
AB There is a regulatory requirement for the potential of a new chem. to cause skin sensitization to be assessed. This requirement is presently

fulfilled by the use of animal tests. In this study a data base of heterogeneous org. compds. from the guinea pig maximization test has been subjected to multivariate QSAR anal. The compds. were described both by whole mol. parameters and structural features assocd. with likely sites of reactivity. Principal component anal. was applied to the data set and although it functions reasonably well to reduce the dimensionality of a large data matrix, it is only moderately useful as a predictive tool when descriptors were chosen rationally. Stepwise discriminant anal. produces a fourteen parameter model, of which twelve were structural features assocd. with reactivity. This however predicts only 82.6% of compds. correctly after cross validation. There is trend for the linear discriminant anal. model to predict compds. as non sensitizers, suggesting that the parameters incorporated were not wholly suitable for discriminating between the two classes. Another criticism of linear discriminant anal. is that it may be unable to cope with the likely embedded data structure. With this in mind, the structural alerts may be better employed in an expert system, to identify potential hazard, where they will not suffer the limitations of a statistical model.

IT **499-83-2**, 2,6-Pyridinedicarboxylic acid
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(multivariate QSAR anal. of skin sensitization database)

RN 499-83-2 CAPLUS

CN 2,6-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



L5 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 1991:228922 CAPLUS

DN 114:228922

TI Preparation of 1,2,5-thiadiazole 1-oxide and 1,1-dioxide derivatives as histamine H2 antagonists for treatment of peptic ulcer diseases

IN Crenshaw, Ronnie R.; Algieri, Aldo A.

PA Bristol-Myers Co., USA

SO Can., 215 pp. Division of Can. Appl. No. 579,079.
CODEN: CAXXA4

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 1263114	A2	19891121	CA 1988-579079	19880930
	ZA 8005250	A	19810930	ZA 1980-5250	19800825
	FR 2476081	A1	19810821	FR 1980-18670	19800828
	FR 2476081	B1	19850412		
	DK 8003718	A	19810305	DK 1980-3718	19800901
	DK 160611	B	19910402		
	DK 160611	C	19910916		
	AU 8061942	A1	19810312	AU 1980-61942	19800901
	AU 541849	B2	19850124		
	IL 60944	A1	19871130	IL 1980-60944	19800901
	IL 75705	A1	19871130	IL 1980-75705	19800901
	SE 8006148	A	19810415	SE 1980-6148	19800903
	SE 449099	B	19870406		
	SE 449099	C	19870716		
	HU 29366	O	19840130	HU 1980-2170	19800903
	HU 190669	B	19861028		
	CA 1167841	A1	19840522	CA 1980-359493	19800903
	SU 1396967	A3	19880515	SU 1980-2976950	19800903

	HU 52490	A2	19900728	HU 1985-912	19800903
	HU 201539	B	19901128		
	HU 57755	A2	19911230	HU 1989-3724	19800903
	HU 205753	B	19920629		
	ES 494765	A1	19811001	ES 1980-494765	19800904
	DD 153838	C	19820203	DD 1980-223725	19800904
	CS 221977	P	19830429	CS 1980-6023	19800904
	JP 63042624	B4	19880824	JP 1980-121855	19800904
	FR 2486528	A1	19820115	FR 1981-15119	19810804
	FR 2486528	B1	19841221		
	CS 246052	B2	19861016	CS 1981-6980	19810922
	CA 1248962	A2	19890117	CA 1983-431960	19830706
	GB 2132190	A1	19840704	GB 1983-18949	19830713
	GB 2132190	B2	19850103		
	AT 8400645	A	19840715	AT 1984-645	19840227
	AT 377257	B	19850225		
	AT 8400646	A	19850815	AT 1984-646	19840227
	AT 380019	B	19860325		
	AT 8403301	A	19850715	AT 1984-3301	19841017
	AT 379806	B	19860310		
	AT 8403302	A	19850715	AT 1984-3302	19841017
	AT 379807	B	19860310		
	AU 8435396	A1	19850314	AU 1984-35396	19841113
	AU 563856	B2	19870723		
	NO 160781	B	19890220	NO 1987-1421	19870406
	NO 160781	C	19890531		
	NO 161737	B	19890612	NO 1987-1420	19870406
	NO 161737	C	19890920		
	JP 63211272	A2	19880902	JP 1988-14800	19880127
	JP 05037990	B4	19930607		
	JP 05078339	A2	19930330	JP 1991-235590	19910823
	JP 07010857	B4	19950208		
	NL 9201236	A	19930301	NL 1992-1236	19920709
	NL 9201237	A	19930301	NL 1992-1237	19920709
PRAI	US 1979-72517		19790904		
	US 1980-117182		19800131		
	US 1980-163831		19800607		
	CA 1980-359493		19800903		
	CA 1982-579079		19821102		
	CA 1983-431960		19830706		
	FR 1980-18670		19800828		
	IL 1980-60944		19800901		
	NL 1980-4967		19800901		
	GB 1980-28326		19800902		
	NO 1980-2576		19800902		
	AT 1980-4434		19800903		
	CS 1980-6023		19800904		
	CA 1982-359493		19821102		
	CA 1982-431960		19821102		
	AT 1984-646		19840227		

OS MARPAT 114:228922

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; p = 1, 2; R7 = leaving group, e.g., halo, alkoxy, alkylthio, (un)substituted PhO or PhS; R12 = A(CH2)mZ(CH2)nNH, R2R3N, HS(CH2)nNH; R2, R3 = H, alkenyl, alkynyl, (un)substituted alkyl, (mono- or dialkyl)amino, CF3CH2, FCH2CH2, OH, alkoxy, HOCH2CH(OH)CH2, cyano, cyanoalkyl, (alkyl)amidino, (un)substituted Ph or phenylalky, etc.; or R2R3 = CH2CH2XCCH2)r; m = 0-2; n = 2-4; r = 1-3; X = CH2, S, (un)substituted NH; Z = S, O, CH2; A = (un)substituted Ph or heterocyclyl; some restrictions on the variables are given], their salts, hydrates, solvates or N-oxides, inhibiting gastric acid secretion, are prepd. by reaction of I (R12 = any of the groups listed in R7) with A(CH2)mZ(CH2)nNH2, HNR2R3, and HS(CH2)nNH2. Thus, a soln. of 5-[(5-methyl-1H-imidazol-4-yl)methylthio]ethylamine in MeOH was added to a

stirred suspension of 3,4-dimethoxy-1,2,5-thiadiazole 1,1-oxide in MeOH to give, after 30 min, I (p = 2, R7 = MeO, R12 = Q) which was stirred 20 min at room temp. with HC.tplbond.CCH2NH2 to give I (p = 2, R7 = NHCH2C.tplbond:CH, R12 = Q). Approx. 175 I were prepd. Thirty-five I inhibited gastric acid secretion in pyloric ligated rats with ED50 of 0.02 to .apprx.10 .mu.mol/kg.

IT **78442-42-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of ulcer inhibitors)

RN 78442-42-9 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[(dimethylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **7170-36-7**

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in prepn. of ulcer inhibitors)

RN 7170-36-7 CAPLUS

CN 2,6-Pyridinedicarboxylic acid, monomethyl ester (8CI, 9CI) (CA INDEX NAME)



EXEMPLARY CLAIM: 1
LINE COUNT: 1991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **449734-09-2P**, Pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)
(prepn. of pyridine-2,4-dicarboxamide and -dicarboxylic acid derivs. as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)
RN 449734-09-2 USPATFULL
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 23 USPATFULL
AB Pyridine-2,3-dicarboxamides of the formula I ##STR1##

in which the variables are as defined in the description, which are suitable for use as herbicides or for the desiccation or defoliation of plants are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:283245 USPATFULL
TITLE: Pyridine-2,3-dicarboxylic acid diamides
INVENTOR(S): Hamprecht, Gerhard, Weinheim, GERMANY, FEDERAL REPUBLIC OF
Menges, Markus, Harthausen, GERMANY, FEDERAL REPUBLIC OF
Menke, Olaf, Altleiningen, GERMANY, FEDERAL REPUBLIC OF
Reinhard, Robert, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Sagasser, Ingo, Eppelheim, GERMANY, FEDERAL REPUBLIC OF
Zagar, Cyrill, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Westphalen, Karl-Otto, Speyer, GERMANY, FEDERAL REPUBLIC OF
Otten, Martina, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Walter, Helmut, Obrigheim, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6472349	B1	20021029	
	WO 2000058288		20001005	←
APPLICATION INFO.:	US 2001-937843		20010928	(9)
	WO 2000-EP2899		20000331	
			20010928	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-19914721	19990331

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: Keil & Weinkauf

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3503
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **298221-10-0P**
(prepn. of pyridine-2,3-dicarboxylic acid diamides as herbicides, desiccants, and defoliants)
RN 298221-10-0 USPATFULL
CN 2,3-Pyridinedicarboxamide, N3-(3-chloro-2-cyanophenyl)-N2-(cyclopropylmethyl)-6-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 23 USPATFULL
AB Coumermycin analogs of general formula I: ##STR1##

wherein X, a linking group, is selected from the group consisting of alkyl, aryl, diaryl, substituted alkyl, substituted aryl, alkyl with hereroatoms in the chain, heteroaryl, cyclic and bicyclic alkyl, and a combination of alkyl, aryl and heteroaryl substituents. The compounds are suitable for use as chemical dimerizers of chimeric proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:179234 USPATFULL
TITLE: Coumermycin analogs as chemical dimerizers of chimeric proteins
INVENTOR(S): Farrar, Michael A., Minneapolis, MN, UNITED STATES
Olson, Steven H., Metuchen, NJ, UNITED STATES
Perlmutter, Roger M., Seattle, WA, UNITED STATES
Slossberg, Llnon H., New Brunswick, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002095026	A1	20020718	
APPLICATION INFO.:	US 2001-840260	A1	20010423	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-203656P	20000512 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 868
CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L5 ANSWER 6 OF 23 USPATFULL

AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:185480 USPATFULL

TITLE: Heterocyclic 2-substituted ketoamides

INVENTOR(S): McIver, John McMillan, Cincinnati, OH, United States
Degenhardt, Charles Raymond, Cincinnati, OH, United States
Eickhoff, David Joseph, Edgewood, KY, United States

PATENT ASSIGNEE(S): The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6307049	B1	20011023	
APPLICATION INFO.:	US 1999-400681		19990921	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102449P	19980930	(60)
	US 1999-122925P	19990305	(60)
	US 1999-147279P	19990805	(60)
	US 1999-147313P	19990805	(60)
	US 1999-147280P	19990805	(60)
	US 1999-147278P	19990805	(60)
	US 1999-147276P	19990805	(60)
	US 1999-136996P	19990601	(60)
	US 1999-137024P	19990601	(60)
	US 1999-137022P	19990601	(60)
	US 1999-137023P	19990601	(60)
	US 1999-137052P	19990601	(60)
	US 1999-137063P	19990601	(60)
	US 1999-136958P	19990601	(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Seaman, D. Margaret

LEGAL REPRESENTATIVE: Brown, Catherine U., Lewis, Len W., McDow-Dunham, Kelly L.

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1

LINE COUNT: 1840

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **262843-24-3P**
(prepn. of N-(arylglyoxyloyl)azacycloalkane-2-carboxamides for treating hair loss)
RN 262843-24-3 USPATFULL
CN 2,3-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 23 USPATFULL
AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:173595 USPATFULL
TITLE:	2-substituted heterocyclic sulfonamides
INVENTOR(S):	McIver, John McMillan, Cincinnati, OH, United States Degenhardt, Charles Raymond, Cincinnati, OH, United States Eickhoff, David Joseph, Edgewood, KY, United States
PATENT ASSIGNEE(S):	The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6300341	B1	20011009	
APPLICATION INFO.:	US 1999-400679		19990921	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102539P	19980930	(60)
	US 1999-122925P	19990305	(60)
	US 1999-147279P	19990805	(60)
	US 1999-147313P	19990805	(60)
	US 1999-147280P	19990805	(60)
	US 1999-147278P	19990805	(60)
	US 1999-147276P	19990805	(60)
	US 1999-136996P	19990601	(60)
	US 1999-137024P	19990601	(60)
	US 1999-137022P	19990601	(60)
	US 1999-137023P	19990601	(60)
	US 1999-137052P	19990601	(60)
	US 1999-137063P	19990601	(60)
	US 1999-136958P	19990601	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Dentz, Bernard
LEGAL REPRESENTATIVE:	McDow-Dunham, Kelly, Brown, Catherine U., Miller, Steven W.

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **262843-24-3P**
(prepn. of heterocyclic sulfonamides as non-immunosuppressive hair growth promoters)
RN 262843-24-3 USPATFULL
CN 2,3-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 23 USPATFULL
AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:128907 USPATFULL
TITLE: Heterocyclic 2-substituted ketoamides
INVENTOR(S): McIver, John McMillan, Cincinnati, OH, United States
Degenhardt, Charles Raymond, Cincinnati, OH, United States
Eickhoff, David Joseph, Edgewood, KY, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001012895	A1	20010809
APPLICATION INFO.:	US 2000-736540	A1	20001213 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-400681, filed on 21 Sep 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102449P	19980930 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Catherine U. Brown - Box 633, The Procter & Gamble Company, Miami Valley Laboratories, P. O. Box 538707, Cincinnati, OH, 45253-8707
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 1794
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **262843-24-3P**
(prepn. of N-(arylglyoxyloyl)azacycloalkane-2-carboxamides for treating hair loss)
RN 262843-24-3 USPATFULL
CN 2,3-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 9 OF 23 USPATFULL

AB Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R.sup.1 is for example H and further values as defined in the specification; R.sup.2 is for example H and further values as defined in the specification; R.sup.3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R.sup.3 values can be the same or different; L is a linking moiety for example --CO--NH.sub.2 -- and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a --S--S-- dimer thereof when R.sup.2 =H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:71572 USPATFULL			
TITLE:	4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors			
INVENTOR(S):	Davies, David Huw, Macclesfield, United Kingdom Boyle, Francis Thomas, Macclesfield, United Kingdom Wardleworth, James Michael, Macclesfield, United Kingdom Kenny, Peter Wedderburn, Macclesfield, United Kingdom Scholes, Peter Beverley, Macclesfield, United Kingdom Matusiak, Zbigniew Stanely, Macclesfield, United Kingdom			
PATENT ASSIGNEE(S):	Zeneca Limited, London, United Kingdom (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6232338	B1	20010515	
	WO 9706138		19970220	
APPLICATION INFO.:	US 1998-11135		19980203	(9)
	WO 1996-GB1810		19960730	
			19980203	PCT 371 date
			19980203	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	GB 1995-15975		19950804	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Ramsuer, Robert W.			
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P..			
NUMBER OF CLAIMS:	11			
EXEMPLARY CLAIM:	1			
LINE COUNT:	3849			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 188353-08-4P
(prepn. of 2-aminomethyl-4-mercaptopyrrolidines and analogs as farnesyl transferase inhibitors)

RN 188353-08-4 USPATFULL

CN 2,5-Pyridinedicarboxamide, N5-[(3,4-dichlorophenyl)methyl]-N2-[(4-mercapto-2-pyrrolidinyl)methyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 10 OF 23 USPATFULL

AB Compounds of formula (I) and their pharmaceutically active salts are gastrin and CCK receptor ligands, where Ar is a monocyclic aromatic group, R.sup.1 is halo, amino, nitro, cyano, sulphamoyl, sulphonyl, trifluoromethyl, C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 alkylamino, C.sub.1 to C.sub.3 dialkylamino, phenyl, substituted phenyl, C.sub.1 to C.sub.3 alkoxy, hydroxy, esterified hydroxy, C.sub.1 to C.sub.3 hydroxyalkyl, C.sub.1 to C.sub.3 alkylcarboxyamino, carboxy, esterified carboxy and amidated carboxy, m is 0, 1, 2, 3, or 4, provided that m is not more than 2 unless R.sup.1 is exclusively halo, x+y=0 or 1, R.sup.2 and R.sup.4 independently are II, or C.sub.1 to C.sub.3 alkyl, R.sup.3 is H or C.sub.1 to C.sub.15 hydrocarbyl, where one or more hydrogen atoms of die hydrocarbyl group may be replaced by a halogen atom, and where up to two of the carbon atoms may be replaced by a nitrogen, oxygen or sulphur atom, provided that R.sup.3 does not contain a --O--O-- group, R.sup.5 is H or C.sub.1 to C.sub.3 alkyl, U is a cyclic moiety, selected from the group consisting of aryl, aromatic heterocyclic, non-aromatic heterocyclic, and cycloalkyl groups, where the aryl or aromatic group contains up to 3 substituents selected from the group consisting of halo, amino, nitro, cyano, sulphamoyl, sulphonyl, trifluoromethyl, C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 alkylamino, C.sub.1 to C.sub.3 dialkylamino, phenyl, C.sub.1 to C.sub.3 alkoxy, hydroxy, esterified hydroxy, C.sub.1 to C.sub.3 hydroxyalkyl, C.sub.1 to C.sub.3 alkylcarboxyamino, carboxy, esterified carboxy and amidated carboxy, Z is a group of the formula (IIa) or (IIb) where R.sup.6 is H or C.sub.1 to C.sub.3 alkyl, X is --CO.sub.2 H, esterified carboxy, amidated carboxy, tetrazolyl, hydroxy, cyano, amidino, --CH.sub.2 OH, --SO.sub.2 NHCOR.sup.7, --SONHCOR.sup.7, --COR.sup.7, --NHSO.sub.2 R.sup.7, --CONHSO.sub.2 R.sup.7,--NHCOR.sup.7 or --SO.sub.2 NHR.sup.8, where R.sup.7 is C.sub.1 to C.sub.6, alkyl, C.sub.1 to C.sub.6 aryl or substituted aryl, and R.sup.8 is --OH, --CN, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 haloalkyl, aryl or substituted aryl, Y is H or a group selected from those recited above for X, and a is 0, 1, or 2. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:96388 USPATFULL

TITLE: CCK and gastrin receptor ligands

INVENTOR(S): Kalindjian, Sarkis Barret, Banstead, United Kingdom
Steel, Katherine Isobel Mary, Beckenham, United Kingdom
Dunstone, David John, London, United Kingdom
Buck, Ildiko Maria, London, United Kingdom

PATENT ASSIGNEE(S): James Black Foundation Limited, London, United Kingdom

The present compounds exhibit excellent effect for controlling paddy field weeds and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:150872 USPATFULL
TITLE:	Pryidine-2,3-dicarboxylic acid diamide derivatives and herbicides comprising said derivatives as active ingredient
INVENTOR(S):	Tonishi, Masanori, Sakai, Japan Katsuhira, Takeshi, Kawachinagano, Japan Ohtsuka, Takashi, Tondabayashi, Japan Miura, Yuzo, Tondabayashi, Japan
PATENT ASSIGNEE(S):	Nihon Nohyaku Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5843868		19981201	
APPLICATION INFO.:	US 1997-825642		19970401	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-104580	19960402

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Fan, Jane
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
LINE COUNT:	1833

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **197918-60-8P**
(prepn. of pyridine-2,3-dicarboxamides as herbicides)

RN 197918-60-8 USPATFULL

CN 2,3-Pyridinedicarboxamide, N2-cyclopentyl-N3-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 23 USPATFULL

AB A compound of formula I ##STR1## X is O or S; A is 6-alkoxy-3-pyridyl optionally substituted by halogen;

Y is hydrogen or alkyl;

R.sup.3 is alkyl or a metal salt complex thereof. This invention contains fungicidal compositions and are used to combat cytopathogenic

fungi.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:57948 USPATFULL			
TITLE:	Anilide derivatives as fungicides			
INVENTOR(S):	Riordan, Peter Dominic, Dunmow, England Osbourn, Susan Elizabeth, Cambridge, England Boddy, Ian Kenneth, Hamilton, New Zealand			
PATENT ASSIGNEE(S):	Agrevo UK Limited, Cambridge, England (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5756524		19980526	
	WO 9525723		19950928	
APPLICATION INFO.:	US 1996-714149		19960918	(8)
	WO 1995-GB570		19950316	
			19960918	PCT 371 date
			19960918	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	GB 1994-5347		19940318	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Rotman, Alan L.			
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
LINE COUNT:	821			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **173056-91-2P**

(prepn. of anilide derivs. as fungicides)

RN 173056-91-2 USPATFULL

CN Benzoic acid, 2,2'-[2,5-pyridinediylbis(carbonylimino)]bis-, dimethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 23 USPATFULL

AB Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure ##STR1## wherein Z, X.sup.1, X.sup.2, x and R.sup.5 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:9505 USPATFULL
TITLE:	Inhibitors of microsomal triglyceride transfer protein and method
INVENTOR(S):	Biller, Scott A., Hopewell, NJ, United States Dickson, John K., Eastampton, NJ, United States Lawrence, R. Michael, Yardley, PA, United States



L5 ANSWER 14 OF 23 USPATFULL

AB The invention relates to pyridine-2,4- and -2,5-dicarboxylic acid derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X have the meanings given, a process for the preparation of these compounds and their use, in particular in medicaments for influencing the metabolism of collagen and collagen-like substances or the biosynthesis of Cl.sub.q.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:88994 USPATFULL

TITLE: Pharmaceutical use of pyridine-2,4- and -2,5-dicarboxylic acid amides

INVENTOR(S): Bickel, Martin, Bad Homburg, Germany, Federal Republic of
Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of
Burghard, Harald, Schmitten, Germany, Federal Republic of
Gunzler, Volkmar, Marburg-Cappel, Germany, Federal Republic of
Henke, Stephan, Bad Soden am Taunus, Germany, Federal Republic of
Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of
Mohr, Jurgen, Grunstadt, Germany, Federal Republic of
Tschank, Georg, Mainz, Germany, Federal Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5672614		19970930
APPLICATION INFO.:	US 1995-482815		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-367770, filed on 3 Jan 1995, now patented, Pat. No. US 5512586 which is a continuation of Ser. No. US 1993-66922, filed on 25 May 1993, now abandoned which is a continuation of Ser. No. US 1992-906676, filed on 30 Jun 1992, now abandoned which is a division of Ser. No. US 1991-726727, filed on 1 Jul 1991, now patented, Pat. No. US 5153208 which is a continuation of Ser. No. US 1989-434309, filed on 13 Nov 1989, now abandoned which is a continuation of Ser. No. US 1988-153087, filed on 8 Feb 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703959	19870210

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Dentz, Bernard

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P.

NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1

LINE COUNT: 916

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **117517-24-5P**
(prepn. of, as collagen formation -inhibiting drug)
RN 117517-24-5 USPATFULL
CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 23 USPATFULL
AB Oligopeptide antiretroviral agents are represented by formula (I), wherein A is a moiety bearing a positive charge and of a size which avoids steric inhibition of binding of said compound to nucleic acid sequences associated with the cellular activity of retroviruses; R.sub.1 is a moiety derived from a dicarboxylic acid; Hew is a five-membered heterocyclic moiety; y and z are independently 0, 1, 2 or 3; and x is 0 or 1. These compounds exhibit antiretroviral activity, especially against Human Immunodeficiency Virus (HIV). ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:27193 USPATFULL
TITLE:	Oligopeptide antiretroviral agents
INVENTOR(S):	Lown, J. William, Edmonton, Canada Micetich, Ronald G., Sherwood Park, Canada
PATENT ASSIGNEE(S):	Synphar Laboratories, Inc., Alberta, Canada (non-U.S. corporation) Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5616606		19970401
APPLICATION INFO.:	US 1995-510333		19950802 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-102715, filed on 6 Aug 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bond, Robert T.		
LEGAL REPRESENTATIVE:	Nikaido, Marmelstein, Murray & Oram LLP		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1,21		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	2157		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **142482-41-5P**
(prepn. of lexitropsin and distamycin analogs and related compds. as antiretroviral agents)
RN 142482-41-5 USPATFULL
CN 2,5-Pyridinedicarboxamide, N,N'-bis[5-[[[5-[[[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of
Burghard, Harald, Schmitten, Germany, Federal Republic of
Gunzler, Volkmar, Marburg-Cappel, Germany, Federal Republic of
Henke, Stephan, Bad Soden am Taunus, Germany, Federal Republic of
Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of
Mohr, Jurgen, Grunstadt, Germany, Federal Republic of
Tschank, Georg, Mainz, Germany, Federal Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5512586		19960430
APPLICATION INFO.:	US 1995-367770		19950103 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-66922, filed on 25 May 1993, now abandoned which is a continuation of Ser. No. US 1992-906676, filed on 30 Jun 1992, now abandoned which is a division of Ser. No. US 1991-726727, filed on 1 Jul 1991, now patented, Pat. No. US 5153208, issued on 6 Oct 1992 which is a continuation of Ser. No. US 1989-434309, filed on 13 Nov 1989, now abandoned which is a continuation of Ser. No. US 1988-153087, filed on 8 Feb 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703959	19870210

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **117517-24-5P**
(prepn. of, as collagen formation -inhibiting drug)
RN 117517-24-5 USPATFULL
CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 23 USPATFULL
AB 2,4- and 2,5-substituted pyridine-N-oxides are provided which are effective as fibrosuppressives and immunosuppressives. Said compounds

substances or the biosynthesis of Cl.sub.q.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 92:82789 USPATFULL

TITLE: Pyridine-2,4- and -2,5-dicarboxylic acid amides and their medicinal compositions and methods of use

INVENTOR(S): Bickel, Martin, Bad Homburg, Germany, Federal Republic of
Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of
Burghard, Harald, Schmitten, Germany, Federal Republic of
Gunzler, Volkmar, Marburg-Cappel, Germany, Federal Republic of
Henke, Stephan, Bad Soden am Taunus, Germany, Federal Republic of
Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of
Mohr, Jurgen, Grunstadt, Germany, Federal Republic of
Tschank, Georg, Mainz, Germany, Federal Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5153208		19921006
APPLICATION INFO.:	US 1991-726727		19910701 (7)

DISCLAIMER DATE: 20080806

RELATED APPLN. INFO.: Continuation of Ser. No. US 1989-434309, filed on 13 Nov 1989, now abandoned which is a continuation of Ser. No. US 1988-153087, filed on 8 Feb 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703959	19870210

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Dentz, Bernard

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett and Dunner

NUMBER OF CLAIMS: 7

EXEMPLARY CLAIM: 1

LINE COUNT: 763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **117517-24-5P**
(prepn. of, as collagen formation -inhibiting drug)

RN 117517-24-5 USPATFULL

CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 19 OF 23 USPATFULL

	Hanauske-Abel, Hartmut, Dexheim, Germany, Federal Republic of Mohr, Jurgen, Grunstadt, Germany, Federal Republic of Tschank, Georg, Mainz, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5037839		19910806
APPLICATION INFO.:	US 1989-434402		19891113 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1988-153087, filed on 8 Feb 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3703959	19870210

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard I.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett and Dunner
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **117517-24-5P**
(prepn. of, as collagen formation -inhibiting drug)
RN 117517-24-5 USPATFULL
CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 22 OF 23 USPATFULL
AB Pyridine-2,4- and 2,5-dicarboxylic acid derivatives, a process for their preparation, the use thereof, and medicaments based on these compounds.

The invention relates to pyridine-2,4- and -2,5-dicarboxylic acid derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2 and X have the indicated meanings, to a process for the preparation of these compounds, and to their use, in particular in medicaments for influencing the metabolism of collagen and collagen-like substances and the biosynthesis of C1q.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	90:85607 USPATFULL
TITLE:	Pyridine-2,4- and 2,5-dicarboxylic acid derivatives, a process for their preparation, the use thereof, and medicaments based on these compounds
INVENTOR(S):	Brocks, Dietrich, Wiesbaden, Germany, Federal Republic of Burghard, Harald, Schmitten, Germany, Federal Republic

EXEMPLARY CLAIM: 1
LINE COUNT: 1991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **449734-09-2P**, Pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)
(prepn. of pyridine-2,4-dicarboxamide and -dicarboxylic acid derivs. as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)
RN 449734-09-2 USPATFULL
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 23 USPATFULL
AB Pyridine-2,3-dicarboxamides of the formula I ##STR1##

in which the variables are as defined in the description, which are suitable for use as herbicides or for the desiccation or defoliation of plants are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:283245 USPATFULL
TITLE: Pyridine-2,3-dicarboxylic acid diamides
INVENTOR(S): Hamprecht, Gerhard, Weinheim, GERMANY, FEDERAL REPUBLIC OF
Menges, Markus, Harthausen, GERMANY, FEDERAL REPUBLIC OF
Menke, Olaf, Altleiningen, GERMANY, FEDERAL REPUBLIC OF
Reinhard, Robert, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Sagasser, Ingo, Eppelheim, GERMANY, FEDERAL REPUBLIC OF
Zagar, Cyrill, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Westphalen, Karl-Otto, Speyer, GERMANY, FEDERAL REPUBLIC OF
Otten, Martina, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF
Walter, Helmut, Obrigheim, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Ludwigshafen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6472349	B1	20021029
	WO 2000058288		20001005
APPLICATION INFO.:	US 2001-937843		20010928 (9)
	WO 2000-EP2899		20000331
			20010928 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-19914721	19990331

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: Keil & Weinkauf

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3503
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **298221-10-0P**
(prepn. of pyridine-2,3-dicarboxylic acid diamides as herbicides, desiccants, and defoliants)
RN 298221-10-0 USPATFULL
CN 2,3-Pyridinedicarboxamide, N3-(3-chloro-2-cyanophenyl)-N2-(cyclopropylmethyl)-6-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 23 USPATFULL
AB Coumermycin analogs of general formula I: ##STR1##

wherein X, a linking group, is selected from the group consisting of alkyl, aryl, diaryl, substituted alkyl, substituted aryl, alkyl with hereroatoms in the chain, heteroaryl, cyclic and bicyclic alkyl, and a combination of alkyl, aryl and heteroaryl substituents. The compounds are suitable for use as chemical dimerizers of chimeric proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:179234 USPATFULL
TITLE: Coumermycin analogs as chemical dimerizers of chimeric proteins
INVENTOR(S): Farrar, Michael A., Minneapolis, MN, UNITED STATES
Olson, Steven H., Metuchen, NJ, UNITED STATES
Perlmutter, Roger M., Seattle, WA, UNITED STATES
Slossberg, Llnon H., New Brunswick, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002095026	A1	20020718
APPLICATION INFO.:	US 2001-840260	A1	20010423 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-203656P	20000512 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 868
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds of the formula (I), wherein R1, R2, R3, R4, R5 and n have the meanings cited in the description said compounds being new effective bronchial therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:37819 USPATFULL
TITLE:	(2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
INVENTOR(S):	Bar, Thomas, Constance, Germany, Federal Republic of Ulrich, Wolf-Rudiger, Constance, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6043263		20000328	
	WO 9821207		19980522	
APPLICATION INFO.:	US 1999-284989		19990512	(9)
	WO 1997-EP6131		19971105	
			19990522	PCT 371 date
			19990522	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19646503	19961112
	EP 1996-118414	19961116

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Gerstl, Robert
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern, PLLC
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	1074

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **204075-07-0**, Ethyl 4-thioamidopyridine-2-carboxylate (for prepn. of (2,3-dihydrobenzofuranyl)thiazoles as phosphodiesterase inhibitors)

RN 204075-07-0 USPATFULL

CN 2-Pyridinecarboxylic acid, 4-(aminothioxomethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 7 OF 22 USPATFULL

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:159968 USPATFULL
TITLE:	Substituted 3-aminoquinuclidines
INVENTOR(S):	Ito, Fumitaka, Chita-Taketoyo, Japan Kokura, Toshihide, Handa, Japan Nakane, Masami, Showakyu, Japan Satake, Kunio, Handa, Japan Wakabayashi, Hiroaki, Kiriya, Japan
PATENT ASSIGNEE(S):	Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5852038		19981222
APPLICATION INFO.:	US 1996-950043		19961118 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-175353, filed on 20 Dec 1993, now patented, Pat. No. US 5716965		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1991-46826	19910522

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wu, Shean C.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Dryer, Mark
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 2341
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **24195-03-7P**
(prepn. and reaction of, in prepn. of substance P antagonists)
RN 24195-03-7 USPATFULL
CN 2,4-Pyridinedicarboxylic acid, 4-methyl ester (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 22 USPATFULL
AB Compounds of the formula ##STR1## wherein W, Ar.sup.1, Ar.sup.2 and Ar.sup.3 are defined as below; and the pharmaceutically acceptable salts of such compounds.

These compounds are substance P antagonists and useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:14812 USPATFULL
TITLE: Substituted 3-aminoquinuclidines
INVENTOR(S): Ito, Fumitaka, Chita-Taketoyo, Japan
Kokura, Toshihide, Handa, Japan
Nakane, Masami, Showakyu, Japan
Satake, Kunio, Handa, Japan
Wakabayashi, Hiroaki, Kiriya, Japan
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5716965		19980210	
	WO 9220676		19921126	
APPLICATION INFO.:	US 1993-175353		19931220	(8)
	WO 1992-US4002		19920519	
			19931220	PCT 371 date
			19931220	PCT 102(e) date

=> d l11 bib abs hitstr 1-2

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1992:214352 CAPLUS
DN 116:214352
TI Preparation of 2,4- and 2,5-substituted pyridine N-oxides as fibrosuppressive and immunosuppressive agents
IN Baader, Ekkehard; Bickel, Martin; Guenzler-Pukall, Volkmar
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 463592	A1	19920102	EP 1991-110343	19910622
	EP 463592	B1	19940817		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 4020570	A1	19920102	DE 1990-4020570	19900628
	ES 2061118	T3	19941201	ES 1991-110343	19910622
	FI 9103118	A	19911229	FI 1991-3118	19910626
	FI 101070	B	19980415		
	IL 98629	A1	19960514	IL 1991-98629	19910626
	CZ 283782	B6	19980617	CZ 1991-1959	19910626
	CA 2045868	AA	19911229	CA 1991-2045868	19910627
	NO 9102541	A	19911230	NO 1991-2541	19910627
	NO 178026	B	19951002		
	NO 178026	C	19960110		
	AU 9179356	A1	19920102	AU 1991-79356	19910627
	AU 636990	B2	19930513		
	CN 1057649	A	19920108	CN 1991-104308	19910627
	CN 1038585	B	19980603		
	BR 9102699	A	19920204	BR 1991-2699	19910627
	ZA 9104958	A	19920325	ZA 1991-4958	19910627
	HU 59104	A2	19920428	HU 1991-2158	19910627
	HU 214627	B	19980428		
	JP 04230264	A2	19920819	JP 1991-156562	19910627
	JP 08032687	B4	19960329		
→	US 5260323	A	19931109	US 1992-978467	19921119
	LV 10431	B	19960220	LV 1993-284	19930504
	LT 3918	B	19960425	LT 1993-1464	19931112
PRAI	DE 1990-4020570		19900628		
	US 1991-721681		19910626		

OS MARPAT 116:214352
GI



AB Title compds. I [R1 = COXR3; X = O, NR; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R = R3 or NRR3 = Q; n = 1-3; A = O, S, CH2, NR7; R7 = H, (substituted) Ph, alkyl, alkenyl, alkynyl, alkoxycarbonyl, cycloalkyl; R2 = COXR3; with provisos] were prepd. as proline- and lysine hydroxylase inhibitors useful as

fibrosuppressive and immunosuppressive agents. Thus, N-oxidn. of 1 g bis[N,N'-2-methoxyethyl)pyridine-2,4-dicarboxamide by 0.62 g m-chloroperbenzoic acid gave 620 mg of the bis(N,N'-2-methoxyethyl)pyridine-2,4-dicarboxamide N-oxide (II). II was tested as a proline hydroxylase inhibitor.

IT **139994-20-0 139994-21-1 139994-22-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-oxidn. of, by chloroperbenzoic acid, in prepn. of fibrosuppressive and immunosuppressive agents)

RN 139994-20-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



RN 139994-21-1 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139994-22-2 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



IT **139994-11-9P 139994-12-0P 139994-13-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as fibrosuppressive and immunosuppressive agent)
RN 139994-11-9 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-dicyclohexyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 139994-12-0 CAPLUS
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-chlorophenyl)methyl]-, 1-oxide (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 12 OF 22 USPATFULL

AB An antipruritic composition for an oral medicine, injection, and external medicine, comprising an effective amount of a chelated zinc (e.g., zinc picolinate) as an antipruritic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 93:48506 USPATFULL

TITLE: Antipruritic composition

INVENTOR(S): Taguchi, Shigeru, Yokohama, Japan
Suzuki, Takashi, Yokohama, Japan
Nishino, Chikao, Yokohama, Japan
Fujinuma, Yoshimori, Yokohama, Japan
Yanagawa, Chuji, Sagamihara, Japan
Yamaguchi, Michihiro, Yokohama, Japan
Yamato, Miwako, Yokohama, Japan
Nakajima, Noriko, Yokohama, Japan
Kitano, Mie, Yokohama, Japan
Okazaki, Tomomi, Yokohama, Japan
Uemura, Masaki, Yokohama, Japan
Inada, Ryuhei, Yokohama, Japan
Tonomura, Yoshiko, Yokohama, Japan

PATENT ASSIGNEE(S): Shiseido Company, Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5219847		19930615
APPLICATION INFO.:	US 1992-918800		19920727 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-640428, filed on 31 Jan 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1989-150291	19890612
	JP 1990-40522	19900220
	JP 1990-83619	19900330

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Schenkman, Leonard

LEGAL REPRESENTATIVE: Wegner, Cantor, Mueller & Player

NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1

LINE COUNT: 2080

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **499-80-9P**, 2,4-Pyridinedicarboxylic acid
(prepn. and reaction of, for antipruritic zinc chelate prepn.)

RN 499-80-9 USPATFULL

CN 2,4-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 13 OF 22 USPATFULL

AB Compounds of formula I ##STR1## wherein A, X.sub.1, X.sub.2, X.sub.3, X.sub.4, Y, Z and R.sub.1 to R.sub.6 have the meanings given in the description, have valuable pharmaceutical properties and are effective especially against tumours. They are prepared in a manner known per se.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	92:44852 USPATFULL
TITLE:	Arylhydrazones and pharmaceutical compositions containing the same
INVENTOR(S):	Stanek, Erfinders J., Arlesheim, Switzerland Caravatti, Giorgio, Allschwil, Switzerland Frei, Jorg, Holstein, Switzerland Capraro, Hans-Georg, Rheinfelden, Switzerland
PATENT ASSIGNEE(S):	Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5118709		19920602
APPLICATION INFO.:	US 1990-574991		19900829 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1989-324368, filed on 5 Mar 1989, now patented, Pat. No. US 4971986		

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1988-1139	19880325

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Morris, Patricia L.
ASSISTANT EXAMINER:	Haley, Jacqueline
LEGAL REPRESENTATIVE:	Fishman, Irving M., Kaiser, Karen G.
NUMBER OF CLAIMS:	17
EXEMPLARY CLAIM:	1
LINE COUNT:	1324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **126534-91-6P**
(prepn. and reaction of, in prepn. of S-adenosylmethioninedecarboxylase inhibitors)

RN 126534-91-6 USPATFULL

CN 2-Pyridinecarboximidic acid, 4-(diethoxymethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 23 USPATFULL

AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:185480 USPATFULL
TITLE: Heterocyclic 2-substituted ketoamides
INVENTOR(S): McIver, John McMillan, Cincinnati, OH, United States
Degenhardt, Charles Raymond, Cincinnati, OH, United States
Eickhoff, David Joseph, Edgewood, KY, United States
PATENT ASSIGNEE(S): The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6307049	B1	20011023	
APPLICATION INFO.:	US 1999-400681		19990921	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102449P	19980930	(60)
	US 1999-122925P	19990305	(60)
	US 1999-147279P	19990805	(60)
	US 1999-147313P	19990805	(60)
	US 1999-147280P	19990805	(60)
	US 1999-147278P	19990805	(60)
	US 1999-147276P	19990805	(60)
	US 1999-136996P	19990601	(60)
	US 1999-137024P	19990601	(60)
	US 1999-137022P	19990601	(60)
	US 1999-137023P	19990601	(60)
	US 1999-137052P	19990601	(60)
	US 1999-137063P	19990601	(60)
	US 1999-136958P	19990601	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Seaman, D. Margaret
LEGAL REPRESENTATIVE: Brown, Catherine U., Lewis, Len W., McDow-Dunham, Kelly L.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1840

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **262843-24-3P**
(prepn. of N-(arylglyoxyloyl)azacycloalkane-2-carboxamides for treating hair loss)
RN 262843-24-3 USPATFULL
CN 2,3-Pyridinedicarboxamide, N,N'-bis(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 23 USPATFULL

AB The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:173595 USPATFULL
TITLE: 2-substituted heterocyclic sulfonamides
INVENTOR(S): McIver, John McMillan, Cincinnati, OH, United States
Degenhardt, Charles Raymond, Cincinnati, OH, United States
Eickhoff, David Joseph, Edgewood, KY, United States
PATENT ASSIGNEE(S): The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6300341	B1	20011009	
APPLICATION INFO.:	US 1999-400679		19990921	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102539P	19980930	(60)
	US 1999-122925P	19990305	(60)
	US 1999-147279P	19990805	(60)
	US 1999-147313P	19990805	(60)
	US 1999-147280P	19990805	(60)
	US 1999-147278P	19990805	(60)
	US 1999-147276P	19990805	(60)
	US 1999-136996P	19990601	(60)
	US 1999-137024P	19990601	(60)
	US 1999-137022P	19990601	(60)
	US 1999-137023P	19990601	(60)
	US 1999-137052P	19990601	(60)
	US 1999-137063P	19990601	(60)
	US 1999-136958P	19990601	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: McDow-Dunham, Kelly, Brown, Catherine U., Miller, Steven W.